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ABSTRACT 
 
Bullard, Kristen M.  Malaria Kinase Inhibition:  a Tool for Antimalarial Drug 
Discovery and Elucidation of Cell Cycle Protein Expression Patterns.  
Published Doctor of Philosophy in Biological Education dissertation, 
University of Northern Colorado, 2013. 
 
   The protozoan parasite, Plasmodium (P.) falciparum, causes the most 
virulent form of malaria and is a significant source of mortality in the developing 
world.  Increasing resistance of this parasite to traditional antimalarials has 
necessitated the identification of new targets for antimalarial drug design.  
Protein kinases, which mediate critical cellular processes such as proliferation, 
growth, and apoptosis, make attractive drug targets as the deregulation of 
cellular phosphorylation events has been linked to human diseases.  In recent 
years, kinase inhibitors have successfully treated such diseases as chronic 
mylogenous leukemia and renal cell carcinoma.  The unique structural and 
mechanistic aspects of many P. falciparum kinases make these proteins 
potentially useful drug targets and the inhibition of these macromolecules 
provides a means to examine heretofore undescribed cellular mechanisms within 
these dynamic parasitic organisms.  First, three libraries of known kinase 
inhibitors were screened against the malaria kinase, PfPK7, using a ATP 
luminescence assay to determine which of these molecules had affinity for the 
ATP binding site of this kinase.  Computational methods were employed to 
determine how small molecule inhibitors were binding to the PfPK7 ATP-binding 
site and properties that are important for determining the druglikeness of each 
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compound were predicted using commercially available software.  In addition, 
small molecules were screened against P. falciparum strain W2 to determine 
their ability to inhibit intraerythrocytic stage growth using a SYBR Green I growth 
assay.  Finally, the well characterized kinase inhibitor Purvalanol B was applied 
blood stage cultures of P. falciparum strain W2 and differences in protein 
expression between inhibitor-treated and wildtype parasites were determined 
using a shotgun proteomics approach.  Out of the 244 small molecules tested, 
eight were found to have affinity for the ATP-binding site of PfPK7 and the 
probable interactions that contribute to small molecule binding as well as the 
predicted properties that contribute to druglikeness were described.  While 
several small molecules were able to inhibit intraerythrocytic parasite growth, 
most inhibitors of PfPK7 identified in the luminescence screen did not 
significantly inhibit P. falciparum growth Disruption of parasite development with 
the kinase inhibitor Purvalanol B yielded differences in protein expression 
between wildtype and inhibitor-treated parasites.  These data further characterize 
the orphan kinase PfPK7 and may suggest this target may not be ideal for 
antimalarial drug design as its inhibition does not correspond with attenuated P. 
falciparum growth in blood stage cultures. Finally, protein differences resulting 
from kinase inhibitor treatment during parasite cell cycle aid in the elucidation of 
the heretofore poorly understood P. falciparum cell cycle mechanisms.  
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AIMS 
 
 Malaria is a devastating disease that is caused by protozoan parasites 
from the genus Plasmodium.  One species of Plasmodium, P. falciparum, is 
increasingly resistant to traditional antimalarial treatments.  The increase in 
resistance is causing a drastic surge in morbidity and mortality as well as 
amplifying an economic hardship for those global populations that can least 
afford the additional burden.  Development of resistant P. falciparum strains calls 
for identification of new drug candidates for antimalarial drug design and 
identification of drug targets within the parasite that are unique and indispensable 
for normal parasite growth.  Kinases from P. falciparum make excellent targets 
for drug discovery because of vast phylogenetic and mechanistic differences 
between parasite and human kinases. As such, inhibition of Plasmodium kinases 
may be a useful tool for pursuing compounds with potential antimalarial activity 
and for providing a means to investigate biological roles of these unique proteins 
within this parasitic organism.  Firstly, this body of work describes the inhibition of 
a unique kinase from P. falciparum, PfPK7, which has been shown to be involved 
in the intraerythrocytic stages of parasite development within the human host.  
Secondly, the extent to which small molecules from three kinase-inhibitor 
focused libraries were able to inhibit intraerythrocytic growth of P. falciparum 
strain W2 blood stage cultures was assessed.  In addition, application of the well-
characterized cyclin-dependent kinase inhibitor Purvalanol B to blood stage 
   
 
  
 
 
2 
cultures of P. falciparum strain W2 allowed for the determination of protein 
content differences between inhibitor-treated and wildtype cultures.  
Aim 1:  To screen 244 known kinase inhibitors against PfPK7.   
Hypothesis:  Screening a kinase inhibitor-focused library against PfPK7 will 
identify several small molecules capable of inhibiting kinase activity at low molar 
concentrations. 
Subaim 1:  To screen 244 known kinase inhibitors using an ATP luminescence 
assay.  An ATP luminescence assay was used to screen small molecule kinase 
inhibitors against PfPK7 by quantifying the protein’s ability to utilize ATP as it 
autophosphorylates in the presence of each small molecule. 
Subaim 2:  To computationally determine likely associations between small 
molecules identified in aim 1 and the ATP-binding site of PfPK7.  All 244 kinase 
inhibitors were docked to the ATP-binding site of the PfPK7 crystal structure 
using GOLD and hits from aim 1 were analyzed to determine which residues 
within the binding site were interacting with each small molecule.   
Subaim 3:  To computationally investigate the probable biologically relevant 
properties of PfPK7 inhibitors.  Computer programs TOPKAT and QikProp were 
used to estimate biological properties such as toxicity, bioavailability, and 
absorption. 
Aim 2:  To screen 244 kinase inhibitors against blood stage cultures of P. 
falciparum strain W2. 
 
Hypothesis:  Small molecules from kinase inhibitor-focused libraries will inhibit 
parasitic growth of P. falciparum strain W2 in blood stage cultures.  A SYBR 
Green I parasitic growth assay was used to evaluate the ability of small 
molecules in the kinase libraries to inhibit growth of intraerythrocytic stages of P. 
falciparum strain W2 in blood stage cultures.   
 
Aim 3:  To determine whether differences in protein expression occur between 
wildtype and Purvalanol B-treated blood stage cultures of P. falciparum strain 
W2. 
 
Hypothesis: Administration of Purvalanol B to blood stage cultures of P. 
falciparum will result in protein expression differences between wildtype and 
inhibitor-treated cultures.  The cyclin-dependent kinase selective inhibitor 
Purvalanol B was applied to tightly synchronized blood stage cultures of P. 
falciparum strain W2 at approximately 20 hours post invasion.  Parasites were 
extracted from cultures at 32 hours post invasion.  Protein was extracted from 
Purvalanol-B treated and control cultures.  Soluble fractions from wildtype and 
Purvalanol B-treated cultures were analyzed with shotgun proteomics. 
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CHAPTER I 
REVIEW OF LITERATURE 
Introduction 
 Malaria is one of the most tragic causes of morbidity and mortality in the 
developing world.  According to the Malaria World Report 2012, a report of 
malaria-related statistics compiled from data drawn from 104 countries where 
malaria is endemic, there were an estimated 154-289 million cases of malaria 
and approximately 700,000 malaria-related deaths in 2012 [1]. Malaria is the 
primary cause of child death in tropical areas and it predominantly impacts 
children under 5 years of age in Sub-Saharan Africa [2].  Young children, 
pregnant women, migrant workers, and travelers are generally the most 
vulnerable to transmission as these groups have little protective immunity [3].  
Tropical and subtropical areas with temperate climates and sufficient 
precipitation allow for the development of the mosquito vector and thus have the 
greatest rates of malaria infection [4](Figure 1).  Many of these areas are found in 
the developing world where people are plagued by socio-economic instability and 
other endemic diseases such as tuberculosis and HIV/AIDS [5].  One of the 
causes of this societal burden, the malaria parasite Plasmodium (P.)   
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5 
falciparum, is becoming increasingly resistant to known antimalarial treatments 
and as such there is an immediate need to identify novel antimalarial agents as 
well as potential drug targets that would make clear the poorly understood 
molecular mechanisms that govern parasite proliferation [6].  
The History of Malaria 
 
 Malaria has been present and shaping human history for centuries.  As 
long ago as 2700 BCE, the Chinese Canon of Medicine Nei Ching, described a 
disease that progressed with symptoms that lead to cycles of reoccurring fevers 
and ultimately an enlarged spleen [7].  In Egypt, Hippocrates was the first to note 
the relationship between transmission of the fever disease and the proximity of 
affected populations to bodies of stagnant water [8].  This observation was 
further solidified by the Romans, who came to the same conclusion and began 
attempting to drain swampy areas in order to prevent disease occurrence [9].   
 As malaria was associated with swampy areas and microorganisms were 
as yet undiscovered, the name for the disease came from what was assumed to 
be its cause:  in 18th century Italian, mala was the word for “bad” and aria was the 
word for “air”.  At the time, people believed that the symptoms of malaria infection 
were caused by the putrid air emanating from the stagnant waters in these 
swampy areas [9] and although the parasitic origin of malaria was discovered in 
1880, the disease name has remained the same. 
 It was the French physician and student of Louis Pasteur, Charles Louis 
Alphonse Laveran, who first identified the cause of malaria in Algeria in 1880 
[10].  Laveran observed trophozoites and gametocytes in slides made from blood 
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specimens of patients with malaria.  He called the parasite Oscillaria malariae.  
Although his findings were largely discounted by members of the scientific 
community because of pressure from well-known bacteriologists who thought the 
cause of malaria must be bacterial, he was vindicated in 1886 with the 
independent observations of Louis Pasteur, William Osler, and Camillo Golgi who 
also observed parasites in blood smears of infected individuals [11].  In addition, 
Camillo Golgi was further able to distinguish between malaria parasites that 
cause tertian and quartan malaria, noting that parasite load contributed to the 
severity of malaria symptoms and that the rupture of red blood cells coincided 
with fever onset [12]. 
 It was clear that the cause of malaria was an infection with a parasitic 
organism; however, how this organism was transmitted was still ambiguous. 
Patrick Manson, a British Medical Officer with an expertise in tropical medicine 
was the first to note microfilariae in the blood and filarial worms in the lymphatic 
vessels of patients suffering from elephantiasis.  He was also the first to note that 
the microfilariae could be picked up from infected humans by mosquitos that 
could then transmit the disease to other humans [13].  After extensive 
correspondence and guidance from Dr. Patrick Manson, British army surgeon 
Ronald Ross felt compelled to test Manson’s theory that malaria was carried and 
transmitted by mosquitoes much in the same way as filariae [14, 15].  Although 
discouraged from several unsuccessful attempts to pinpoint the malaria vector 
species, on August 20th 1897, he toiled at his microscope [16].  It was on this day 
that his labors were rewarded and when dissecting three mosquitoes from an 
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Indian Anopheline species he found within the midguts of these specimens a key 
element to malaria transmission, Plasmodium oocysts.  Ross, a dedicated if not 
widely successful poet, wrote the following about his discovery: 
This day relenting God  
Hath placed within my hand  
A wondrous thing; and God  
Be praised. At his command, 
Seeking His secret deeds  
With tears and toiling breath,  
I find thy cunning seeds,  
O million-murdering Death. 
I know this little thing   
A myriad men will save.  
O Death, where is thy sting?  
Thy victory, O Grave? 
   Ronald Ross [17] 
 
Anopheline mosquitos were further solidified as the malaria vector in 1898 when 
Giovanni Battista Grassi recruited a human volunteer and successfully 
transmitted malaria to a human host using mosquitos infected with P. vivax [18].  
The next year the entire life cycle of P. falciparum within blood cells was 
observed by three researchers including Grassi [18].  Soon after the complete 
intraerythrocytic life cycle was observed, a heated feud ensued between Grassi 
and Ross when Grassi failed to recognizes Ross’s contributions to the malaria 
transmission puzzle and instead published his findings without crediting Ross for 
his earlier discovery [19].  However, the disagreement between the two scientists 
was resolved when Ross was awarded the Nobel Prize in Physiology or Medicine 
in 1902 [20]. 
 Researchers then began investigating the reason why some patients with 
malaria infection could not be cured when treated with quinine administered less 
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than six days into infection.  There seemed to be a brief time during the prepatent 
period when parasites were resistant to antimalarial drugs.  The mystery of this 
period was solved in 1948 when Shortt and Garnham used rhesus monkeys 
infected with P. cynomolgi and later human volunteers infected with P. vivax to 
elucidate the exoerythrocytic cycle of parasite development in liver cells [21].  It 
was now clear that the malaria life cycle was much more complex than origionally 
thought and this understanding allowed researchers a better grasp of parasite 
growth requirements. 
Much had been learned about malaria using animal models and human 
volunteers; however, it wasn’t until 1976 when William Trager and James Jensen 
developed a technique for culturing the intraerythrocytic life cycle stages of the 
parasite in blood stage cultures that malaria research became accessible to 
many labs across the globe [22].  
The P. falciparum Life Cycle 
 There are five species in the genus Plasmodium that cause human 
pathology: P. ovale, P. malariae, P. vivax, P. knowlesi, and P. falciparum.  
Malaria caused by P. falciparum parasites is the most lethal [23] and as the 
intraerythrocytic life cycle stages of P. falciparum are responsible for the 
pathology observed in human illness, many studies are aimed at elucidating the 
mechanisms involved in the development of falciparum malaria during these 
stages.    
 The P. falciparum life cycle requires two vectors for completion.  The 
sexual stages of the life cycle take place in mosquitoes from the genus 
   
 
  
 
 
9 
Anopheles, while the asexual exoerythrocytic (EE) and intraerythrocytic (IE) life 
cycle stages take place within the human host.  The life cycle begins when a 
female Anopheles mosquito takes a blood meal and injects infectious sporozoites 
from its saliva into a vertebrate host (Figure 2).  After inoculation, sporozoites 
travel to the liver where they infect certain hepatocytes.  Inside these 
hepatocytes, parasites undergo exoerythrocytic schizogony, a type of multi-
nuclear division that releases several thousand merozoites capable of infecting 
erythrocytes into the bloodstream.  Upon contact with a susceptible red blood cell 
(RBC), the merozoite will secrete digestive enzymes from its apical surface in 
order to invade and take over the RBC.  Once inside the cell, the parasite 
undergoes intraerythrocytic schizogony, the product of which is 8-24 new 
merozoites that are capable of infecting additional RBCs.  The EE life cycle 
requires five and a half to six days for completion, while the IE life cycle is 
completed in 36 to 48 hours. 
 A small fraction of infected RBCs mature into micro and macro 
gametocytes, which travel to the peripheral blood to be taken up by a mosquito 
during a blood meal [24].  Sexual stage replication takes place within the 
mosquito midgut and the cycle is completed when sporozoites travel to the 
mosquito salivary glands where they mature and prepare to be inoculated into a 
new vertebrate host.  
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Morphological Characteristics of P. falciparum 
 Sporozoites, the parasite form that is transmitted to human hosts from the 
mosquito’s saliva, are approximately 10 µm to 15 µm in length with a diameter of 
approximately 1 µm.  The outermost structure of the sporozoite is referred to as a 
pellicle and is composed of one outer membrane and two inner membranes [25-
27].  Just beneath the double membrane of the pellicle an organization of 
subpellicular microtubules resides, which functions to maintain the shape of the 
sporozoites and support the movement of the organisms from circulating blood to 
the liver parenchyma [28].  Also present in the apical portion are three polar rings 
and a nonfunctional cytostome.  The nucleus is housed in the mid-portion of the 
parasite, while a mitochondrion and a spherical body occupy the posterior  
portion.  The parasite also possess two long structures called rhoptries that 
extend from the apical end to the mid-portion, while the bulk of remaining anterior 
cytoplasm contains several electron dense micronemes [29]. 
 Approximately 24 hours after sporozoite injection, the parasites penetrate 
liver parenchyma when a domain of circumsporozoite protein, a protein that 
covers the outside of sporozoites, attaches to a complementary surface on a 
receptor of the liver cell basolateral membrane [30].  Rhoptries then facilitate 
invasion by excreting substances that solidify parasite attachment to the RBC 
and make the cellular membrane of the host cell easier to disrupt [31].  
Exoerythrocytic forms in liver cells become early trophozoites and apical 
organelles such as rhoptries and micronemes disappear as the parasite begins 
to take in host cell cytoplasm for digestion.  Once the cell has grown in size, the 
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parasite undergoes schizogony and merozoites that are released from liver cells 
regain many of their earlier apical organelles. 
 The apical complex including rhoptries, micronemes, and polar bodies 
redevelop in order to help the invading parasite to latch onto the RBC [32].  The 
apical complex allows invasion by orienting the apical end of the parasite towards 
the RBC and secreting a series of proteins that form a “moving junction.”  The 
moving junction effectively invaginates the host cell membrane and ushers the 
parasite inside the host cell while forming the protective parasitophorous 
vacuolar membrane between the parasite and host cell cytoplasm [33-38]. 
 Once ensconced within the RBC, the malaria parasite again begins 
development as a trophozoite.  The early trophozoite occupies approximately ¼ 
the diameter of the RBC and has the appearance of a signet ring (Figure 3, 
stages 1-15) with either one or two chromatin dots [39].  The ring shape is a 
result of the ingestion of host cell cytoplasm through the parasite’s primary 
cytostome.  The cytoplasm is kept in a large central food vacuole that pushes the 
nucleus of the parasite to the periphery.  As the parasite feeds on hemoglobin 
from the food vacuole, the food vacuole shrinks and the waste product hemozoin 
can be seen [40].  Hemozoin is a polymer of heme molecules and is the result of 
hemoglobin digestion by the parasite [41, 42].  The early trophozoite stage, 
sometimes referred to as the “ring stage”, is the only stage of development that is 
commonly observed in circulating blood with the exception of the gametocyte 
forms [43].  Mid and late trophozoite forms (Figure 3, stages 16-20) are darkly 
pigmented when stained with Giemsa as much of the RBC is taken up by newly  
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Figure 3:  Intraerythrocytic life cycle stages of P. falciparum.  Early trophozoite 
(1-15), mid to late trophozoite (16-20), schizont (21-25), merozoite (26), and 
gametocyte (27-30) stages of P. falciparum as would be seen in a Giemsa-
stained blood smear (The National Library of Medicine, 1971).   
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replicated nuclear material, which the parasite has produced in preparation for 
intraerythrocytic schizogony [39].  Late trophozoites then transition into the 
schizont stage (Figure 3, stages 21-25).  The 8-24 newly synthesized nuclei are 
surrounded packets of cytoplasm during the segmenter phase of schizogony.  
When the schizont bursts, metabolic wastes and residual material are released 
into the bloodstream along with new merozoites [44]  
 The exact mechanism involved in determining whether a parasite will 
engage in the intraerythrocytic cycle or whether it will instead develop into a 
gametocyte (Figure 3, stages 27-30) remains unclear [45-47].  However, it has 
been shown that some schizonts produce merozoites that invade RBCs and 
commit to the 10-12 day development period during which a single 
microgametocyte or macrogametocyte is formed [48-51].  Fewer 
microgametocytes are formed than macrogametocytes and these life cycle 
stages tend to be crescent shaped with a total length one and one half times 
greater than that of the RBC [52]. In addition, microgametocytes are darkly 
pigmented upon staining, have a large concentrations of hemozoin in their 
center, and contain evenly diffused chromatin.  In contrast, the chromatin of 
macrogametocytes is more concentrated giving the macrogametocyte a darker 
color when compared to microgametocytes. 
 The developmental stages of P. falciparum that take place within the 
mosquito also have distinct morphological characteristics; however, they are not  
described here (see [53] for a review) as this body of work elucidates aspects of 
parasite biology during P. falciparum development within the human host .  
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Pathogenesis of P. falciparum Malaria 
 Pathology associated with malaria infections is caused by the 
inflammatory response of the host and by the depletion of red blood cells, which 
causes anemia [54, 55].  Severity of infection is largely determined by the 
species of Plasmodium with which the host is infected.  P. vivax and P. ovale 
cause less complicated forms of malaria, but are able to lie dormant during 
exoerythrocytic stages of parasite development and are thus able to avoid the 
host immune response [56].  P. falciparum infections cause the most severe 
pathology [57].  Common symptoms during the initial stages of malaria are flu-
like and involve all or some of the following: loss of appetite, muscle pain, fatigue, 
headache, and slight fever [58].  The first paroxysm, which is a cycle of chills and 
fever, occurs anywhere from 6 to 14 days post inoculation and lasts anywhere 
from 20-36 hours in P. falciparum infections as these parasites tend to be less 
synchronous than other malaria parasites in vivo [59-61].  Inhibition of cellular 
pathways involved in parasite development within human RBCs has the potential 
to reduce the clinical consequences of malaria infections as replication during 
this time results in human pathology.  However, little is known about the 
regulation of molecular pathways that contribute to parasite proliferation during 
intraerythrocytic growth.  By targeting and inhibiting proteins that are active 
during these stages it may be possible to elucidate parasite replication 
mechanisms and to identify potential antimalarial drug targets, which would later 
make the identification lead compounds for antimalarial drug design. 
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History of Antimalarial Chemotherapy 
 One of the first chemical compounds used to treat malaria was the drug 
quinine, which is a component of cinchona tree bark [62].  The origin of quinine in 
Europe as a treatment for malaria is still a mystery.  One explanation suggests 
that in 1629 the Spanish Countess of Chincona, who was traveling with her 
husband, arrived in Lima, Peru and shortly thereafter became ill with fever [63, 
64].  In an account from Sebastinao Bado, the Countess drank a concoction 
made from the bark of a local tree and was cured of her fever ailment [65].  The 
Countess then traveled back to Europe with her husband and introduced the bark 
as a treatment for malarial ailments.  However, in 1930 a biography of the Count 
of Chinchon authored by his secretary, Don Antonio Suardo, was discovered that 
contradicts this series of events.  Unaware of the future discovery of the diary, 
Carolus Linnaeus, the Swedish botanist, named the tree from which quinine is 
derived for the Spanish Countess [66].  Unfortunately, he misspelled the title 
name, Chinchon, and now the tree is referred to as the cinchona tree.  
Regardless of how the compound was identified, the widespread adoption of 
quinine as an antimalarial occurred and it can be said for certain that it was and 
remains a crucial compound for the treatment of malaria [67].  Indeed, until the 
1940s, it was the only widespread compound used as an antimalarial [68]. 
 The drug chloroquine, discovered by Hans Andersag in 1934, was largely 
ignored as a potential antimalarial because it was thought to be too toxic to 
administer to humans [69].  However, after US government-sponsored clinical 
trials, chloroquine was found to be useful as an antimalarial and in 1947 it was 
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introduced for prophylactic use [69].  The antimalarial effects of chloroquine are 
due to the ability of the drug to prevent the crystallization of heme molecules, 
which are a product of host cell hemoglobin digestion [70].  Loose heme 
molecules are toxic to the parasite, therefore, these molecules are biocrystallized 
into a substance called hemozoin that is much more readily tolerated by the 
organism [71].  Upon entering the parasite cell, chloroquine molecules quickly 
become protonated and are unable to leave the parasite cell by diffusion [72].  
The protonated chloroquine molecules cap heme molecules, making them 
unable to biocrystallize heme.  Modified heme molecules accumulate within the 
parasite, become toxic because they prevent normal function of the parasite 
membrane, and eventually cause lysis of the parasite cell. 
 While chloroquine has been shown to interfere in the metabolism of 
hemoglobin by the parasite, other successful antimalarials target different 
essential pathways in parasite development.  Success treating bacterial 
infections with antifolates had shown researchers that these drugs were able to 
inhibit necessary routes of DNA synthesis within several species of bacteria [73, 
74].  Researchers then began to determine whether antifolate compounds would 
result in similar pathway disruptions in malaria parasites.  These efforts were 
successful and sulpha drugs and folic acid antagonists such as sulphadoxine, 
pyrimethamine, and proguanil were shown to inhibit parasite replication by 
preventing synthesis of folic and folinic acid [75, 76].  The prevention of folic and 
folinic acid synthesis prohibits the formation of nucleotides for DNA synthesis, 
which is necessary for the parasite to complete schizogony.  Adoption of an 
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antibacterial treatment strategies for the treatment of parasitic disorders such as 
malaria represented a paradigm shift for researchers of tropical medicine:  it may 
not be necessary to search through the proverbial haystack to discover 
antiparasitic compounds when one can harness the information gathered from 
previously successful drug discovery efforts. 
 While new strategies for antimalarial drug discovery were slowly 
emerging, so was parasite resistance to widely used and effective antimalarial 
drugs.  Resistance of parasites to chloroquine was first observed in Colombia in 
1956 [77].  Soon after, reports of resistance began to emerge in multiple regions 
from the Colombian-Venezuelan border to Kenya and Tanzania. The Vietnam 
war was being waged and as many as 1% of U.S. troops were succumbing to 
malaria infection per day [78].  In the wake of this devastation, the U.S. launched 
what was, at the time, the largest drug discovery effort ever undertaken.  From 
this effort, which involved a screen of over 250,000 compounds, the drugs 
mefloquine and halofantrine emerged and were marketed by F. Hoffmann-La 
Roche and Smith Kline Beecham as Lariam and Halfan respectively [78].  While 
the exact mechanism of action for the aforementioned antimalarial drugs has not 
fully been uncovered, they are similar in structure to chloroquine and thought to 
act in much the same way.  Since the introduction of mefloquine, adverse side 
effects and unfavorable drug interactions have emerged that render this drug 
less effective or dangerous for many individuals [79].  
     While the US was desperately trying to bolster its Vietnam War efforts 
with a massive drug discovery initiative, China was undergoing a movement that 
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in the west was known as the Chinese Cultural Revolution.  During this time, Tu 
Youyou, a Chinese pharmacologist and her team of investigators were also 
working to identify a cure for malaria [80].  The Vietnam War and the resulting 
malaria infections that ensued were also wreaking havoc on the soldiers of 
China’s ally, North Korea.  In order to alleviate North Korea’s malaria problem, 
the Chinese government set up a large drug discovery project called 523 with the 
express goal of pinpointing an effective cure for malaria that would allow North 
Korean soldiers to have the upper hand in a jungle war [81].  After screening 
thousands of synthetic compounds against the parasite without success, Chinese 
scientists resorted to reading ancient medical texts with the hope of harnessing 
traditional Chinese herbal remedies for a cure.  It was at this time that Tu Youyou 
uncovered the writings of Ge Hong in a text, Emergency Prescriptions Kept Up 
One’s Sleeve, written 1600 years before [80].  In this book, Ge Hong described 
the preparation of a tea from Artemisia annua, the sweet wormwood plant that 
was used as a treatment for intermittent fevers.  Although artemisinin was tested 
previously with little efficacy against the parasite, the preparation method 
suggested in the ancient text led researchers to believe that it was necessary to 
prepare an artemisinin formula that would assure the compound retained activity.  
When Chinese researchers tested the formula, it was 100% effective at treating 
mice and monkeys infected with drug-resistant Plasmodium [81].  In 2011, Tu 
Youyou was awarded the Lasker~DeBakey Clinical Medical Research Award for 
the discovery of artemisinin.  The discovery of artemisinin represents the last 
historically significant finding of a truly effective antimalarial compound.  While 
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this compound has remained efficacious in treating the most deadly cases of 
malaria, the emergence of artemisinin-resistant parasite strains has now been 
observed in four nations [1].          
Resistance Mechanisms 
 Perhaps the most alarming problem concerning malaria is the growing 
resistance of malaria parasites to almost all known traditional antimalarial 
treatments.  Parasite resistance to first line drug treatments, such as chloroquine, 
is encountered almost everywhere malaria is endemic 
(www.cdc.gov/Malaria/drug_resistance).  The replication rate of Plasmodium 
species allows the parasite to readily adapt to changes in its environment 
including the toxic drug effects of many antimalarials.  Resistance quite often 
occurs as a result of changes in drug targets where a single point mutation in a 
gene in the parasitic DNA leads to an amino acid change in the protein encoded 
by that gene [82].  This amino acid difference decreases the affinity of the 
inhibitor for its target and renders the inhibitor ineffective or at least less effective.  
Point mutations in dihydrofolate reductase (DHFR) and dihydropteroate synthase 
(DHPS) are responsible for the resistance of parasites to the anti-folate drugs 
pyrimethamine and sulphadoxine respectively. Survival strategies are based in 
part on developing large numbers of daughter progeny, drug treatment eventually 
selects for those parasites that carry mutations for parasite survival.  Malaria 
strains eventually evolve drug resistance, especially when drugs are 
administered as monotherapies or lower than therapeutic dosed, and as a result 
are much less susceptible to treatment with commonly used antimalarials [83].  
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The quick and efficient replication strategy of the parasite the allows for the 
reestablishment of infection with the now more virulent form of Plasmodium. 
  Other parasitic resistance strategies result from the upregulation of 
proteins involved with shuttling substances such as antimalarial drugs out of 
cellular compartments or upregulation of proteins that metabolize toxic 
substances into less bioactive forms [84].  The upregulation of these proteins 
decreases the amount of drug that is available to bind the drug target and 
renders previously effective doses of drug ineffective.  Chloroquine resistance 
has been an observed phenomenon since the 1960s, which was only 10 years 
after its introduction [85, 86].  This type of resistance mechanism has been 
attributed to the reduction of chloroquine concentration in the food vacuole, which 
is the parasitic structure affected by this drug [87].  The reduction in chloroquine 
concentration resulted from a mutation in the gene coding for a molecular 
transporter, pfcrt [88].  However, the exact mechanism leading to this resistance 
is still unknown [89].  The significant resistance of Plasmodium parasites to the 
drug mefloquine, which is in the same drug family as chloroquine and works by 
much the same mechanism, occurred in only six years and has been attributed to 
the upregulation of multidrug resistance proteins pfmdr1 and pfcrt, which 
transport toxic substances out of the parasitophorous vacuolar membrane [90].     
 Artemisinin and artemisinin derivatives, which are effective against 
resistant strains of malaria parasites and are able to clear parasites from the 
body quickly, are the latest drugs for which parasites are developing resistance 
[1].  Researchers along the Thai-Cambodian border have warned that artemisinin 
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resistance is not only evolving in parasites, but also that the emergence of 
resistance must be contained in the very near future in order to prevent the 
spread of resistant parasites strains to neighboring regions; a migration which 
could have devastating effects [91-94].  Administering a single drug with a single 
molecular target as a treatment for malaria increases the risk of resistance 
development because it is likely to exert a selective pressure that would result in 
mutation of that target.  As such, the World Health Organization has suggested 
that artemisinin combination therapy (ACT) be administered as first line drug 
treatment for all cases of uncomplicated falciparum malaria in order to reduce the 
likelihood of resistance development (WHO guidelines for the treatment of 
malaria, 2006).  A recent study suggested that parasite resistance to 
dihydroartemisinin (DHA) was associated with an increase in both pfmdr1, a 
multidrug resistance transporter, copy number and antioxidant activity within 
DHA-challenged P. falciparum parasite clones [95].  If strains of malaria parasites 
develop that are increasingly resistant to ACT, a massive global public health 
problem will arise and for the first time in 50 years, there will be no effective 
treatment for the most virulent forms of malaria.   
 Clearly there is a need to develop novel and efficacious drug treatments 
for the treatment of multidrug-resistant malaria strains.  When researchers began 
to understood that they could utilize drug development strategies that had been 
previously successful in the treatment of bacterial diseases and apply those 
strategies to treating parasitic diseases, for the first time drug discovery efforts 
could be directed at inhibiting specific necessary pathways within the parasite.  In 
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recent years it has become possible to make the drug discovery process even 
more efficient as we are now able to target individual proteins within a disease 
organism or cell in order to inhibit necessary functions of that organism. 
Protein Kinases 
 Protein kinases are biological macromolecules that regulate cellular 
processes by transferring a terminal phosphate group from ATP to an amino acid 
residue with a free hydroxyl (-OH) on a target protein.  Most kinases transfer 
phosphate groups to either serine or threonine residues; however, there are 
subsets of kinases that act specifically on tyrosine or on all three types of 
residues.  Bacterial cells, plants, and some less complex eukaryotes also contain 
histadine kinases, which autophosphorylate on a histadine residue and transfer a 
phosphate group to an aspartate residue on the target protein.  The 
phosphorylation events that are carried out by kinases are reversible so proteins 
that are activated, inactivated, or otherwise modified by the addition of a 
phosphate group can return to their original state of activity with the removal of 
the phosphate group by another type of protein, a phosphatase.  
 Protein kinases are responsible for the regulation of cellular processes 
such as homeostasis, growth, and cell division [96, 97].  The deregulation of 
these critical proteins has been associated with disease processes such as 
diabetes, cancer, and several neurodegenerative disorders [98, 99].  Drug 
discovery aimed at the inhibition of protein kinases has afforded the development 
of several successful drug therapies such as imatinib, which was marketed by 
Novartis under the name Gleevec for the treatment of chronic mylogenous 
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leukemia in 2002 [100].  At the current time, more than 11 kinase inhibitors have 
successfully progressed through the drug discovery pipeline and been approved 
for clinical use by the United States Food and Drug Administration (FDA).  In 
addition, 150 clinical trials for future kinase-targeted therapies are ongoing  [101].  
Of the inhibitors approved for clinical use, Sunitnib (Pfizer), Pazapanib 
(GlaxoSmithKline), and Sirafenib (Onyx and Bayer Pharmaceuticals) target 
VEGFR isoforms and Erlotinib (Roche), Gefitinib (AstraZeneca), and Lapatinib 
(GlaxoSmithKline) selectively target EGFR.  KIT, PDGFR, and ABL1-2 are the 
molecular targets of Dasatinib (Bristol Myers), Nilotinib (Novartis), and Imatinib.  
Dasatinib targets SRC as well.  Interestingly, all the aforementioned drugs act at 
least in part by competing for the ATP-binding site of their respective kinase 
targets (reviewed in [102]).  These drug discovery successes lend credence to 
the fact that despite the general evolutionary conservation of the kinase ATP-
binding site, the selective targeting kinases with ATP competitive inhibitors is not 
only feasible but is also an effective drug design strategy.  The large quantity of 
research in the area of kinase inhibition, especially in oncology research, has 
yielded kinase inhibitors, such as cyclin-dependent kinase inhibitors, that are 
selective for particular kinases and can be utilized as scaffolds for future drug 
screening efforts.  Recent achievement in the area of kinase inhibition for 
disease treatment along with the need to identify new and effective antimalarial 
drugs point to kinase inhibition as a potential tool for antimalarial drug discovery.     
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The Malaria Kinome 
 There are between 86-99 protein kinases in the P. falciparum genome 
depending on the algorithm used for classification [103, 104].  In order to 
preserve the ability to complete phosphate transfer, the catalytic domain of 
kinases has remained relatively well conserved across genomes in comparison 
to other non-catalytic domains within these proteins, which have been at liberty to 
diverge evolutionarily [105].  That kinase domains have such a great degree of 
conservation has raised questions as to whether it is possible to identify inhibitors 
that are selective for Plasmodium kinases.  Indeed, it is imperative during the 
drug discovery process to evaluate the likelihood that molecules will affect host 
kinases and thus likely have deleterious side effects.  Differences in structure 
and function between parasite and host kinases would increase the likelihood 
that inhibitors targeting P. falciparum kinases will not interfere with host kinase 
function and indeed, there are several characteristics of P. falciparum kinases 
that increase the probability of identifying parasite kinase-selective inhibitors. 
 Many canonical motifs are highly conserved throughout all typical protein 
kinases [106-110] and with few variations, these motifs are present in P. 
falciparum kinases as well. Conserved motifs are generally located within the 
catalytic domain of the protein, while other regulatory pockets that surround the 
catalytic domain and insertions of low complexity tend to be much more divergent 
in sequence [111, 112].  By identifying small molecules that take advantage of 
small differences between human and malaria kinases, it is possible to 
selectively target parasite proteins.  The publication of the P. falciparum genome 
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sequence in 2002 and the accumulation of this sequence data in the Plasmodium 
database PlasmoDB have enabled the ongoing characterization of proteins from 
this genus [104, 113].  Interestingly results from analysis of the P. falciparum 
kinome revealed that many kinases from this genus are chimeras of mammalian 
kinases and have characteristics and sequences from more than one kinase 
family [104, 114].  Functional analysis of selected kinases from this dataset has 
revealed that sequence similarity in these proteins does not necessarily indicate 
protein function, which underscores the unique nature and need for further 
functional characterization of Plasmodium proteins [115, 116].   
 Included in the kinome are kinases that cluster within traditional eukaryotic 
protein kinase (ePK) families and kinases that are more divergent in sequence 
from traditional ePKs and cannot be clustered into a family  (Table 1).  The latter 
group of kinases is termed the orphan kinase group as its members have no ePK 
ortholog.  One such group, the FIKK family, is limited to organisms from the 
phylum Apicomplexa.  Generally, any given Apicomplexan organism will have no 
more than one representative from this kinase family within its kinome [117].  
Unlike other Apicomplexan organisms, P. falciparum contains twenty such 
proteins which localize to the RBC membrane and participate in conveying 
extracellular signals between the parasite and host [117, 118].  The unique 
nature of orphan kinases make these proteins promising targets for drug design 
and inhibitors of orphan kinases may leave host cell kinases unaffected and 
cause fewer deleterious side-effects when compared to other less selectively 
targeted drugs. 
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Table 1:  The Malaria Kinome.  Distribution of P. falciparum kinases into 
eukaryotic and unclassified kinase groups as well as kinase family designation, 
representation of each kinase family within the P. falciparum kinome, and a list of 
characterized proteins from each group [119]. 
 
Classification Major Kinase Group Number of 
Proteins 
within 
Kinome 
Characterized Proteins  
 
   
Eukaryotic protein 
kinase (ePK) 
Cyclic-nucleotide and 
calcium/phospholipid 
kinase (AGC) group 
 
5 
 
 
PfPKA (Syin et al., 2001)                   
PfPKG (Deng & Baker, 2002)                             
PfPKB (Kumar, Vaid, Syin, & 
Sharma, 2004) 
   
 Cyclin-dependent 
(CDK), mitogen-
activated (MAPK), 
glycogen-synthase 
(GSK), and CDK-like 
kinase (CMGC) group 
 
26 Pfcrk-1 (C. Doerig et al., 
1995) 
Pfcrk-3 (Ward, et al., 2004) 
Pfcrk-4 (Ward, et al., 2004) 
Pfcrk-5 (Ward, et al., 2004) 
Pfmap-1 (C. M. Doerig et al., 
1996; Graeser, Kury, 
Franklin, & Kappes, 
1997; Lin, Goldman, & 
Syin, 1996) 
Pfmap-2 (Dorin et al., 1999) 
PfPK5 (Ross-Macdonald, 
Graeser, Kappes, 
Franklin, & 
Williamson, 1994)  
PfPK6 (Ross-Macdonald, et 
al., 1994) 
Pfmrk (Li, Robson, Chen, 
Targett, & Baker, 
1996) 
    
 Calmodulin-dependent 
kinase (CaMK) group 
 
13 PfCDPK1 (Zhao et al., 1994)  
PfCDPK3 (Li, Baker, & Cox, 
2000) 
PfCDPK4 (Billker et al., 2004)  
PfCDPK5 (Dvorin et al., 2010) 
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Table 1 Continued 
 
  
Classification Major Kinase Group Number of 
Proteins 
within 
Kinome 
Characterized Proteins  
 
   
 Tyrosine kinase (TyrK) 
group 
 
0 NA     
 Casein kinase 1 (CK1) 
group 
 
1 PfCK1 (Barik, Taylor, & 
Chakrabarti, 1997)  
 
    
 Yeast sterile mutant 
(STE) group 
 
0 NA     
 Tyrosine kinase-like 
(TKL) group 
 
4 PfTKL3 (A. Abdi, 
Eschenlauer, Reininger, & 
Doerig, 2010) 
    
 Aurora kinase family 3 PfArk-1 (Reininger, Wilkes, 
Bourgade, Miranda-Saavedra, 
& Doerig, 2011) 
 
    
  Never in 
mitosis/Aspergills 
(NIMA) group 
4 Pfnek-1 (Dorin et al., 2001; 
Dorin-Semblat et al., 2011)  
Pfnek-2 (Reininger et al., 
2009)  
Pfnek-3 (Ward, et al., 2004) 
Pfnek-4 (Reininger, Garcia, 
Tomlins, Muller, & Doerig, 
2012) 
    
Other FIKK family 20      
 Orphan kinases NA PfPK7 (Dorin, et al., 2005; 
Dorin-Semblat, Sicard, 
Doerig, & Ranford-Cartwright, 
2008; Koyama et al., 2012; 
Merckx et al., 2008) 
PfPK9 (Philip & Haystead, 
2007) 
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The cyclin-dependent (CDK), mitogen-activated, glycogen synthase, and CDK-
like group (CMGC) accounts for more than 25% of all malaria kinases.  In other 
eukaryotic organisms, this group is important for cell proliferation and 
development and the large representation of CMGC kinases underscores the 
importance of cellular replication within the parasite [120]. 
 The CamK group is also highly represented in the parasite, which may 
belie the importance of calcium in parasitic signaling pathways.  Also of note is 
the marked absence of kinases that cluster within the TyrK or STE groups and 
the traditional three-component MAPK pathway appears to be absent as there 
are no MAPKKs or MAPKKKs within P. falciparum [104].  The absence of these 
kinases may indicate modes of cellular regulation within the parasite that are 
distinct from those of other eukaryotic organisms.  Disruption of kinase function 
during cell replication and analysis of downstream effects after this disruption 
may provide clues to the abstruse mechanisms of regulation in intraerythrocytic 
P. falciparum parasites. 
P. falciparum Protein Kinase 7 (PfPK7) 
 The phylogenetic and mechanistic differences between host and 
Plasmodium kinases are particularly pronounced in orphan kinases from this 
species.  In an effort to uncover a MAPKK homolog in the Plasmodium genome, 
researchers identified PfPK7, a kinase that displays regions of sequence 
similarity to more than one protein kinase family [115].  The C-terminal region 
displays maximal homology with MEK3/6 while the N-terminal region is more 
closely related in sequence to fungal protein kinase A.  This protein is expressed 
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in both sexual stages in the mosquito vector and asexual stages in the human 
host.  While PfPK7 was able to autophosphorylate and to phosphorylate several 
substrates, it was not able to phosphorylate MAPK homologs in vitro; thus 
making it an improbable candidate for a Plasmodium MAPKK [115].  
 Co-crystallization of PfPK7 both with an ATP analog and with a PfPK7 
inhibitor revealed several interesting structural and functional aspects of this 
protein.  PfPK7 is 343 residues in length [121].  The N-terminal lobe contains two 
alpha helices, while the C-terminal lobe is comprised of twisted antiparallel β-
sheets.  Four low complexity inserts are found in this protein and the highly 
conserved serine, threonine or negatively charged residue that would normally 
reside in the activation loop of active kinases has been replaced in this kinase by 
a positively charged residue.  As a consequence, PfPK7 ligands have negatively 
charged atoms, which bind to this site.  In addition, the P. falciparum myelin basic 
protein, PFRAB11B, has been pinpointed as an endogenous substrate [121].  In 
the same study by Merckx et al. (2008) the researchers found that the small 
molecule, K510, was able to compete with ATP for the ATP-binding site and 
inhibit this protein during thermal shift assays.   
 A high-throughput screen of small molecules revealed several 
imidazopyridazine compounds that showed an inhibitory effect on the function of 
PfPK7 in vitro and chemical synthesis yielded several more molecules with the 
same imidazopyridazine core that had varying inhibitory effects against the 
enzyme [122].  One research group utilized the imidazopyridazine molecules 
from the previous study to build 2D and 3D QSAR models in order to predict the 
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binding affinity of small molecules for the PfPK7 binding site.  A computational 
docking study of the imidazopyridazine molecules was also conducted to define 
probable interactions between these molecules and the PfPK7 binding site [123].  
Several studies have contributed information regarding the structure of PfPK7 
and its ATP-binding site; however, in order to evaluate its potential as an 
antimalarial drug target, it is essential to determine the effect of these inhibitory 
compounds in blood stage cultures of the parasite. 
 In another study, PfPK7(-) clones were shown to have a decreased 
asexual growth rate during intraerythrocytic life cycle stages as fewer merozoites 
were produced per schizont and a decreased capability of forming oocysts in the 
mosquito vector during sexual stage development was also observed [124].  A 
decrease in schizont population with PfPK7 inactivity can be explained in part by 
data that suggest PfPK7 is involved in melatonin signaling in the parasite [125].  
It has previously been shown that melatonin signaling regulates the malaria cell 
cycle by increasing intraerythrocytic schizont stage populations by a mechanism 
involving an increase in cytoplasmic calcium concentrations [126, 127].  
Furthermore, PfPK7(-) clones were unable to enrich schizont populations in the 
presence of melatonin and an expected increase in cytoplasmic calcium 
concentration was not detected [125].  Data from these studies suggest this 
kinase is involved in a molecular pathway that aids in the regulation of the 
malaria cell cycle.  The putative role of PfPK7 in parasite proliferation during the 
erythrocytic stages of parasite development, which are directly responsible for 
disease progression combined with data that suggest disruption of PfPK7 activity 
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contributes to decrease intraerythrocytic growth rates make this protein an 
attractive target for drug intervention.  Small molecule inhibitors of this protein 
could potentially be formulated into an antimalarial therapy that would reduce 
parasite burden and alleviate the devastating and often fatal symptoms 
associated with P. falciparum malaria.  In addition, defining optimal 
characteristics of a PfPK7 inhibitor, further elucidating interactions between small 
molecule inhibitors and the PfPK7 ATP-binding site, and determining whether 
PfPK7 inhibitors affect intraerythrocyte parasite growth will aid future research 
aimed at pinpointing a small molecule that would selectively inhibit this kinase 
and allow for investigation of its biological role in the parasite. 
Malaria Cell Cycle Regulation 
 As kinase function plays such a pivotal role in the eukaryotic cell cycle and 
disruption of cell cycle kinases has been shown to impede cellular replication, 
inhibition of kinases that function during parasite replication may provide a way to 
halt intraerythrocytic growth of P. falciparum parasites [128, 129].  The value of 
parasite cell cycle disruption is twofold:  first, it may point to new promising drug 
targets that are imperative for parasite survival and second, it may serve as a 
valuable tool for investigating poorly understood malaria cell cycle protein 
expression patterns.   
 The overall goal of the cell cycle in eukaryotic cells is not only to achieve 
cell division but also to ensure that genetic information is accurately passed on 
from one generation to the next.  P. falciparum also seeks with its cell cycle to 
create sufficient daughter progeny to ensure its own survival in the harsh 
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environment of the vertebrate host.  The parasite accomplishes this goal by 
producing 8-32 daughter cells during schizogony.  As discussed above, the 
malaria parasite must also complete replicative cycles in many different 
environments [130]: sexual stage development takes place inside the arthropod 
vector while both the exoerythrocytic and intraerythrocytic life cycle stages 
develop within humans.  In order to complete replication, the parasite must 
temporally express and regulate proteins that will ensure the correct sequence of 
cell cycle events during each of these stages [131-133].  Here we focus on 
modes of cell cycle regulation that occur during the intraerythrocytic stages of 
parasite development as these stages are the direct cause of human pathology. 
 Little is known about the regulation of the parasite life cycle in comparison 
to the vast amount of information that is available about regulation of the 
mammalian cell cycle.  In order to set a framework for the malaria cell cycle, the 
following section includes information that relates what we know about malaria 
cell cycle regulation to what is known about the cell cycle in more complex 
eukaryotic organisms. Typical higher eukaryotic cell cycle characteristics and 
regulators as well as known characteristics and regulators of the malaria cell 
cycle are discussed.   
 In contrast to the asexual intraerythrocytic malaria cell cycle, which 
produces many progeny, the end products of asexual division in higher 
eukaryotic cells are two daughter cells that can be considered genetically 
identically to the parent cell.  In higher eukaryotes, regulation of this cell cycle is 
accomplished by kinases from Aurora, Polo, and NIMA families and particularly 
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by CDKs which, while not catalytically active one their own, drive and regulate 
the cell cycle when in conjunction with a type of regulatory protein called a cyclin 
[134].  The action and control of different CDK/cyclin complexes within context of 
the cell cycle as well as other cell cycle regulators are well characterized in 
higher eukaryotes [135-137].  In contrast, researchers are only now beginning to 
understand the biological role of these critical cell cycle molecules in the malaria 
parasite [138] as reviewed in [139].   
 While the progression of the cell cycle in malaria is not clearly understood 
at this time, in mammalian cells the cell cycle consists of four distinct phases.  
These are growth phase 1 (G1), in which the cell grows and acquires the 
necessary means to duplicate the genome; synthesis (S), in which the cell 
semiconservatively duplicates its genome one time; growth phase 2 (G2), in 
which the cell continues to grow and prepare for cell division; and mitosis (M), in 
which the duplicated nuclear material is divided into separate packets [140].  
Mitosis generally leads to cytokinesis, which is the division of the cytoplasm.  Cell 
cycle is highly regulated in mammalian cells and the deregulation of this process 
can cause cell cycle arrest and finally apoptosis or cancer, which is characterized 
by uncontrolled cell division [141-143].  CDKs, as previously described, 
contribute to these control mechanisms and exert their influence by associating 
with cyclins and other proteins that regulate CDK function such as CDK inhibitors 
(CKIs) [134, 140, 144].  Additional regulatory proteins such as p53 provide 
checkpoints at which time the cell can decide if all the necessary requirements to 
continue with cell cycle progression are met [145-147]. 
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        Most eukaryotic cells exist in a non-dividing state called (G0) and in order 
to divide, a cell must enter a G1 state and begin to synthesize necessary factors 
for division. The progression passed G1 is determined by the size of the cell and 
the presence or absence of mitogenic factors [148, 149].  The restriction point 
that resides between the G1 and S phases is controlled by retinoblastoma protein 
(pRb) and a family of transcription factors [150, 151].  Phosphorylation of pRb by 
the Cdk4, 6 – cyclin D and later Cdk2-cyclin E, which governs centrosome 
duplication events prior to S phase permits passage through the checkpoint [152-
156].  CKIs also provide regulation at this time.  The cyclin dependent kinase 
inhibitor p21 inhibits CDK1/2 complexes and the expression of this protein is 
controlled by the tumor suppressor protein p53 [157].  In addition, the cell must 
check for the presence of damaged DNA, which would be detrimental to newly 
formed daughter cells.  DNA damage increases the activity of kinases that 
activate p53, which induces cell cycle arrest with the idea that the cell will have 
more time to correct DNA damage [158].  Progression through this checkpoint is 
also largely controlled by the presence of critical growth factors, without which 
the cell cycle cannot continue  [149].   
        S phase is the DNA synthesis phase of the cell cycle.  During this phase, 
the genomic content of the cell must be duplicated accurately.  During late 
anaphase or early G1, the origins of replication complexes (ORCs) are formed 
along the DNA [159] and DNA synthesis begins at these complexes, which must 
commence only one per cell cycle [160].  In order for the transition from G1 to S 
to proceed in an ordered fashion, cyclins must be expressed and then degraded 
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in a temporally accurate manner [161].  Cdk2-cyclin E first phosphorylates pRb.  
Phosphorylation of pRb permits the degradation of cyclin D and allows for the 
accumulation of cyclin A, which then complexes with Cdk-2 and allows for the 
progression into S phase [162-164].  Cyclin E is quickly degraded as cyclin A is 
upregulated and the Cdk2-cyclin-A complex forms [165].  This complex 
phosphorylates substrates and activates proteins necessary for synthesis to 
continue.  Cdc7 kinase also positively regulates synthesis of new DNA by 
phosphorylating Mcm proteins that are associate with DNA [166].  An intra-S 
checkpoint exists to check for the presence of any abnormalities in DNA 
synthesis including any DNA breaks and blocked replication forks [167-169].   
        During G2 phase, the cell is preparing to enter mitosis.  Progression from 
G2 to M phase also depends on the presence of cyclins, in particular cyclin B, 
which is upregulated prior to mitosis [170, 171].  Cyclin B associates with Cdk1 
and the Cdk1-cyclinB complex is then shuttled to the nucleus where it permits 
transition into mitosis.  Cdk1 is highly regulated by Cdc25, Wee1, and Myt1 and 
the shuttling of these inhibitory and activating molecules from the nucleus to the 
cytoplasm.  Cdk7 is a cyclin-dependent kinase activating kinase (CAK) that 
positively regulates the activities of other kinases including Cdk1, Cdk2, Cdk4, 
and Cdk6  (as reviewed in[172]) along with the accessory proteins cyclin H and 
MAT1 [173-176].  Soon thereafter, cyclin B is degraded as the cell proceeds with 
mitosis [171].  During the G2 checkpoint, the cell assess whether it is safe to 
separate sister chromatids.  During this checkpoint, the presence or absence of 
damaged DNA is sensed [177-182].  If DNA damage exists, protein kinases 
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transduce a signal indicating to the cells that damage exists and effector 
molecules will arrest the cell cycle.   
        Mitosis is cell cycle stage where the nucleus divides and two daughter 
cells are formed.  Before entry into mitosis, the genome is duplicated as are 
centrosomes and histone proteins are synthesized.  Asters form at microtubule 
organizing centers in prophase.  During prometaphase, chromosomes attach to 
microtubules via their kinetochores from both poles of the cell.  Microtubules 
rearrangements pull chromosomes until they line up along the metaphase plate 
during metaphase.  During the metaphase checkpoint, chromosome alignment 
and spindle assembly are checked by proteins such as the the Mad1/Mad2 
complex and Bub1 that make up the spindle assembly checkpoint (SAC) [183-
185].  The SAC ensures that anaphase does not commence until all sister 
chromatid pairs are attached on either end of their kinetochore.  Anaphase is 
triggered by activation of the anaphase-promoting complex/cyclosome (APC/C) 
along with the associated protein Cdc20.  This activation triggers a series of 
events that leads to release of the phosphatase Cdc14 from the nucleolus and 
the subsequent decrease in Cdk1 activity as well as degradation of anaphase 
inhibitor proteins [186, 187].  Chromosomes then migrate to opposite poles and 
the cell makes preparations for the final stages of mitosis.  During telophase, the 
cleavage plane forms and cytokinesis follows shortly thereafter.  The end product 
of this division in mammalian cells is the formation of two daughter cells. 
       While it is anticipated that cell cycle regulators and mechanisms are 
conserved to a degree, it is evident modes of P. falciparum cell cycle regulation 
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differ from those of previously well-characterized organisms.  The 
intraerythrocytic life cycle stages, described in detail above, consist of the ring or 
early trophozoite stage, the feeding trophozoite stage, and the schizont stage, in 
which 8-32 merozoites are formed and are ultimately released to infect new 
erythrocytes.  Therefore, in contrast to the mammalian cycle, which produces 
only two daughter cells per cell cycle, the parasite must produce many new 
daughter cells per round of replication.  The preinvasion merozoite and ring 
stages are thought to be analogous to the G1 phase of the mammalian cell cycle 
and S phase can be thought of as beginning around 18 hours post invasion (hpi) 
[188-192].  At this time, the haploid DNA content has been observed to be 
multiplied as much as 16-20 fold in 4 to 6 hours [193].  In contrast to the highly 
organized division of nuclear material in mammalian cells, the genetic 
duplications in P. falciparum are asynchronous both within one schizont and also 
between schizonts [194].  This is highly unusual considering that schizonts in a 
particular area of the body are subjected to the same environmental factors.  
Another important distinction between mammalian cell replication and that of P. 
falciparum is a difference in nuclear envelope dynamics.  The nuclear envelope 
disintegrates in mitosis and is reformed in mammalian cells, but  this structure 
remains intact during schizogony [195]. 
   The phase of the parasite life cycle that is analogous to G1 phase in 
mammalian cells takes place during growth of preinvasion merozoites and ring 
stages of P. falciparum.  During this time, Pfcyc-1, Pfmrk, and Pfcrk-3, which are 
related to CDKs or their associated proteins, are expressed as are PfPK1 and 
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Pfmap-2.  Pfmrk is a protein kinase that is related in sequence to mammalian 
CDK7 and is present both during G1 phase and S phase [196].  In mammalian 
cells, CDK7 pairs with cyclin H and is involved in cell cycle control and indeed, 
Pfmrk has been shown to stably complex with human cyclin H, which increases 
kinase activity [197].  However, in humans CDK7 acts to regulate the activity of 
other human kinases such as CDK1 and it was shown that the putative 
Plasmodium homolog of CDK1, PfPK5, is not affected by interaction with Pfmrk 
in vitro [116]. This lack of activation may indicate that while Pfmrk is similar in 
sequence to PfPK7, it does not function as a true CAK and further studies are 
needed to clarify the role of this kinase during cell proliferation.  Pfcyc-1 is a 
cyclin that is expressed prior to S phase [116].  It is most closely related in 
sequence to mammalian cyclin H and it has been shown that Pfcyc-1 is able to 
stimulate the phosphorylation of histone H1 and CTD by Pfmrk [116].  However, 
Pfcyc-1 has also been shown to activate PfPK5 much more strongly than Pfmrk.   
  Pfcrk-3 is a large Plasmodium kinase that is active during G1 and  S 
phases and has been shown to colocalize with histone proteins [198].  It displays 
maximal homology to eukaryotic CDKs that participate in transcription control.  
Data suggest that this protein acts in complex other proteins and 
coimmunoprecipitation of Pfcrk-3 with its associated proteins revealed a complex 
that possessed both kinase and histone deacetylase activities, which is 
consistent with the known activity of CDKs that have been shown to exert 
transcriptional control by associating with proteins that modify chromatin 
structure.    
   
 
  
 
 
40 
  During S phase, nuclear replication takes place.  In contrast to mammalian 
cell S phase, P. falciparum S phase continues even after the parasite has 
entered into mitosis and the parasite seems to lack a definite G2/M period [193].  
The lack of distinction between phases potentially makes distinguishing between 
proteins that are involved in synthesis and those that are involved in mitosis 
difficult.  However, microarray analysis has been able to tease out proteins that 
are expressed during early synthesis from those that are expressed primarily in 
mitosis [199].  The proteins whose expression patterns overlap may prove more 
difficult to classify.  Proteins that are expressed during parasite S phase and may 
be involved in cell cycle control include PfPK5, PfPK6, and two cyclins, Pfcyc-2 
and Pfcyc-4.   
  PfPK5 is most closely related to yeast p34cdc2 (which is also known as 
CDK1) [200].  PfPK5 is able to phosphorylate histone H1 and casein.  The 
activity of PfPK5 can be stimulated by the presence of cyclins and, in fact, it has 
been shown that PfPK5 is quite promiscuous with respect to its activation these 
proteins [116].  The expression of this protein peaks in late trophozoites and 
early schizonts and given that an accumulation of PfPK5 activity was observed in 
cell cycle inhibitor-treated P. falciparum parasites, it has been suggested that the 
protein may play a role in S phase regulation [189].   
  PfPK6 is also expressed during S phase and is similar in sequence to both 
CDKs and MAPKs [201].  This protein is active in the absence of cyclins and is 
able to phosphorylate a subunit of a protein required for synthesis of DNA 
components, malaria ribonucleotide reductase (R2).  The same study showed 
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that while PfPK6 does not contain a PSTAIRE domain that would indicate the 
presence of a cyclin-binding site on this protein, it is inhibited by the CDK 
inhibitors olomoucine and roscovitine.  
  Both putative cyclins that are expressed during S phase Pfcyc-2 and 
Pfcyc-4 are strongly associated with histone H1 kinase activity; however it is 
unclear whether the former functions as a true cyclin [202].  The latter protein, 
Pfcyc-4, shows greatest expression during segmenters (phase where cytoplasm 
accumulates around individual nuclei).  The same study characterized an 
additional protein, Pfcyc-3, which while not strongly expressed during S phase or 
schizogony, is also associated with histone H1 kinase activity and able to 
activate PfPK5. 
  Several proteins have been identified in P. falciparum with sequence 
similarity to proteins involved in DNA synthesis pathways and are maximally 
expressed during 35-40 hpi.  These proteins include PfORC1 and PfORC5, the 
homologs of which function to combine into a 6 subunit origin recognition 
complex, which then serves as the basis for the larger pre-replication complex in 
other eukaryotes [203, 204].  Additional Plasmodium proteins have been 
identified and are thought to contribute to the pre-replication complex.  Six P. 
falciparum minichromosome maintenance complex proteins [205], P. falciparum 
proliferating cell nuclear antigen [206], and P. falciparum replication protein A 
[207] have all been characterized.  The presence of pre-replication complex 
components within the parasite indicate that the process of DNA synthesis may 
occur in much the same manner as that observed in yeast or mammalian cells.  
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However, as one of the purposes of pre-replication complex assembly it to 
assure that only one round of DNA replication takes place in other cells, clearly 
there are mechanisms in the parasite that allow for both pre-replication complex 
assembly and multiple rounds of nuclear division.  
  Members of the NIMA-related protein kinase family are also regulators of 
the parasite cell cycle.  Five members of this family have been identified 
including Pfnek-1, Pfnek-3, and Pfnek-2.  Members of this family may function as 
MAPKKs in a unique Plasmodium MAPK signaling pathway [104].  The canonical 
MAPK signaling pathway generally plays a role in cell cycle progression and 
involves a MAPKKK phosphorylating a MAPKK, which in turn phosphorylates a 
MAPK.  However, this pathway remains a mystery in P. falciparum because a 
MAPKK has yet to be identified.  Pfmap-1 and Pfmap-2 are expressed in asexual 
stage parasites and are closely related to ePK MAPKs and it has been shown 
that Pfnek-3 is able to phosphorylate Pfmap-2 [208].  In addition, it has been 
shown that activity of Pfnek-1 is necessary for completion of the asexual 
intraerythrocytic life cycle [209]   
  Additional noteworthy differences between P. falciparum and cell cycle 
control in other higher eukaryotes include the fact that CDKs seem to outnumber 
cyclins in P. falciparum.  One must keep in mind however that 60% of the P. 
falciparum proteome is made up of proteins of unknown function, which may 
point to the presence of atypical cell cycle modulators [210].  Another point is that 
although several of these proteins display sequence similarity to ePKs, there are 
no definite orthologs in the P. falciparum kinome for specific mammalian kinases 
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with the exception of PfPK5 and Pfcrk-1.  A final noteworthy difference is that 
CKIs (p21, p16), which act as negative modulators of CDK function seem to be 
absent in P. falciparum [104].  Myt1 and Wee1 orthologs are also absent as is 
Cdc25.  In conclusion, the there are many differences between the machinery 
and regulatory mechanisms of P. falciparum and mammalian cell cycle 
regulation.  Several questions emerge when considering governing mechanisms 
driving P. falciparum and higher eukaryote cell cycle patterns.  Many years of 
concentrated effort will be required to reconcile these differences; however, 
discovering the keys to malaria cell cycle dynamics may help alleviate the world’s 
malaria burden by providing tools to stop parasite replication and thus disease 
progression.  
 Given the dearth of knowledge that currently exists regarding the 
biological roles of malarial kinases and the absolute necessity of finding novel 
antimalarial drugs, this study contributes information about the structure and 
function of the orphan kinase PfPK7 and provides possible leads for antimalarial 
drug design.  In addition this study utilized the previously characterize cyclin-
dependent protein kinase inhibitor Purvalanol B to explore changes in protein 
expression that result following inhibitor application during parasite S phase.  The 
main research questions from this study are as follows. 
Q1  Will a screen of three well-characterized kinase inhibitor-focused 
 libraries yield molecules that are capable of inhibiting PfPK7 in low 
 molar concentrations. 
Q2  What interactions between the ATP-binding site of PfPK7 and small 
 molecules determine the affinity of these small molecules for the 
 binding site? 
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Q3  Are small molecules from three kinase-inhibitor-focused libraries 
 able to inhibit intraerythrocytic growth of P. falciparum strain W2 
 parasites in blood stage cultures? 
Q4  Are small molecule inhibitors of PfPK7 able to inhibit 
 intraerythrocytic growth of P. falciparum strain W2 parasites in 
 blood stages cultures? 
Q5  Does application of cyclin-dependent protein kinase inhibitor 
 Purvalanol B to synchronized P. falciparum strain W2 blood stage 
 cultures during S phase result in morphological differences 
 between wildtype and inhibitor-treated parasites? 
Q6  What are the differences in protein expression profiles between P. 
 falciparum blood stage cultures that have been treated with cyclin-
 dependent protein kinase inhibitor Purvalanol B during S phase and 
 wild types parasites in the same stage of parasite growth?  
 This study contributes much needed structural information that will guide 
the harvesting of potential inhibitory compounds from chemical space in the 
future and also potentially provides a means for researchers in the future to study 
the effects of chemically knocking down PfPK7 function in the parasite; a process 
that would help elucidate the pathways in which PfPK7 functions.  Further, by 
treating synchronized parasites with cyclin-dependent kinase inhibitor Purvalanol 
B during S phase and comparing protein expression profiles from these parasites 
to protein expression patterns of wildtype parasites during the same phase of 
parasite growth, this study contributes information about potential protein 
interactions during this phase of the cell cycle and may provide insights into the 
result of inhibiting S phase machinery in P. falciparum parasites. 
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CHAPTER II 
MATERIALS AND METHODS 
Compound Libraries 
 
 The small molecules screened were purchased from EMD Millipore 
Chemicals in the form of three kinase inhibitor libraries.  Inhibitor SelectTM 96-
Well Protein Kinase Library I (539744) consisted of 80 small molecules that were 
primarily tyrosine kinase inhibitors.  Inhibitor SelectTM 96-Well Protein Kinase 
Inhibitor Library II (539745) consisted of 80 small molecules that were primarily 
selective inhibitors of kinases from the CMGC kinase group.  Inhibitor SelectTM 
96-Well Protein Kinase Inhibitor Library III consisted of 84 small molecules, which 
were primarily selective targets of serine/threonine kinases.  The majority of 
these small molecules were cell permeable and well-characterized.  In addition, 
most were ATP-competitive and suspended in dimethyl sulfoxide (DMSO) at a 
10mM concentration with the exception of three small molecules from library III, 
which were at a concentration of 5mM. 
Small Molecule Preparation 
 Small molecules 324840, 428205, 676489, 203290, 420298, 569397, 
217714, 218710, 506106, 528116, 551590, 506163 were ordered from EMD 
Millipore Chemicals and dissolved in DMSO.  Purvalanol B was purchased from 
Tocris Bioscience.  Compounds were prepared in 10 mM stock solutions, filter 
sterilized, and stored in single use aliquots at -80°C. 
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Protein Preparation 
 PfPK7 gene condon optimization, synthesis of the coding region of PfPK7, 
subcloning into a bacterial expression vector, optimization of protein expression, 
and verification of protein expression were carried out by GenScript Corp. New 
Jersey, USA.  Protein was shipped on dry ice, aliquotted into single use aliquots, 
and stored at -80°C. 
ATP Luminescence Assay 
 An ATP luminescence assay, which determines levels of kinase activity by 
measuring residual ATP after a kinase reaction, was used to quantify PfPK7 
activity levels after incubation with each small molecule.  Kinase-Glo® 
Luminescent Kinase Assay (Promega) was used and the suggested protocol was 
optimized for protein and ATP concentration. Kinase reactions took place at a 
final volume of 50 µl and each small molecule was initially screened against 
PfPK7 at 0.1 µM, 1 µM, and 10 µM in triplicate.  Small molecules were incubated 
in master mix (40 mM HEPES, 15 mM MnCl2, 15 mM MgCl2, 50 mM NaCl2, 2 
mM DTT, 0.5 µM PfPK7) for 10 minutes at room temperature in the dark.  ATP 
was added at 1 µM and reactions were then incubated for 30 minutes at room 
temperature in the dark.  Following incubation with ATP, Kinase-Glo® buffer was 
added in equal volumes to the reaction mixtures and plates were again incubated 
for 10 minutes at room temperature in the dark.  Plates were then read with a 
Wallac Victor 2 Multi-label Counter (Perkin Elmer) for luminescence.  Positive 
control wells contained kinase buffer (40 mM HEPES, 15 mM MnCl2, 15 mM 
MgCl2, 50 mM NaCl2, 2 mM DTT), 1 µM ATP and 2 % DMSO.  Negative controls 
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contained master mix, 1 µM ATP, and 2 % DMSO. Percent inhibition (Equation 1) 
was determined for each small molecule at each concentration in order to 
determine hits from the screen.  Molecules that had inhibited more than 70 % of 
kinase activity at 10 µM were considered hits and were chosen for IC50 
determination.    Z factor scores (Equation 2), a means of determining statistical 
effects size for high-throughput screening assays, were determined for each 
assay and scores were consistently above 0.7.  In order to determine IC50 
concentrations of hits from the initial screen, small molecules were diluted in 12 
point 1:2 dilution series and added to wells starting at a final concentration of 200 
µM.  Reactions were carried out in triplicate for each concentration and each 
molecule was tested independently 3 times.  Results were analyzed with 
nonlinear regression using GraphPad Prism® version 5 software with the 
sigmoidal dose-response (variable slope) equation.  Z-factor scores for all assays 
in the IC50 determination process were above 0.7. 
 
Equation 1:  Equation for Percent Inhibition.  The average of negative control 
wells subtracted from the average of positive control wells yields normal activity 
and inhibited activity is calculated by subtracting the average of inhibitor-treated 
wells from positive control wells.  Inhibited activity was then subtracted from 
normal activity before dividing the answer by normal activity.  The answer is then 
multiplied by 100 to yield percent inhibition. 
 
 
 
 
 
% Inhibition =""
(normal activity –inhibited activity)"
(normal activity)"
"100 
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Equation 2:  Definition of Z-factor.  The sum of the standard deviation of positive 
controls (σp) plus the standard deviation of negative controls (σn) all multiplied by 
three all over the positive control mean (µp)  plus the negative control mean (µn) 
subtracted from 1 yields the Z factor score.  The Z-factor is a measure of 
statistical effects size and is used in highthroughput screens to determine if 
observed differences in an assay are significant. 
 
Computational Docking of Small Molecules 
Maestro and Macromodel 
 Structure-data files (SDF) for all small molecules were downloaded from 
EMD Millipore Chemicals website.  The crystal structure file 2PML was used for 
the docking studies and was downloaded from the Protein Data Bank [121].  The 
crystal structure file 2PML was assembled from a protein that had been 
cocrystalized with an analog of ATP, at a resolution of 2.6 Å.  DS ViewerPro 
(Accelrys) was used to visualize the protein and the ATP analog, 
phosphoaminophosphonic acid-adenylate ester (ANP), was removed from the 
ATP-binding site.  Maestro and Macromodel (Schrodinger software suite) were 
used to add hydrogens and minimize each structure respectively.  In 
Macromodel, structures were minimized with the dielectric constant set to 4.0 to 
account for an aqueous environment and maximum iteration number was set to 
1000. OPLS_2005 forcefield was used to define algorithm parameters and local 
energy minimums were determined with Polak-Ribiere Conjugate Gradient 
(PRCG) methodology [211].  Solutions were considered converged at 0.05 kJ/Å-
mol. After minimization, structures were exported as .mol2 files for later docking 
and analysis.  Modified 2PML was saved as a PDB file. 
Z-factor =""1 - 
3(σp + σn) 
µp + µn 
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Docking and Scoring of Small Molecules  
 The ligand-docking program GOLD was used to determine the most likely 
orientations of small molecules within the ATP-binding site of PfPK7.  The center 
of the docking sphere was set by determining the coordinates of the N9 nitrogen 
of ANP in the 2PML text file.  The centroid was set at x=-12.021, y=6.897, and 
z=-19.854 and the active site radius was set at 10 Å.  The 2PML crystal structure 
was first validated by recapitulating the docking of ANP and adenosine 
monophosphate (AMP) within the crystal structure ATP-binding site.  Following 
this validation, each small molecule was docked to the ATP-binding site and the 
most likely 50 orientations were determined.  Each orientation was scored with 
the fitness function Chemscore using default search settings and annealing 
parameters.   Docking data were analyzed in Maestro and DS ViewerPro 5.0. 
Computational Investigation of Druglikeness 
QikProp 
 Small molecule hits were evaluated for druglikeness by determining their 
adherence to Lipinski’s rule of five .  Most effective orally available medications 
are formulated from relatively small and lipophilic molecules.  Christopher 
Lipinski defined the following set of criteria for determining whether a given 
molecule will have desirable pharmacokinetics in the body:  not more than 5 
hydrogen bond donors, not more than 10 hydrogen bond acceptors, a molecular 
mass less than 500 Daltons, and an octanol-water partition coefficient (logP) not 
greater than 5 [212, 213].  If a compound violates more than one of the 
aforementioned criteria its usefulness as a lead drug compound is limited.   LogP 
   
 
  
 
 
50 
was calculated by the previously described model [214-216].  The Schrodinger-
applied percent human oral absorption model was also employed. In addition, 
human colon adenocarcinoma (Caco-2) cell permeability was calculated using 
the model developed from Boehringer-Ingelheim and AstraZeneca in order to 
predict absorption across intestinal epithelium [217, 218].  Prediction of hERG 
inhibition was performed using the model previously described [219, 220].  The 
hERG predictor determines whether or not small molecules are likely to block K+ 
channels and thus alter membrane potential especially in cardiac muscle where 
these channels are prevalent. 
TOPKAT 
 Prediction of Ames mutagenicity was used to determine if small molecules 
were likely to be mutagens.  The model used to predict Ames mutagenicity was 
developed using compounds that were tested with the US EPA GeneTox 
protocol [221]. Evaluation of 894 compounds tested by the Japanese Ministry of 
International Trade and Industry 1 text protocol was used to develop the model 
used by TOPKAT to predict aerobic biodegradability.  The prediction of 
Developmental Toxicity Potential was determined using the model developed for 
TOPKAT that was trained by 374 open-literature references out of the 
approximately 3000 studies that were reviewed by developers.  A quantitative 
structure-toxicity relationship (QSTR) model was constructed using weight of 
evidence rodent carcinogenicity.  According to the United States Food and Drug 
Administration (FDA) weight of evidence protocol, a given molecule is considered 
a carcinogen if it is a single site carcinogen in two or more sexes/species of test 
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animals or a multiple site carcinogen in one or greater sexes/species of test 
animal.  The QSTR gives predicted carcinogenic values based on this protocol 
and on experimental carcinogenicity rodent model studies conducted by the 
National Toxicology Program (NTP) and the National Cancer Institute (NCI).     
Maintaining P. falciparum Cultures 
 P. falciparum strain W2 was obtained from Malaria Research and 
Reference Reagent Resource Center (MR4) as part of the BEI Resources 
Repository, NIAID, NIH:  Plasmodium falciparum W2, MRA-157, deposited by DE 
Kyle.  All experiments with this strain were conducted at Biosafety Level 2.  
Parasites were thawed from liquid nitrogen and maintained as previously 
described with slight modifications [22].  Briefly, parasites were kept in malaria 
culture medium (MCM) (RPMI 1640 (Gibco), 25 mM HEPES, 23 mM NaHCO3, 
and 25 µg/ml gentamicin sulfate (Sigma-Aldrich), pH 7.4) that was supplemented 
with 10 % human serum (type AB-) at 5 % hematocrit (Blood type O+) in an 
atmosphere of 5 % CO2, 5 % O2, and a balance of N.  A temperature of 37°C 
was maintained.  Cultures were split 1:50 when parasitemia reached 3-5 %.  
Parasite growth synchronization protocol was adapted from Lambros and 
Vanderberg, 1979 [222].  Cultures that were primarily rings at approximately 5 % 
parasitemia were centrifuged to pellet RBCs.  CMCM was removed and 20X 
volume of packed cells of 5 % D-sorbitol in PBS was added.  Cultures were 
allowed to rest at room temperature for 15 minutes and were then centrifuged to 
pellet RBCs.  RBCs were washed once in MCM without serum and were then 
resuspended in MCM with serum.  Synchronized cultures were split 1:10 and 
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allowed to grow for 48 hours after which blood smears were taken and Giemsa 
(HARLECO)-stained to count parasitemia levels and estimate life cycle stage.  
The procedure was repeated until >90 % of parasites were in the same life cycle 
stage as verified by Giemsa staining.   
SYBR Green I Growth Assay 
 In the SYBR Green I assay, parasites are incubated with inhibitor for 72 
hours and growth of parasites is detected by applying buffer containing the 
fluorescent intercalating agent SYBR Green I.  Extent of SYBR Green I DNA 
binding can be determined by reading for fluorescence and as human RBCs are 
anuclear, fluorescence is the direct result of parasite DNA presence.  In order to 
determine the extent to which small molecules can inhibit intraerythrocytic 
parasite growth, the SYBR Green I parasite growth assay was performed with 
minor alterations as previously described [223]. Briefly, a 96 well plate format 
was used.  One hundred µl total volume was used in each well and 99 µl 
contained CMCM with 0.5 % parasitemia.  One µl of small molecule was added 
in each well and each small molecule was screened in triplicate at 1 µM.  
Negative control wells contained CMCM, 2% hematocrit, and no parasites.  
Positive control wells contained CMCM and 2 % hematocrit with 0.5 % 
parasitemia. 1 µl of DMSO was added to all control wells.  Plates were kept at 
37°C in a modular incubator that was gassed at 20 L/min for 5 minutes with 5 % 
O2, 5 % CO2, and a balance of nitrogen daily.  After an incubation period of 72 
hours, equal volumes of lysis buffer (20mM Tris base, 5 mM EDTA,  0.008 % 
Saponin, 0.08 % Triton X-100, pH 7.5 with 0.2 µl SYBR Green I/ml of lysis buffer) 
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was added to each well.  Plates were then incubated in the dark for 1 hour and 
then read on a Wallac Victor 2 Multi-label Counter (Perkin Elmer) for 
fluorescence (excitation 485 nm and emission 535 nm).  IC50 determinations 
were made by diluting 10 mM stock compounds in 12 point 1:2 dilution series 
from a starting final concentration of 200 uM.  The assay was performed as 
indicated above and final fluorescence readings were analyzed with nonlinear 
regression analysis using GraphPad Prism® version 5 software with the 
sigmoidal dose-response (variable slope) equation.  Z factor scores were 
tabulated for all assays and were found to exceed 0.7. 
Culturing Parasites with Purvalanol B 
 Parasites were maintained and synchronized as described above and at 5 
% parasitemia, parasites were resynchronized and placed at 37°C for 24 hours.  
At 24 hpi, parasitemia and life cycle stage were confirmed with Giemsa-stained 
blood smears and 3X the IC50 concentration (determined by SYBR Green I 
growth assay to be 29.8 µM) of Purvalanol B (Sigma-Aldrich) in DMSO was 
applied to cultures, which were again gassed and incubated for 12 hours at 37°C.  
Three treatment cultures and three control cultures were prepared.  Control 
cultures were incubated with DMSO only for 12 hours.  At 36 hpi, parasitemia 
and life cycle staged were confirmed with Giemsa-stained blood smears.  At 36 
hpi RBCs were pelleted and washed 3X in PBS to remove serum proteins.  All 
centrifugation steps took place at 4°C.  RBCs were then lysed in 20X volume of 
packed cells in 0.05 % saponin (Fluka BioChemika) in PBS on ice for 10 minutes.  
Lysates were then washed 3X in PBS to remove RBC ghosts and once in 10 mM 
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Tris HCl (Sigma-Aldrich) to remove heme-binding proteins before final 
sedimentation.  Parasites were centrifuged at 8000 rpm for 10 minutes and the 
resulting parasite pellets were stored at -80°C.   
Protein Extraction 
 Parasite lysates were resuspended in 1 ml of 10 mM Tris HCl  
supplemented with protease inhibitor cocktail (pI) (Sigma-Aldrich) and were flash 
frozen 2X to begin to release proteins.  Suspensions were then sonicated on ice 
5X 20 seconds (1 second on and 1 second off) at 10 % amplitude to complete 
protein release.  Samples were centrifuged at 14,000 rpm for 30 minutes at 4°C 
to sediment hemozoin and the resulting supernatant was removed for later 
analysis.  Protein concentration was determined for all samples using a DC 
assay (Biorad).  For each sample, 60 µg were sent to Colorado State University’s 
Proteomics and Metabolomics Facility for evaluation with shotgun proteomics.  
Proteins underwent mass spectrometry analysis following trypsin digestion.  
Mass Spectrometry Analysis 
 First peptides were purified and concentrated using on-line enrichment 
columns (Thermo Scientific 5 µm, 100 µm ID x 2 cm C18 column).  Then 
chromatographic peptide separation was performed on a reverse phase 
nanospray column (Thermo Scientific EASYnano-LC, 3 µm, 75 µm ID x 100mm 
C18 column) using a 90 minute linear gradient from 10%-30% buffer B (100% 
ACN, 0.1% formic acid) at a flow rate of 400 nanoliters/min.  Peptides were 
eluted directly into the mass spectrometer (Thermo Scientific Orbitrap Velos) and 
spectra were collected over a m/z range of 250-2000 Daltons using a dynamic 
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exclusion limit of 2 MS/MS spectra of a given peptide mass for 30 seconds 
(exclusion duration of 90 seconds).  Samples (0.5 µg) were analyzed in 
randomized duplicate injections.  Compound lists of the resulting spectra were 
generated using Xcalibur 2.2 software (Thermo Scientific) with a S/N threshold of 
1.5 and 1 scan/group. 
Protein Data Analysis 
 MS/MS spectra were searched against the Uniprot Plasmodium 
falciparum concatenated reverse database (version 03/06/2013) using the 
Mascot database search engine (version 2.3) and the SorcererTMSEQUEST 
version 3.5 LFDR (local false discovery rate) was calculated using a Bayesian 
algorithm to confirm peptide probabilities based on likelihoods calculated using 
parent mass accuracy.  Search parameters were as follows:  monoisotopic mass, 
parent ion mass tolerance of 20 ppm, fragment ion mass tolerance of 0.8 Da, 
fully tryptic peptides with 1 missed cleavage, variable modification of oxidation of 
M and fixed modification of carbamidomethylation of C.  Search results for each 
independently analyzed sample were imported into the Scaffold software 
(Version 4, Proteome Software, Portland, OR).  Peptide and protein probability 
thresholds of 95 % and 99 % respectively were applied and a minimum of two 
unique peptides were required.  Manual validation of MS/MS spectra was 
performed for all protein identifications above the probability thresholds that were 
based on only two unique peptides.  Criteria for manual validation included the 
following:  1) minimum of 80 % coverage of theoretical y or b ions (at least 5 in 
order); 2) absence of prominent unassigned peaks greater than 5 % of the 
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maximum intensity; and 3) indicative residue specific fragmentation, such as 
intense ions N- terminal to proline and immediately C- terminal to aspartate and 
glutamate (used as additional parameters of confirmation). 
P. falciparum Quantitative Analysis 
 Spectral counting (SpC) and average total ion current (TIC) relative 
quantitative analyses were performed and t-tests as well as fold changes were 
calculated for each method.  While the two methods of analysis are distinct, they 
are both valid and yielded complementary results.  The cutoff and thresholds 
used for this analysis were as follows:  1) 99 % protein probability; 2) 2 peptide 
minimum; and 3) 95 % peptide probability.  There were a minimum of 10 spectral 
counts (sum) per biological group and a minimum presence (2 peptides) in 2/3 
biological replicates.  For each biological replicate, a scaling factor was 
determined by dividing the sum of spectral counts by the average spectral counts 
across all biological samples.  Each protein was divided by the scaling factor of 
the biological replicate in which it was present.  T-tests as well as fold change 
analysis were then performed on normalized data in Scaffold.  Mean and 
standard deviation of spectral counts were calculated before and after 
normalization to assure that normalization had equaled out the mean spectral 
counts between the biological samples.    
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CHAPTER III 
SCREEN OF KNOWN KINASE  
INHIBITORS AGAINST  
PFPK7 
 
Introduction 
 The alarming development of P. falciparum resistant parasite strains, 
especially in the region of Southeast Asia has made necessary the identification 
of promising targets for antimalarial drug design.  Unique structural aspects of P. 
falciparum kinases along with recent successes developing protein kinase-
targeted drug therapies for the treatment of diseases including cancer, 
inflammatory disorders, and diabetes make selective targeting of the ATP-
binding site from these macromolecules a promising antimalarial drug 
development strategy. 
 The majority of aforementioned successful kinase-targeted drugs compete 
for the ATP-binding site of their respective targets.  However, compounds that 
bind to the ATP-binding site tend to cross-react with the ATP-binding sites of 
other kinases because of the high degree of evolutionary sequence conservation 
that occurs in this domain of the protein.  The cross-reactivity of these small 
molecules is due to the characteristics that are shared not only among the ATP-
binding site of kinases, but also to analogous characteristics of kinase inhibitors.  
For instance, a modified purine base is often used as a scaffold for kinase 
inhibitor development because this base preserves hydrogen bonding 
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interactions between small molecules and the hinge region of kinases, which 
links together the N- and C- terminal lobes of the proteins.  This approach has 
the added benefit of providing molecules that can be used as a starting point in 
many different kinase-targeted drug discovery efforts (as reviewed in [224]).  
Analysis of 72 well-characterized kinase inhibitors against 442 kinases, which 
represents greater than 80 % of the human kinome, revealed that while some 
kinase inhibitors, such as the CDK inhibitor staurosporine, are widely 
promiscuous, others such as the EGFR/HER2 kinase inhibitor, Lapatinib, are 
notably selective for their respective targets [225].  Therefore, while cross-
reactivity between kinases does occur, it is clearly possible to identify an inhibitor 
capable of exploiting the unique characteristics of its target molecule to the effect 
of selectively inhibiting the target protein and few others. 
 The wealth of structural information that has been gleaned over the past 
decade in the form of protein kinase crystal structures has revealed key 
characteristics of kinases that may govern the ability to selectively target a 
particular kinase and can be utilized during the rational drug design of small 
molecule inhibitors targeting the ATP-binding site.  A hydrophobic pocket that lay 
adjacent to the ATP-binding region, access to which is controlled by a 
gatekeeper residue, may be exploited if the gatekeeper residue is a small amino 
acid such as a glycine and the small molecule in question is able to span the 
binding site to establish hydrophobic interactions within this pocket.  Further, 
correspondence between key residues in the hinge region and areas in the small 
molecule allow for the formation of foundational hydrogen bonds and interactions 
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between the binding pocket floor also increase affinity [226].  The catalytic lysine 
residue and an acidic group that generally stabilize the phosphate groups of ATP 
may further add to affinity of small molecules by contributing to the formation of 
hydrogen bonds.  In addition, the orientation of phenylalanine within the DGF 
motif further contributes optimal affinity.    
     The orphan kinase PfPK7 was chosen as a potential target for 
screening in this study because of its unique attributes.  As an orphan kinase, 
PfPK7 has no eukaryotic kinase ortholog and maintains structural characteristics 
that are different from mammalian kinases [121].  Unique attributes of PfPK7 
coupled with the data that show PfPK7(-) parasites display decreased growth 
rates compared to wildtype parasites make PfPK7 a potential target for 
antimalarial drug discovery [124].  Further, as the biological function of this 
kinase is undetermined, identification of a PfPK7 inhibitor would allow for the 
exploration of PfPK7 function the parasite.  
 Two hundred forty-four compounds from three kinase inhibitor-focused 
libraries were screened against PfPK7 with an ATP luminescence assay.  
Molecules that were able to compete for the ATP-binding site of PfPK7 were then 
tested to determine the IC50 concentrations.  In addition, these small molecules 
were computationally docked to the ATP-binding site of the PfPK7 crystal 
structure in order to determine the probable binding site interactions between 
inhibitors and the protein.  In order to conduct the docking studies, the binding 
sphere was identified by determining the coordinates of the N9 nitrogen of ANP 
within the PDB file, 2PML, which is cocrystallized  with the ATP analog within its 
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binding site.  Docking studies were carried out using GOLD and results were 
visualized with DS ViewerPro and Maestro.   
 As kinases utilize ATP to carry out phosphotransfer activity, the ATP 
luminescence assay determines the ability of kinases to utilize ATP in the 
presence of potential small molecule inhibitors.  If the small molecule is able to 
outcompete ATP for the binding site, more free ATP will exist in the reaction 
mixture following a kinase reaction.  An enzyme that binds free ATP is then 
incubated with the reaction mixture and greater ATP concentrations result in 
luminescence increase, which allows for quantitation of ATP utilization compared 
to controls.  This assay platform offers a non-radioactive method for quantitating 
the inhibitory effects of small molecules on ATP-utilizing target proteins and 
allows for high-throughput screening, which increases the number of compounds 
that can be evaluated in a single assay. 
 GOLD is a software program for predicting the probable docking modes of 
ligands in protein binding sites and is part of the GOLD suite (Hermes) of 
programs.  GOLD utilizes a genetic algorithm for ligand-protein docking that 
predicts the minimum free energy of association during an iterative docking 
process, which yields multiple predicted binding modes.  In addition, this program 
allows for a limited amount of backbone flexibility for up to ten select residues 
within the binding site, which aids user-directed parameterization of the docking 
process for a particular protein-ligand complex (kinase-ATP).  One method to 
validate how precisely and accurately any algorithm will predict small molecule 
docking orientations is to strip a cocrystalilized molecule from the protein crystal 
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structure file and then dock the ligand back into the binding site with the aid of 
the desired program.  Following the docking, the researcher can then determine 
whether the algorithm is able to recapitulate the docking orientation indicated in 
the original crystal structure PDB file.  GOLD was originally validated with a test 
set of 100 ligand-protein complexes and then more extensively validated in a 
Cambridge Crystallographic Data Center/Astex collaborative study using 305 
ligand-protein complexes [227, 228].  Since that time two additional validation 
studies were carried out; an Astex test of 85 highly diverse ligand-protein 
complexes and an Astex non-native test that utilized 1112 crystal structures for 
65 proteins that were in a non-native state [229, 230].  Data from the extensive 
validation of GOLD revealed that the algorithm was able to reproduce the 
experimental binding mode in 71-80 % of cases and that this percentage 
increased when the protein-ligand complex was well-characterized as is the case 
for kinase-ATP complexes. 
 DS ViewerPro is the molecular visualization software program in the 
Accelrys Discovery Studio.  This program allows for easy manipulation of 3D 
structures such as adding and removing multiple docked small molecules from 
protein binding sites.  The software program Maestro is the unifying interface for 
all Schrodinger software.  It allows both 2D and 3D representation of protein-
ligand complexes as well as visualization and measurement of electrostatics, 
binding pocket shape, and protein-ligand interactions.  Maestro also allows for 
the superimposition of multiple structures or structure orientations, which enables 
detailed comparisons of possible small molecule binding modes as well as 
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assignment of a consensus orientation for multiple small molecules within one 
binding site. 
 The accumulation of information regarding the druglikeness of small 
molecules has allowed computational biologists to train in silico models which, 
when used to test compounds with similar qualities to drugs that are well-
described in chemical space, are able to predict characteristics such as cell 
permeability, toxicity, likely metabolites, and solubility.  These models predict 
structural properties such as number of hydrogen bond participants and 
molecular weight as well as physicochemical properties such as solubility and 
permeability.  In addition, properties that contribute to pharmacokinetic 
activities and toxicity can also be predicted.  Following the prediction of these 
properties, it is then possible to determine how well small molecules adhere to 
Lipinski’s rule of five for predicting druglikeness.  Testing small molecule drugs 
for all pharmacokinetically relevant properties that impact drug design in vitro 
becomes expensive and often unfeasible, which means that a lack of funds 
may result in limited exploration of compounds with potentially curative 
properties. Harnessing information gleaned from previously tested compounds 
and coupling this information with target activity data, provide a means to 
efficiently and economically identify lead compounds for drug design. 
 Combining in vitro activity data with in silico molecular interaction and 
pharmacological data enables the informed selection of molecules with the 
greatest potential of having druglike properties and acting as potent inhibitors of 
their intended biological targets.  A screen of three kinase-inhibitor focused 
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libraries against the malaria kinase PfPK7 revealed compounds that were able to 
inhibit kinase activity at low molar concentrations and molecular interaction data 
that will inform future studies aimed at identifying selective PfPK7 inhibitors.    In 
addition, the estimation of pharmacologically relevant properties distinguished 
those molecules that are most druglike from those with problematic 
characteristics for drug development. 
Results 
ATP Luminescence Assay 
 EMD kinase libraries I, II, and III were tested for their ability to inhibit 
malaria kinase PfPK7 at three concentrations, 0.1 µM, 1 µM, and 10 µM.  The 
screen of these three inhibitor libraries containing a total of 244 compounds 
revealed 12 compounds capable of inhibiting PfPK7 as indicated by greater than 
70% inhibition of kinase activity at a 10 µM concentration.   Four molecule hits 
were identified from EMD Kinase Library I using the ATP luminescence assay: 
324840, 428205, 676489, and 203290.  Of the four compounds that hit from this 
library, 676489 and 203290 had IC50 values above 1.0e-4 so these compounds 
were not explored further.  The screen of EMD Kinase Library II revealed four 
compounds that were able to inhibit 70% of kinase activity at 10 µM.  The 
compounds 420298, 569397, 217714, and 218710 were chosen for IC50 
determination.  EMD Kinase Library III was also screened and four molecules 
from this library were able to inhibit 70% of kinase activity at 10 µM;  506106, 
528116, 551590, and 506163.  Of the four molecules that hit from the third 
library, 506163 had an IC50 value above 1.0e-4 so it was excluded from further 
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analysis.  506106 was not explored further as upon exploration of available data 
on this compound it was found to be an allosteric inhibitor that targets the 
autoregulatory domain of group I p21-activated kinases and thus its inhibitory 
effects may not be due to competition for ATP within the PfPK7 ATP-binding site.  
The eight remaining compounds were tested three times in triplicate and 
displayed inhibitory activities ranging between 6.26e-7±1.5e-7 M and 8.63e-
5±1.46e-5 M against PfPK7 (Table 2). 
Docking of Small Molecules 
 In order to validate the crystal structure 2PML and to assure that the 
molecular docking program GOLD was able to recapitulate the orientation of the 
ATP analog, ANP, within the ATP-binding site, adenosine monophosphate was 
docked to the binding site of 2PML (Figure 4).  GOLD was able to reproduce the 
binding orientation as well as the molecular interactions observed in the crystal 
structure 2PML.  Results from computational docking of small molecules to the 
crystal structure file 2PML of PfPK7 revealed several interactions between small 
molecules and the ATP-binding site that contributed to the affinity of compounds 
for this binding site (Figure 5a-5h).  Interaction profiles were determined for each 
small molecule thus enabling the characterization of the most favorable 
interactions for promoting compound affinity.  PfPK7 was found to possess a  
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Table 2:  IC50 Luminescence Values for PfPK7 Small Molecule Inhibitors.  
Column one indicates the EMD kinase library number from which the small 
molecule originated.  Column two indicates the EMD molecule and column 
three gives the IC50 luminescence values for each compound plus the 
standard deviations in Molar concentration.  The final column depicts the 
structure of each small molecule. 
Library 
Number 
Compound IC50 
Luminescence 
Structure 
I 324840 5.71e-5±1.52e-6 
 
I 428205 8.63e-5±1.46e-5 
 
II 420298 2.08e-6±1.22e-6 
 
II 569397 1.41e-6±1.35e-6 
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Table 2 Continued 
Library 
Number 
Compound IC50 
Luminescence 
Structure 
II 217714 3.71e-5±3.75e-6 
 
II 218710 1.98e-5±1.26e-6 
 
III 528116 6.26e-7±1.5e-7 
 
III 
 
551590 1.17e-5±2.24e-6 
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Figure 4: AMP Docked to the PfPK7 ATP-binding site.   AMP docked to the ATP-
binding site of the crystal structure 2PML using GOLD.  Red hash marks 
represent hydrogen bonds between AMP and residues within the ATP binding 
site of 2PML.  Hydrogen bonds at Glu118 and Met120 in the hinge region orient 
the purine backbone of AMP in the binding site and additional hydrogen bonds at 
Asp123 and Ser176 stabilize the molecule, while a hydrogen bond at Lys55 
orients the phosphate group (Made in PyMOL).  
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leucine and isoleucine rich hydrophobic pocket.  In general, molecules that 
showed high affinity for the binding site were stabilized by hydrophobic 
interactions at Leu34, Ile42, Ala53, Leu101, and Leu179 (Table 3).  In addition, 
probable π/ π stacking interactions in either parallel or perpendicular orientations 
at one or both of the tyrosine residues 117 and 119 further increased affinity of 
small molecules for the binding site.  Hydrogen bonds, varying in number from 1 
to 4, formed most often at residues Asn35, Glu118, Met120, Asp123, Ser176, 
and Asp190.  Small molecules that displayed the highest affinity for the binding 
site were those that made three hydrogen bonds, maintained hydrophobic 
contacts with all residues in the hydrophobic pocket, and formed π/ π stacking 
interactions with both Tyr117 and Tyr119. 
Biologically Relevant Property Prediction 
 Software programs QikProp and TOPKAT were used to predict the 
biologically and pharmacologically relevant properties of the eight small molecule 
hits from the PfPK7 luminescence assay screen.  QikProp was first used to 
predict the structural and physicochemical properties of the compounds (Table 
4).  Previous research has shown that molecules that violate no more than one of 
Lipinski’s rules are more likely to act as good compounds for drug design than 
those molecules that do not adhere well to these criteria.  Molecules 428205, 
217714, and 551590 all violated one of Lipinski’s rules, while the remaining 
compounds adhered to all of the criteria.  Most drug-like compounds maintain a 
LogP octanol/water partition coefficient less than five, which assures that the 
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Figure 5a:  324840 in the ATP-binding site of PfPK7.  Upper: representation of 
the small molecule 324840 in the PfPK7 ATP-binding site and dashed red lines 
indicate hydrogen bonds.  Lower:  2D structure of small molecule 324840.  
Hydrogen bonds are indicated by red hash marks, blue sigmoidal curves indicate 
hydrophobic interactions, and the green π/π symbol indicates pi/pi stacking 
interactions (Made in PyMOL). 
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Figure 5b:  428205 in the ATP-binding site of PfPK7.  Upper:  a 3D 
representation of the small molecule 428205 in the PfPK7 ATP-binding site red 
dashed lines indicate hydrogen bonds.  Lower: a2D structure of small molecule 
428205.  Hydrogen bonds are indicated by red hash marks, blue sigmoidal 
curves indicate hydrophobic interactions, and the green π/π symbol indicates 
pi/pi stacking interactions (Made in PyMOL). 
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Figure 5c:  420298 in the ATP-binding site of PfPK7.  Upper:  a 3D 
representation of the small molecule 420298 in the PfPK7 ATP-binding site red 
dashed lines indicate hydrogen bonds.  Lower:  a 2D structure of small molecule 
420298.  Hydrogen bonds are indicated by red hash marks, blue sigmoidal 
curves indicate hydrophobic interactions, and the green π/π symbol indicates 
pi/pi stacking interactions (Made in PyMOL). 
Tyr119 
π/π 
N
N
N
H
O
O
CH3
H
OH
H3COOC
Glu118 
Met120 
Leu34 
π/π 
Tyr117 
Ile42 
Ser176 
   
 
  
 
 
72 
 
 
Figure 5d:  569397 in the ATP-binding site of PfPK7.  Upper:  a 3D 
representation of the small molecule 569397 in the PfPK7 ATP-binding site and 
red dashed lines indicate hydrogen bonds.  Lower: a 2D structure of small 
molecule 569397.  Hydrogen bonds are indicated by red hash marks, blue 
sigmoidal curves indicate hydrophobic interactions, and the green π/π symbol 
indicates pi/pi stacking interactions (Made in PyMOL). 
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Figure 5e:  217714 in the ATP-binding site of PfPK7.  Upper:  a 3D 
representation of the small molecule 217714 in the PfPK7 ATP-binding site and 
red dashed lines indicate hydrogen bonds.  Lower: a 2D structure of small 
molecule 217714.  Hydrogen bonds are indicated by red hash marks, blue 
sigmoidal curves indicate hydrophobic interactions, and the green π/π symbol 
indicates pi/pi stacking interactions (Made in PyMOL). 
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Figure 5f:  218710 in the ATP-binding site of PfPK7.  Upper:  a 3D representation 
of the small molecule 218710 in the PfPK7 ATP-binding site and red dashed 
lines indicate hydrogen bonds.  Lower:  a 2D structure of small molecule 218710.  
Hydrogen bonds are indicated by red hash marks, blue sigmoidal curves indicate 
hydrophobic interactions, and the green π/π symbol indicates pi/pi stacking 
interactions (Made in PyMOL). 
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Figure 5g:  528116 in the ATP-binding site of PfPK7.  Upper:  a 3D 
representation of the small molecule 528116 in the PfPK7 ATP-binding site and 
red dashed lines indicate hydrogen bonds.  Lower:  a 2D structure of small 
molecule 528116.  Hydrogen bonds are indicated my red hash marks, blue 
sigmoidal curves indicate hydrophobic interactions, and the green π/π symbol 
indicates pi/pi stacking interactions (Made in PyMOL). 
 
Tyr119 
N
N
Br
N
N
S
CH3
O
O
O2N
CH3
Leu34 
π/π 
Met120, Leu101, Ala53 
Lys55 
Leu179, Ile42 
π/π 
 Tyr117 
   
 
  
 
 
76 
 
 
Figure 5h:  551590 in the ATP-binding site of PfPK7.  Upper:  a 3D 
representation of the small molecule 551590 in the PfPK7 ATP-binding site and 
red dashed lines indicate hydrogen bonds.  Lower:  a 2D structure of small 
molecule 551590.  Hydrogen bonds are indicated by red hash marks, blue 
sigmoidal curves indicate hydrophobic interactions, and the green π/π symbol 
indicates pi/pi stacking interactions (Made in PyMOL). 
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molecule is hydrophilic enough to be soluble in the aqueous environment of the 
body and lipophilic enough to be cell permeable.  Compound 528205 was the 
only molecule with a LogP over five.  LogS for aqueous solubility values for most 
drug-like molecule fall between -6.5 and 0.5.  All small molecules tested were 
predicted to have LogS values between these numbers with the exception of 
528205.  The molecular weight for all compounds was below 500 Daltons and 
they had a wide spread of predicted cell permeability values ranging from poor to 
excellent.  All compounds were predicted have excellent oral absorption with the 
exception of 217714 and 551590. 
 TOPKAT was used to predict small molecule toxicity values (Table 5).  
218710 and 551590 were predicted to be moderate blockers of hERG K+ 
channels and only 217714 and 551590 were predicted to be mutagens.  Aerobic 
biodegradability could not be predicted for most compounds as the structure of 
the compounds fell outside of the model’s prediction space with the exception of 
218710, which was predicted to have excellent aerobic biodegradability.  
Molecule 324840 was predicted to be very developmentally toxic and 428205 
was predicted to be moderately developmentally toxic.  Weight-of-evidence 
rodent carcinogenicity models predicted only small molecule 428205 would act 
as a carcinogen. 
Discussion 
 Small molecule 324840 has been shown to be a potent 
alkynamidopyrimidine ATP competitive inhibitor of human erbB-1, erbB-2, and  
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erbB-4 tyrosine kinase receptors with IC50s in the sub nanomolar range.  324840 
met all requirements for Lipinski’s rule with an acceptable number of hydrogen 
donors and acceptors and a LogP under 5.  Molecular weight was found to be 
355.76 Daltons and the LogS fell within acceptable parameters indicating the 
small molecule would be reasonably soluble in an aqueous environment.  
Additionally, 324840 was predicted to be highly cell permeable as determined by 
both the Caco-2 and MDCK models and percent human oral absorption was 
predicted to be high.  Toxicity predictions revealed that the small molecule was 
likely to be neither mutagenic nor carcinogenic; however, the probability of 
developmental toxicity high and there was a slight chance the compound could 
act as a hERG K+ channel blocker and interfere with cardiac function.  With an 
IC50 of almost 60 µM, the small molecule does not possess great affinity for the 
PfPK7 binding site.  Information from the docking study revealed that while this 
small molecule does form 3 hydrogen bonds with the ATP-binding site, it does 
not interact with the hinge region and is thus not optimally oriented to take full 
advantage of interactions with Tyr117 or the catalytic lysine. 
 Small molecule 428205 has been shown to be a pyrrolopyrimidine 
compound that acts as a potent and selective ATP-competitive inhibitor of human 
lymphocyte-specific protein tyrosine kinase, which is most highly represented in 
T cells.  Molecule 428205 was found to violate one requirement of Lipinski’s rule 
of five.  It was found to have an acceptable number of both hydrogen bond 
donors and acceptors and the molecular weight was found to be 370.45 Daltons.  
However, LogP was predicted to be above five, which may in part explain the 
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predicted poor aqueous solubility as the molecule will partition more readily into a 
lipophilic environment.  The percent human oral absorption was predicted to be 
high and cell permeability as predicted by both the Caco-2 and MDCK models 
was predicted to be high.  The molecule was not predicted to be mutagenic, but 
was predicted to be highly carcinogenic, a HERG K+ channel blocker, and a 
developmental toxicant.  Further, with an IC50 of 86 µM this molecule does not 
have great affinity for the binding site.  This lack of affinity is most likely due to 
the fact that its orientation within the binding site suggests only one hydrogen 
bond.  The small molecule does form hydrophobic interactions with the leucine-
rich hydrophobic pocket; however, it fails to interact with the hinge region or form 
pi/pi stacking interactions with Tyr117.  
 Small molecule 420298 has been shown to inhibit multiple human kinases 
including its primary target CaM kinase II.  420298 meets all requirements for 
Lipinski’s rule of five.  It has an acceptable number of both hydrogen bond 
donors and hydrogen bond acceptors and the molecular weight was found to be 
467.48 Daltons.  The aqueous solubility, LogS, was predicted to be acceptable 
and human percent oral absorption was predicted to be high.  Additionally, the 
small molecule was predicted to be moderately cell permeable by the Caco-2 
and MDCK models.  Toxicity predictions revealed a slight probability of HERG H+ 
channel blockage, but no probability of carcinogenicity. This small molecule has 
affinity for the binding site with an IC50 of about 2 µM.  Docking studies predict the 
most likely orientation of this small molecule will make hydrogen bonds with 
residues Met120 and Glu118 in the hinge region of the kinase and form an 
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additional hydrogen bond with Ser176, which was an association observed in the 
docking of ATP as well.  Further, pi/pi stacking interactions and extensive 
hydrophobic interaction formation all contribute to this molecule’s affinity for the 
binding site.  However, given the promiscuity of this small molecule and its size, 
420298 may not make the most promising lead compound for drug design. 
 Small molecule 569397 is a potent ATP-competitive, promiscuous human 
kinase inhibitor the primary target of which is PKA.  Small molecule 569397 met 
all requirements for Lipinski’s rule of five.  It has an acceptable number of 
hydrogen bond donors and acceptors and the molecular weight falls within the 
range observed for 95 % of druglike compounds at 466.34 Daltons.  Aqueous 
solubility, LogS, and percent human oral absorption were both predicted to be 
high.  Caco-2 and MDCK cell permeability models predicted the small molecule 
to be moderately cell permeable and while toxicity predictions revealed no 
mutagenic effects or carcinogenicity, a slight probability of HERG K+ channel 
blockage was detected.  This small molecule binds to the PfPK7 ATP-binding site 
with a similar affinity to that of 420298 and is similar in structure.  Docking studies 
also predict this small molecule to bind in much the same was as 420298 and 
similar problems with selectivity would likely occur where this small molecule to 
be utilized as a lead compound. 
 Small molecule 217714 is a triazolo-diamine and acts as a potent inhibitor 
of human Cdk1/cyclin B and Cdk2/Cyclin A with IC50s in the picomolar range.  
Small molecule 217714 violated one requirement for Lipinski’s rule of five with 
more than five hydrogen bond donors.  However, the compound meets all other 
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requirements with hydrogen bond acceptor numbers within range and a 
molecular weight of 425.43 Daltons.  Aqueous solubility, Log S, was within range 
of 95 % of all drug-like molecules and percent human oral absorption was 
predicted to be moderate.  In addition, the small molecule was predicted to be 
reasonably cell permeable by both the MDCK and Caco-2 models. No probability 
of developmental toxicity, carcinogenicity, or mutagenicity was predicted.  
However, the small molecule may cause moderate hERG K+ channel blockage.  
217714 had little affinity for the PfPK7 ATP-binding site with an IC50 of 37 µM and 
this is most likely due to its proposed orientation within the binding site.  While 
hydrogen bonds between the small molecule and the catalytic lysine as well as 
Ser176 are formed, the small molecule does not contain functional groups in 
close proximity to Tyr119 or Tyr117 that would allow for the formation of pi/pi 
stacking interactions.   
 Small molecule 218710 is a tetrabrominated cinnamic acid that is a potent 
and ATP-competitive inhibitor of human Casein Kinase II. Small molecule 
218710 met all requirements for Lipinski’s rule of five with hydrogen bond donor 
and receptor numbers within the acceptable range and a molecular weight of 
463.75 Daltons.  LogS predictions indicated that the molecule would be 
sufficiently soluble in an aqueous environment and percent human oral 
absorption was predicted to be excellent.  Cell permeability models predicted 
moderate to excellent cell permeability and no probability of carcinogenticity, 
mutagenicity, or developmental toxicity were found using toxicity modeling 
equations.  A slight chance of hERG K+ channel probability was detected.  This 
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molecule also showed little affinity for the binding site, which is in part explained 
by how 218710 is oriented in the binding site.  Hydrogen bonds are formed at 
Lys55 and Asp190; however, the small molecule fails to take advantage of the 
hydrophobic pocket or pi/pi stacking interactions with residues possessing 
aromatic R groups. 
 Small molecule 528116 is a imidazopyridine molecule, ATP-competitive 
and capable of acting as a potent inhibitor of human proteins from the 
phosphatidylinositol 3-kinase-related kinase family.  Compound 528116 meets all 
requirements for Lipinski’s rule of five and has acceptable numbers of hydrogen 
bond donors and acceptors.  Molecular weight was well within the desired range 
at 452.28 and LogP was 2.35.  The molecule was predicted to have adequate 
aqueous solubility as well as percent human oral absorption.  Additionally, 
528116 was only moderately cell permeable, however toxicity models indicated 
little to no probability of hERG K+ channel blockage, mutagenicity, 
carcinogenicity or developmental toxicity.  528116 was the most promising small 
molecule inhibitor of PfPK7 that was identified in the screen with an IC50 in the 
nanomolar range.  The compound formed a hydrogen bond with the catalytic 
lysine in the binding pocket and made extensive hydrophobic interactions with 
the leucine-rich hydrophobic pocket.  While it did not form hydrogen bonds with 
the hinge region residues, it was oriented such that slight modification would 
allow for such an interaction.  The NO2 functional group is of concern as this 
functional group tends to form covalent bonds with interacting residues.  
However, future testing of 528116 analogs without this functional group would 
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determine whether its presence is necessary to preserve compound affinity.  
Unfortunately, small molecule analogs for this compound are not commercially 
available and would have to be synthesized before testing which would be cost 
prohibitive   
 Small molecule 551590 is a flavanol molecule that is ATP- competitive 
and has selective inhibitor activity against PIM1 kinase.  This small molecule 
violates 1 of Lipinski’s rule of five with more than five hydrogen bond donors.  
LogP and LogS value both fall within acceptable parameters and the molecule is 
relatively small compared with the other analyzed small molecules with a 
molecular weight of 318.24 Daltons.  Both cell permeability and percent human 
oral absorption were predicted to be poor and the Ames Mutagenicity model 
indicated a strong probability that the compound would act as a mutagen.  
However, the small molecule was not predicted to be a hERG K+ channel 
blocker, a developmental toxicant or a carcinogen.  This compound had 
moderate affinity for the PfPK7 ATP-binding site with an IC50 around 12 µM.  
Within the binding site, the molecule made hydrogen bonds with both Met120 
and Lys55 as well as established hydrophobic interactions with the hydrophobic 
pocket.  However, the molecule did not hydrogen bond with Glu118 in the hinge 
region and while pi/pi stacking interactions were likely with Tyr117, the molecule 
was not oriented to interact with Tyr119. 
 Several small molecules from the kinase inhibitor-focused libraries were 
able to inhibit PfPK7 in low molar concentrations. In recent years, researchers 
have found that PfPK7 inhibitors are particularly difficult to pinpoint because the 
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gatekeeper residue, behind which resides a hydrophobic pocket, is a bulky 
tyrosine which effectively prohibits small molecules from reaching and interacting 
with this site in the pocket [231].  It may prove difficult to find a compound with 
great affinity for the binding site given this bulky impediment.  Further, small 
molecule analogs for the eight small molecule hits from this screen were not 
commercially available and thus a structure-activity relationship could not be 
established; however the docking studies were able to indicate favorable 
interactions which could inform future drug discovery efforts aimed at selectively 
inhibiting this protein.      
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CHAPTER IV 
SCREEN OF KINASE INHIBITORS AGAINST 
 PLASMODIUM FALCIPARUM STRAIN  
W2 BLOOD STAGES 
 
Introduction 
 Luminescence assays are able to determine the affinity of ATP-
competitive small molecules for the binding site of their intended target, but 
they depend upon recombinant protein from the organism of interest and are 
carried out in controlled conditions different from the normal environment in 
which the organism resides.  Small molecules that are able to inhibit the 
protein of interest may however, not make ideal lead compounds if they are not 
able to inhibit cell growth or development within the organism from which the 
target originated.  Once small molecules that bind to the intended target with 
high affinity are identified, it is then necessary to determine the affect of those 
small molecules on parasite growth. 
 Human malaria disease symptoms are caused by a depletion of human 
red blood cells and the immune response elicited by infection with malaria 
parasites.  These symptoms are a direct result of parasite propagation within 
human red blood cells and it is for this reason that we chose to target a kinase 
that is expressed during these stages of parasite growth.  After identifying 
several compounds that were able to inhibit our intended target, PfPK7, we 
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next had to determine if small molecule kinase inhibitors were able to inhibit 
parasite growth in blood stage cultures of P. falciparum strain W2.  
 The traditional method of measuring in vitro growth of Plasmodium 
species blood stage cultures is the [3H] hypoxanthine incorporation assay, 
which was described by Chulay et al. in 1982 [232].  This assay relies upon the 
increased uptake of tritiated hypoxanthine by parasites.  A direct relationship 
was found between increasing incorporation of the radioactive isotope and 
increasing parasite numbers.  The radioisotope method was a vast 
improvement over previous parasite growth estimation methods, which 
involved the tedious counting of Giemsa-stained slides to estimate parasitemia.  
The [3H] hypoxanthine method was also found to be highly sensitive and 
reproducible.  However, the use of radioactive reagents necessary for this 
procedure drastically limited the number of laboratories able to conduct the [3H] 
hypoxanthine parasite growth assay to those approved for use and able to 
dispose of radioactive substances.  Radioisotope assays are both expensive 
and time consuming to carry out.  In addition, the caustic components of the 
assay pose potential health risks to researchers performing the technique. 
 In 2004, Bennett et al. described a Plasmodium blood stage growth 
detection method that utilized a DNA-binding fluorophore to estimate parasite 
growth in place of the traditional radioisotope method [233, 234].  SYBR Green 
I is a dye that intercalates with DNA, prefers G and C base pairs, and 
preferentially binds to double stranded DNA over single stranded DNA or RNA.  
The broad excitation and emission spectra of this DNA-binding dye make it a 
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very versatile option for the development of assays to quantify DNA.  As 
human red blood cells contain neither DNA nor RNA, the application of SYBR 
Green I to infected red blood cells that have been lysed with an appropriate 
agent allows for the quantification of only parasitic DNA.  Since its introduction, 
the SYBR Green I parasite growth assay has been continuously validated.  
One study comparing known antimalarial IC50 values that were determined with 
both the traditional radioisotope method and the SYBR Green I method found 
that the values resulting from the SYBR Green I growth assay were 
comparable to the values resulting from the [3H] hypoxanthine incorporation 
assay [234].  In addition, reliable IC50 values were able to be determined in less 
time, at a lower cost, and without the hazard of handling radioactive materials.  
Since its validation, the SYBR Green I parasite growth assay has been used to 
track developing resistance to current antimalarials and to screen small 
molecules and naturally occurring compounds for potential antimalarial activity 
[235-237].  
 We conducted a preliminary screen of three kinase inhibitor-focused 
libraries against P. falciparum strain W2 using the SYBR Green I parasite 
growth assay to determine if these compounds had the ability to inhibit 
intraerythrocytic parasite growth.  All compounds were screened in triplicate at 
1 µM and percent inhibition was calculated.  In addition, small molecules that 
were determined to be inhibitors of the parasitic kinase PfPK7 were further 
tested to determine IC50 values for the compounds.  The overall objective of 
the kinase inhibitor screen was to determine if the small molecules represented 
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in the three libraries were able to attenuate parasitic growth and to see whether 
or not previously identified small molecule inhibitors of PfPK7 were among the 
compounds able to inhibit parasite growth.  
Results 
 The three EMD kinase libraries contained small molecules that had been 
previously characterized.  Data regarding any human targets of the compounds 
as well as preliminary cytotoxicity data was known for most compounds.  
However, these small molecules had not yet been tested against P. falciparum 
blood stage cultures.  The initial screen of three kinase inhibitor-focused 
libraries containing 244 small molecules yielded 22 small molecules that were 
able to inhibit greater than 75 percent of intraerythrocytic parasite growth at 1 
µM.  Mean percent inhibition and standard deviations were calculated for all 
compounds at 1 µM (Table 6).  
 Following the initial screen of these molecules, the PfPK7 luminescence 
assays were performed to determine which of the molecules were able to 
inhibit this protein in low molar concentrations.  Out of the 244 small molecules 
contained in the libraries, 8 compounds displayed inhibitory activity against the 
protein.  These eight molecules were then tested against the parasite in order 
to determine the IC50 in blood stage cultures.  The assays were performed in 
triplicate and each compound was tested three times.  The IC50 concentrations 
for each small molecule were calculated using GraphPad Prism (Version 5)  
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Table 6:  Structure of Hits from EMD Kinase Library Screen Against P. falciparum 
Strain W2.  The first column indicates the small molecule number and the second 
column contains the structures of each compound.  The third column is the mean 
percent inhibition for each compound at 1 µM. 
 
Compound Structure Mean Percent 
Inhibition and 
Standard Deviation 
at 1 µM 
189406 
 
79.6 ± 2.8 
422706 
 
78.4 ± 3.2 
506126 
 
77.3 ± 1.9 
402085 
 
83.3 ± 2.1 
371957 
 
76.7 ± 1.8 
219478 
 
79.8 ± 5.3  
118501 
 
81.8 ± 3.1 
341251 Not Available 92.4 ± 2.5 
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Table 6 Continued 
 
Compound Structure Mean Percent 
Inhibition and 
Standard Deviation 
at 1 µM 
189406 
 
79.6 ± 2.8 
422706 
 
78.4 ± 3.2 
506126 
 
77.3 ± 1.9 
402085 
 
83.3 ± 2.1 
371957 
 
76.7 ± 1.8 
219478 
 
79.8 ± 5.3  
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81.8 ± 3.1 
341251 Not Available 92.4 ± 2.5 
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Table 6 Continued 
 
Compound Structure Mean Percent 
Inhibition and 
Standard Deviation 
at 1 µM 
124029 
 
75.2 ± 1.9 
365252 
 
88.9 (500 µM) ± 0.9 
218713 
 
78.3 ± 5.4 
203294 
 
75.4 ± 3.1 
665203 Not Available 77.2 ± 2.7 
401486 
 
76.1 ± 1.1 
420298 
 
76.7 ± 2.3 
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(Table 7).  Small molecules 324840, 428205, 217714 and 218710 displayed 
weak to no inhibitory activity against P. falciparum blood stage parasites as 
indicated by SYBR Green I growth assay IC50 values greater than 100 µM. 
551590 was also a weak inhibitor of parasite growth and 420298, 569397, and 
528116 displayed similar activities against the parasite. 
Discussion 
 The screen of 244 inhibitors from EMD kinase libraries I, II, and III 
revealed 22 molecules that were able to inhibit blood stage growth of P. 
falciparum strain W2 blood stage culture at 1 µM.  Interestingly, 11 of these 
molecules have a similar core structure and thus may bind to the same 
macromolecule within the parasite.  Small molecules 203294, 365252, 361553, 
420298, 402085, 371957, 402081, 361550, 361551, 402086, and 361556 
possess an indirubin-like core structure.  These molecules can be further 
subdivided into 402085, 402081, 361550, 361551, 402086, and 361556 which 
maintain the true indirubin core structure and all act as inhibitors of Cdk2/cyclin 
A, Cdk1/cyclin B, and GSK-3 isoforms.  The remaining small molecules from this 
group, 203294, 365252, 361553,420298, and 371957 are more similar in 
structure to the CDK inhibitor staurosporine and are inhibitors of human PKC, 
PKA, and GSK-3.  Future studies aimed at determining the IC50 values of these 
compounds and identifying their in vivo target may be fruitful as they could 
potentially yield a new drug target for antimalarial drug development researchers. 
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Compound Structure IC50 Concentration for 
PfPK7 Inhibitors in 
SYBR Green I Assay 
324840 
 
>1.0e-4 
428205 
 
>1.0e-4 
420298 
 
1.08e-5 ± 2.65e-6 
569397 
 
8.39e-6 ± 6.58e-6 
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Table 7.  IC50 Concentrations for PfPK7 Inhibitors in SYBR Green I 
Assay.  Column one contains the compound name and column two 
indicates the structure of each compound.  Column three contains the 
IC50 molar concentration for each PfPK7 inhibitor in the SYBR Green I 
Assay.   
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Compound Structure IC50 Concentration for 
PfPK7 Inhibitors in 
SYBR Green I Assay 
217714 
 
>1.0e-4 
218710 
 
>1.0e-4 
528116 
 
1.59e-5 ± 4.88e-6 
551590 
 
8.98e-5 ± 1.28e-5 
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Table 7 Continued 
   
 
  
 
 
102 
 Small molecules 324840, 428205, 217714, and 218710 were not able to 
efficiently inhibit intraerythrocytic development of blood stage P. falciparum with 
SYBR Green I IC50 values above 100 µM.  Molecule 324840 was predicted to be 
both soluble in an aqueous environment and cell permeable, but its overall 
affinity for the PfPK7 binding site was low and this could partially explain its 
failure to affect parasite growth.  Conversely, 428205 had a LogP above five and 
was predicted to have poor aqueous solubility and these qualities could indicate 
this molecule is not able to function in an aqueous and hydrophilic environment 
such as the parasite cytoplasm.  Compounds 217714 and 218710 were predicted 
to have adequate pharmacokinetic properties.  The failure of small molecules to 
inhibit the protein may be due to activation of efflux pumps, which shuttle small 
molecules out of cellular compartments before they can reach their intended 
targets or perhaps to metabolism of the compounds into biologically inactive 
forms.  551590 was a weak inhibitor of parasite growth and this may be due to 
the predicted poor cell permeability of this molecule in both Caco-2 and MDCK 
models.  Three PfPK7 inhibitor molecules were able to inhibit parasite growth; 
528116, 420298, and 569397.  The inhibitory activity of these small molecules on 
blood stage cultures of P. falciparum could have been due in part to the inhibition 
of PfPK7 as these molecules had the highest affinity for the binding site in 
luminescence assays; however, given the noted promiscuity of 420298 and 
569397 as well as the NO2 group of 528116, it is also likely that the inhibitory 
effects of these proteins on the parasite are due to off target effects.  
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CHAPTER V 
TREATMENT OF P. FALCIPARUM BLOOD  
STAGE CULTURES WITH  
PURVALANOL B 
 
Introduction 
 Since the sequencing of the P. falciparum genome and the initial 
characterization of the proteome in 2002, several studies have used molecular 
techniques aimed at further elucidating the similarities and differences between 
Plasmodium proteins and well-characterized proteins from other organisms.  In 
recent years with the advent of increasingly accessible and sensitive 
methodology, analysis of mixed protein samples that identify hundreds of 
proteins at a time has become possible.  Instead of characterizing the function of 
one protein in isolation, researchers may now begin to determine the affect that 
change in the cellular environment has on the entire proteomic complement of a 
given cell type using techniques that are able to resolve individual proteins in 
complex protein mixtures. 
 These increasingly sensitive techniques have been used to characterize 
the P. falciparum life cycle and to pinpoint several proteins that are specific for 
each stage of development within the parasite [210].  Similarly, potential vaccine 
candidates have been identified by profiling parasite isolates during crucial 
stages of parasite development and determining those proteins present in 
abundance [238].   
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 These techniques are also able to determine relative changes in 
abundance between wildtype parasite and parasites that have been subjected to 
some environmental change such as drug challenge.  MudPIT or similar complex 
sample analysis techniques have been used to characterize changes in P. 
falciparum protein complement that result from challenge with such antimalarials 
as pyrimethamine, tetracycline, chloroquine, and artemisinin [239, 240].  This 
large-scale approach has the benefit of characterizing the effect of drug 
application on many proteins in an organism at a time.  Given P. falciparum 
parasite propensity to develop rapid resistance to applied drugs, it is 
advantageous to determine any changes in protein expression as a result of 
compound application.  By looking at changes in protein compliment, we may be 
able to predict resistance development before it occurs or perhaps develop 
strategies to stave off the effects of waning drug efficacy.  Though this strategy 
has been applied to determine effects of many antimalarial drugs on protein 
expression, to date no experiment has been performed to characterize the effect 
of kinase inhibitors on P. falciparum intraerythrocytic growth. 
 The kinase inhibitor Purvalanol B has been shown to inhibit function of P. 
falciparum kinases including those necessary for the completion of the 
intraerythrocytic life cycle such as PfPK5 and PfCK1 [133, 241].  In fact an 
experiment using proteins isolated from P. falciparum culture lysates showed that 
when fractionated lysates were applied to a column containing immobilized 
Purvalanol B, the only visible band from a gel of the resulting eluent was PfCK1 
[241].  However, it is important to note that given the concentration of inhibitor 
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applied to treatment cultures, it is likely that the small molecule affected more 
than one protein during the incubation period. 
 We incubated blood stage cultures of P.falciparum strain W2 with the CDK 
inhibitor Purvalanol B during 25-36 hpi and following inhibitor incubation, cultures 
were lysed and proteins were extracted.  Soluble fractions were digested with 
trypsin and sent for analysis.  Giemsa-stained slides were used to determine the 
ability of parasites to proceed through schizogony and a shotgun proteomics 
approach was used to determine relative differences in protein expression 
between wildtype and Purvalanol B-treated parasites.        
Results 
 Giemsa-stained slides analyzed before inhibitor treatment indicated all 
parasite cultures contained approximately 6% parasitized RBCs and were 
composed of >90% trophozoite parasites with one nucleus (approximately 25 
hpi) prior to treatment with Purvalanol B.  Student t-test analysis of parasitemia 
counts from post-treatment slides indicated no significant change in parasitemia 
during the 12 hour Purvalanol B exposure period in any of the culture flasks 
(p=0.7966).  However, parasite stage differences were observed between the 
treatment groups and those treated only with DMSO vehicle (Figure 6).  While 
control cultures were composed of mostly multinucleated cells, the inhibitor-
treated cultures contained predominantly parasites with only one nucleus.  A 
student t-test revealed a significant difference in the number of cells that were 
able to form multiple nuclei between the control and inhibitor-treated cultures 
(p=.00006).    
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Figure 6:  Control and Purvalanol B-Treated Parasites Before and After Inhibitor 
Application.  A.  representative image of cultured control parasitized RBCs prior 
to treatment with Purvalanol B; B. representative image of cultured control 
parasitized RBCs after the 12 hour treatment period.  The arrow is pointing to 
multinucleated cells. C. parasitized RBCs from a treatment flask prior to 
treatment with Purvalanol B; D. is an image of parasitized RBCs 12 hours after 
Purvalanol B application.  All slides were stained with Giemsa stain. 
 
 Of the six samples analyzed using MudPIT, three were control group 
biological replicates and three were Purvalanol B-treated biological replicates.  A 
total of 52038 P. falciparum spectra and 25506 human spectra were identified.  
Peptide threshold of 95 % and decoy false discovery rate of 0.08 % and 0.01 % 
for P. falciparum and human respectively were used for the Mascot search.  With 
a protein threshold of 99% and a minimum of two unique peptides found per 
A B 
C!! D 
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protein, the 52038 spectra identified in the P. falciparum Mascot search 
corresponded to 518 P. falciparum proteins among the six samples (Appendix A).  
The same parameters were used in the human Mascot search and the 25506 
spectra were assigned to 76 human proteins (Appendix B) among the six 
samples.  Of 518 protein identifications from the P. falciparum search, 414 
proteins were found both in control and treatment samples (Figure 7).  57 
proteins were found only in the treatment samples (Table 8), and 47 proteins 
were found only in the control samples (Table 9).   
     
 
Figure 7:  Number of Proteins in Control and Purvalanol B-treated 
Samples.  Left indicates the number of proteins found only in control 
samples, while right indicates the number of proteins found only in 
treatment samples.  The intersection indicates the number of proteins 
common to both sample types. 
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Table 8:  Proteins in Only P. falciparum Control Samples.  Column one provides 
the protein name and column two the accession number of each protein.  Any 
identifications made from the reverse concatenated database are not 
represented. 
 
Protein Accession Number 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.103 PE=4 SV=1 
C0H4U0_PLAF7 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL2120w PE=4 SV=1 
Q8I4Y9_PLAF7 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE1465w PE=4 SV=1 
C0H4G7_PLAF7 
DNA repair protein, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PFE0270c PE=3 SV=1 
Q8I447_PLAF7 
Histidine--tRNA ligase, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0428 PE=4 SV=1 
Q8IL22_PLAF7 
40S ribosomal protein S28e, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0585 PE=4 SV=1 
Q8IKL9_PLAF7 
10b antigen, putative OS=Plasmodium falciparum (isolate 
3D7) GN=PF10_0213 PE=4 SV=1 
Q8IJI4_PLAF7 
Ubiquitination-mediated degradation component, putative 
OS=Plasmodium falciparum (isolate 3D7) GN=PF08_0020 
PE=4 SV=1 
C0H4Y0_PLAF7 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF07_0016 PE=4 SV=1 
Q8IC27_PLAF7 
Vacuolar ATP synthase subunit E, putative 
OS=Plasmodium falciparum (isolate 3D7) GN=PFI1670c 
PE=3 SV=2 
Q8I2H3_PLAF7 
V-type ATPase, subunit C, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFA_0300c PE=4 SV=1 
Q8I280_PLAF7 
Arginyl-tRNA synthetase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL0900c PE=3 SV=1 
Q8I5M2_PLAF7 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0332 PE=4 SV=1 
Q8II42_PLAF7 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0990w PE=4 SV=1 
C0H4F1_PLAF7 
Proteasome, putative OS=Plasmodium falciparum (isolate 
3D7) GN=PFI1545c PE=4 SV=1 
Q8I0U7_PLAF7 
DNA-directed RNA polymerase OS=Plasmodium falciparum 
(isolate 3D7) GN=PFC0805w PE=3 SV=1 
O77375_PLAF7 
P-type calcium transporting ATPase OS=Plasmodium 
falciparum GN=serca PE=3 SV=1 
E1CC54_PLAFA 
60S ribosomal protein L23a, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0132 PE=3 SV=1 
Q8IE82_PLAF7 
Coatomer alpha subunit, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF0330w PE=4 SV=1 
C6KSR5_PLAF7 
Pfmdr2 protein OS=Plasmodium falciparum GN=pfmdr2 
PE=3 SV=1 
Q25693_PLAFA 
60S ribosomal protein L14, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0296 PE=4 SV=1 
Q8ILE8_PLAF7 
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Table 8 Continued 
 
Protein Accession Number 
Heat shock protein 90, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF11_0188 PE=3 SV=1 
Q8III6_PLAF7 
ORF 2 protein (Fragment) OS=Plasmodium falciparum 
GN=ORF 2 PE=2 SV=1 
Q02602_PLAFA 
Ring-exported protein 1 OS=Plasmodium falciparum 
(isolate 3D7) GN=REX1 PE=4 SV=1 
Q8I2G1_PLAF7 
40S ribosomal protein S24 OS=Plasmodium falciparum 
(isolate 3D7) GN=PFE0975c PE=3 SV=1 
Q8I3R6_PLAF7 
Glutamate--cysteine ligase (Gamma-glutamylcysteine 
synthetase) OS=Plasmodium falciparum GN=GCS PE=2 
SV=1 
Q9TY17_PLAFA 
Activator of Hsp90 ATPase homolog 1-like protein, putative 
OS=Plasmodium falciparum (isolate 3D7) GN=PFC0360w 
PE=4 SV=2 
O97256_PLAF7 
Ubiquitin conjugating enzyme E2, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL0190w PE=3 SV=1 
Q8I607_PLAF7 
Coatamer protein, beta subunit, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0277 PE=4 SV=2 
Q8ILG6_PLAF7 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.62 PE=4 SV=1 
Q8IB31_PLAF7 
60S ribosomal protein L36 OS=Plasmodium falciparum 
(isolate 3D7) GN=PF11_0106 PE=3 SV=2 
Q8I713_PLAF7 
Serine rich protein homologue OS=Plasmodium falciparum 
PE=3 SV=1 
Q26015_PLAFA 
6-cysteine protein, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=Pf41 PE=4 SV=1 
Q8I1Y0_PLAF7 
DNA replication licensing factor mcm7 homologue, putative 
OS=Plasmodium falciparum (isolate 3D7) GN=PF07_0023 
PE=3 SV=1 
Q8IC16_PLAF7 
Rab2, GTPase OS=Plasmodium falciparum (isolate 3D7) 
GN=Rab2 PE=3 SV=1 
Q8I5A9_PLAF7 
Cytidine triphosphate synthetase OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0100 PE=4 SV=1 
Q8ILZ3_PLAF7 
Ubiquitin carboxyl-terminal hydrolase OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE1355c PE=3 SV=1 
Q8I3J3_PLAF7 
Glycogen synthase kinase 3 OS=Plasmodium falciparum 
(isolate 3D7) GN=PfGSK-3 PE=4 SV=2 
O77344_PLAF7 
Acetyl-CoA synthetase OS=Plasmodium falciparum (isolate 
3D7) GN=PFF1350c PE=4 SV=1 
C6KTB4_PLAF7 
DNAJ protein, putative OS=Plasmodium falciparum (isolate 
3D7) GN=PF08_0032 PE=4 SV=1 
Q8IB72_PLAF7 
DNA topoisomerase 2 OS=Plasmodium falciparum (isolate 
3D7) GN=PF14_0316 PE=3 SV=1 
Q8ILC8_PLAF7 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL0895c PE=4 SV=1 
Q8I5M3_PLAF7 
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Table 8 Continued 
 
 
Protein Accession Number 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.103 PE=4 SV=1 
C0H4U0_PLAF7 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL2120w PE=4 SV=1 
Q8I4Y9_PLAF7 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE1465w PE=4 SV=1 
C0H4G7_PLAF7 
DNA repair protein, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PFE0270c PE=3 SV=1 
Q8I447_PLAF7 
Histidine--tRNA ligase, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0428 PE=4 SV=1 
Q8IL22_PLAF7 
40S ribosomal protein S28e, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0585 PE=4 SV=1 
Q8IKL9_PLAF7 
10b antigen, putative OS=Plasmodium falciparum (isolate 
3D7) GN=PF10_0213 PE=4 SV=1 
Q8IJI4_PLAF7 
Ubiquitination-mediated degradation component, putative 
OS=Plasmodium falciparum (isolate 3D7) GN=PF08_0020 
PE=4 SV=1 
C0H4Y0_PLAF7 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF07_0016 PE=4 SV=1 
Q8IC27_PLAF7 
Vacuolar ATP synthase subunit E, putative 
OS=Plasmodium falciparum (isolate 3D7) GN=PFI1670c 
PE=3 SV=2 
Q8I2H3_PLAF7 
V-type ATPase, subunit C, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFA_0300c PE=4 SV=1 
Q8I280_PLAF7 
Arginyl-tRNA synthetase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL0900c PE=3 SV=1 
Q8I5M2_PLAF7 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0332 PE=4 SV=1 
Q8II42_PLAF7 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0990w PE=4 SV=1 
C0H4F1_PLAF7 
Proteasome, putative OS=Plasmodium falciparum (isolate 
3D7) GN=PFI1545c PE=4 SV=1 
Q8I0U7_PLAF7 
DNA-directed RNA polymerase OS=Plasmodium falciparum 
(isolate 3D7) GN=PFC0805w PE=3 SV=1 
O77375_PLAF7 
P-type calcium transporting ATPase OS=Plasmodium 
falciparum GN=serca PE=3 SV=1 
E1CC54_PLAFA 
60S ribosomal protein L23a, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0132 PE=3 SV=1 
Q8IE82_PLAF7 
Coatomer alpha subunit, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF0330w PE=4 SV=1 
C6KSR5_PLAF7 
Pfmdr2 protein OS=Plasmodium falciparum GN=pfmdr2 
PE=3 SV=1 
Q25693_PLAFA 
60S ribosomal protein L14, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0296 PE=4 SV=1 
Q8ILE8_PLAF7 
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Table 9:  Proteins Only in P. falciparum Treatment Samples.  Column one 
provides the protein name and column two the accession number for each 
protein.  Any identifications made from the reverse concatenated database are 
not represented.    
 
Protein Accession Number 
Putative uncharacterized protein 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL8P1.103 PE=4 SV=1 
C0H4U0_PLAF7 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL2120w PE=4 
SV=1 
Q8I4Y9_PLAF7 
Putative uncharacterized protein 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE1465w PE=4 SV=1 
C0H4G7_PLAF7 
DNA repair protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0270c PE=3 
SV=1 
Q8I447_PLAF7 
Histidine--tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0428 PE=4 
SV=1 
Q8IL22_PLAF7 
40S ribosomal protein S28e, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0585 PE=4 SV=1 
Q8IKL9_PLAF7 
10b antigen, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF10_0213 PE=4 SV=1 
Q8IJI4_PLAF7 
Ubiquitination-mediated degradation component, 
putative OS=Plasmodium falciparum (isolate 
3D7) GN=PF08_0020 PE=4 SV=1 
C0H4Y0_PLAF7 
Putative uncharacterized protein 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF07_0016 PE=4 SV=1 
Q8IC27_PLAF7 
Vacuolar ATP synthase subunit E, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFI1670c PE=3 SV=2 
Q8I2H3_PLAF7 
V-type ATPase, subunit C, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFA_0300c PE=4 SV=1 
Q8I280_PLAF7 
Arginyl-tRNA synthetase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL0900c PE=3 SV=1 
Q8I5M2_PLAF7 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0332 PE=4 
SV=1 
Q8II42_PLAF7 
Putative uncharacterized protein 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE0990w PE=4 SV=1 
C0H4F1_PLAF7 
Proteasome, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFI1545c PE=4 
SV=1 
Q8I0U7_PLAF7 
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Table 9 Continued 
 
Protein Accession Number 
DNA-directed RNA polymerase OS=Plasmodium 
falciparum (isolate 3D7) GN=PFC0805w PE=3 
SV=1 
O77375_PLAF7 
P-type calcium transporting ATPase 
OS=Plasmodium falciparum GN=serca PE=3 
SV=1 
E1CC54_PLAFA 
60S ribosomal protein L23a, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0132 PE=3 SV=1 
Q8IE82_PLAF7 
Coatomer alpha subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFF0330w PE=4 SV=1 
C6KSR5_PLAF7 
Pfmdr2 protein OS=Plasmodium falciparum 
GN=pfmdr2 PE=3 SV=1 
Q25693_PLAFA 
60S ribosomal protein L14, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0296 PE=4 SV=1 
Q8ILE8_PLAF7 
Heat shock protein 90, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0188 PE=3 
SV=1 
Q8III6_PLAF7 
ORF 2 protein (Fragment) OS=Plasmodium 
falciparum GN=ORF 2 PE=2 SV=1 
Q02602_PLAFA 
Ring-exported protein 1 OS=Plasmodium 
falciparum (isolate 3D7) GN=REX1 PE=4 SV=1 
Q8I2G1_PLAF7 
40S ribosomal protein S24 OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0975c PE=3 
SV=1 
Q8I3R6_PLAF7 
Glutamate--cysteine ligase (Gamma-
glutamylcysteine synthetase) OS=Plasmodium 
falciparum GN=GCS PE=2 SV=1 
Q9TY17_PLAFA 
Activator of Hsp90 ATPase homolog 1-like 
protein, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PFC0360w PE=4 SV=2 
O97256_PLAF7 
Ubiquitin conjugating enzyme E2, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL0190w PE=3 SV=1 
Q8I607_PLAF7 
Coatamer protein, beta subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0277 PE=4 SV=2 
Q8ILG6_PLAF7 
Putative uncharacterized protein 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL8P1.62 PE=4 SV=1 
Q8IB31_PLAF7 
60S ribosomal protein L36 OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0106 PE=3 
SV=2 
Q8I713_PLAF7 
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Table 9 Continued 
 
Protein Accession Number 
Serine rich protein homologue OS=Plasmodium 
falciparum PE=3 SV=1 
Q26015_PLAFA 
6-cysteine protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=Pf41 PE=4 SV=1 
Q8I1Y0_PLAF7 
DNA replication licensing factor mcm7 
homologue, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF07_0023 PE=3 SV=1 
Q8IC16_PLAF7 
Rab2, GTPase OS=Plasmodium falciparum 
(isolate 3D7) GN=Rab2 PE=3 SV=1 
Q8I5A9_PLAF7 
Cytidine triphosphate synthetase 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0100 PE=4 SV=1 
Q8ILZ3_PLAF7 
Ubiquitin carboxyl-terminal hydrolase 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE1355c PE=3 SV=1 
Q8I3J3_PLAF7 
Glycogen synthase kinase 3 OS=Plasmodium 
falciparum (isolate 3D7) GN=PfGSK-3 PE=4 
SV=2 
O77344_PLAF7 
Acetyl-CoA synthetase OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF1350c PE=4 
SV=1 
C6KTB4_PLAF7 
DNAJ protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF08_0032 PE=4 
SV=1 
Q8IB72_PLAF7 
DNA topoisomerase 2 OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0316 PE=3 
SV=1 
Q8ILC8_PLAF7 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL0895c PE=4 
SV=1 
Q8I5M3_PLAF7 
Spermidine synthase OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0301 PE=1 
SV=1 
Q8II73_PLAF7 
Putative uncharacterized protein 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF08_0137 PE=4 SV=1 
Q8IAK9_PLAF7 
PfSec23 protein OS=Plasmodium falciparum 
(isolate 3D7) GN=Pfsec23 PE=2 SV=1 
Q8IB60_PLAF7 
Replication factor C subunit 1 OS=Plasmodium 
falciparum GN=rfc1 PE=4 SV=1 
Q9GQW6_PLAFA 
60S ribosomal protein L8, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE0845c PE=4 SV=1 
Q8I3T9_PLAF7 
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Table 9 Continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein Accession Number 
Ubiquitin carboxyl-terminal hydrolase a, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFD0680c PE=4 SV=1 
Q8I1U8_PLAF7 
Orotate phosphoribosyltransferase 
OS=Plasmodium falciparum GN=oprt PE=2 SV=1 
Q8N0R1_PLAFA 
Calmodulin OS=Plasmodium falciparum (isolate 
3D7) GN=PF14_0323 PE=3 SV=2 
CALM_PLAF7 
Haloacid dehalogenase-like hydrolase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0190 PE=4 SV=1 
Q8III4_PLAF7 
Thymidylate kinase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=TMK PE=1 SV=1 
Q8I4S1_PLAF7 
Myosin-A OS=Plasmodium falciparum (isolate 
FCBR / Columbia) PE=2 SV=1 
MYOA_PLAFB 
Probable DNA-directed RNA polymerase II 
subunit RPB11 OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0023 PE=3 SV=1 
RPB11_PLAF7 
Zinc finger protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0313 PE=4 
SV=1 
Q8IDC0_PLAF7 
60S ribosomal protein L28, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0437 PE=4 SV=1 
Q8IHU0_PLAF7 
!
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 Gene ontology (GO) terms, which used a set of defined terms to describe 
gene product properties, were extracted for all possible proteins.  GO terms are 
split into three domains:  1) cellular component describes the parts of the cell or 
the extracellular environment in which the gene product functions; 2) molecular 
function describes the gene product’s function at the molecular level; 3) biological 
process is the overall series of events in which the gene product participates 
(e.g. signal transduction).  It is important to note that one protein may be 
described by several GO terms and thus fall into more than one category.  The 
number of proteins categorized into each GO domain and subdomain were 
approximately the same in treated and control samples (Figure 8a-8c).   
 As no difference in the number of proteins that were assigned to each GO 
term existed between treated and control proteins, GO terms assigned to all six 
samples were described together (Figure 9a-9c).  Within the cellular component 
subdomain, the predominating GO terms in descending order were unknown 
(278), cytoplasm (178) intracellular organelle (154), and organelle part (85).  
Molecular function (394), binding (242), and catalytic activity (221) were the 
predominating terms from the molecular function GO subdomain.  Finally, the 
biological process subdomain GO term categorization yielded three major terms; 
cellular process (322), metabolic process (293), and unknown (155).  All other 
biological process terms such as biological regulation, response to stimulus, 
establishment of localization, and locomotion were assigned to less than 10 % of 
all categorized proteins.  
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Figure 9a:  Cellular Component GO Terms for P. falciparum Search Proteins.  
Each section of the pie represents a GO term and corresponding number of 
proteins that were assigned each term is located in brackets beside the term 
name. 
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Figure 9b:  Molecular Function GO Terms for P. falciparum Search Proteins.  
Each section of the pie represents a GO term and corresponding number of 
proteins that were assigned each term is located in brackets beside the term 
name. 
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Figure 9c:  Biological Process GO Terms for P. falciparum Search Proteins.  
Each section of the pie represents a GO term and corresponding number of 
proteins that were assigned each term is located in brackets beside the term 
name. 
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 Differences in relative protein abundance between the control and 
Purvalanol B-treated parasites were quantified by both spectral counting (SpC) 
and average total ion current (TIC) analyses of normalized data in Scaffold.  T-
tests were performed and fold changes were calculated for each protein.  
Proteins with a t-test p-value below 0.05 and  ≥ 1.5 fold change in either SpC or 
TIC analyses were considered upregulated in treatment compared to control and 
proteins with a p-value below 0.05 and a fold change of ≤ 0.5 in either SpC or 
TIC analyses were considered down regulated in treatment compared to control. 
 A total of 10 proteins were shown to be differentially regulated in treatment 
samples relative to control samples (Table 10).  There were 8 proteins shown to 
be upregulated and 2 proteins shown to be downregulated in Purvalanol B-
treated parasite samples compared to samples incubated with DMSO vehicle.  
Upregulated proteins included proteasome component C8 (O77396_PLAF7), 
subunit of proteasome activator complex (Q8I374_PLAF7), structure-specific 
recognition protein (Q8IL56_PLAF7), adenylosuccinate synthetase 
(PURA_PLAF7 (+1)), proteasome subunit alpha type (Q8IDG3_PLAF7), 
cysteinyl-tRNA synthetase (Q8IJP3_PLAF7), thioredoxin reductase 2 
(TRXR2_PLAF7 (+1)), and 40S ribosomal protein S6 (Q8IDR9_PLAF7).  
Proteins that were downregulated in treatment compared to control samples 
included RNA binding protein (Q8I374_PLAF7) and Helicase (Q8IL13_PLAF7).  
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Table 10:  Differentially Regulated Proteins Between Purvalanol B-treated and 
Control Samples.  Column one indicates the protein name, while column two 
indicates the UniProt accession number.  The t-test p-value is in the third column 
and fold change is indicated in the forth column.       
Protein Name Accession 
Number 
P-
value 
Fold 
Change 
Proteasome	  component	  C8,	  putative	  
OS=Plasmodium	  falciparum	  (isolate	  3D7)	  
GN=PFC0745c	  PE=4	  SV=1	  
 
O77396_PLAF7	  
 
0.0016	   2.1	  
Subunit	  of	  proteaseome	  activator	  complex,	  
putative	  OS=Plasmodium	  falciparum	  (isolate	  
3D7)	  GN=PFI0370c	  PE=4	  SV=1	  
 
Q8I374_PLAF7	  
 
0.015	   2	  
Structure	  specific	  recognition	  protein	  
OS=Plasmodium	  falciparum	  (isolate	  3D7)	  
GN=PF14_0393	  PE=4	  SV=1	  
 
Q8IL56_PLAF7	  
 
0.027	   2.2	  
Adenylosuccinate	  synthetase	  OS=Plasmodium	  
falciparum	  (isolate	  3D7)	  GN=Adss	  PE=3	  SV=1	  
 
PURA_PLAF7	  
(+1)	  
 
0.032	   1.8	  
Proteasome	  subunit	  alpha	  type	  OS=Plasmodium	  
falciparum	  (isolate	  3D7)	  GN=PF13_0282	  PE=3	  
SV=1	  
 
Q8IDG3_PLAF7	  
 
0.038	   1.6	  
Cysteinyl-­‐tRNA	  synthetase,	  putative	  
OS=Plasmodium	  falciparum	  (isolate	  3D7)	  
GN=PF10_0149	  PE=3	  SV=2	  
 
Q8IJP3_PLAF7	  
 
0.04	   2.8	  
Thioredoxin	  reductase	  2	  OS=Plasmodium	  
falciparum	  (isolate	  3D7)	  GN=trxr2	  PE=2	  SV=2	  
 
TRXR2_PLAF7	  
(+1)	  
 
0.049	   2.9	  
40S	  ribosomal	  protein	  S6,	  putative	  
OS=Plasmodium	  falciparum	  (isolate	  3D7)	  
GN=PF13_0228	  PE=4	  SV=1	  
 
Q8IDR9_PLAF7	  
 
0.037	   1.5	  
 Helicase,	  putative	  OS=Plasmodium	  falciparum	  
(isolate	  3D7)	  GN=b	  PE=3	  SV=2 
Q8IL13_PLAF7	  
 
0.019	   0.3	  
RNA	  binding	  protein,	  putative	  OS=Plasmodium	  
falciparum	  (isolate	  3D7)	  GN=PFI1175c	  PE=4	  SV=1	  
 
Q8I2R8_PLAF7	  
 
0.021	   0.2	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Discussion 
 A total of 518 proteins were found among six samples using MudPIT.  
Treatment and control samples contained 414 proteins, while 47 and 57 proteins 
were found solely in the control and Purvalanol B-treated samples respectively.  
While differences in morphology were evident between the control and treated 
cultures in blood smears of intraerythrocytic P.falciparum parasites, GO terms 
extracted for proteins indicated no differences in GO subdomain assignments for 
cellular component, molecular function, or biological process.  Calculation of fold 
change and t-test p-values indicated 10 proteins that were differentially regulated 
between control and treated groups.   
 Of the 10 differentially regulated proteins, 8 were found to be upregulated.  
40S ribosomal protein S6 is a ribosomal protein and cycteinyl-tRNA synthetase 
an apicoplast- localized protein that are both involved in translation.  
Adenylosuccinate synthetase is an enzyme that catalyzes the formation of 
adenylosuccinate from inosine monophosphate and aspartate [242].  It is 
important to note that P. falciparum lacks the necessary synthesis machinery for 
de novo synthesis of purine and thus all purine precursors are salvaged from the 
host (as reviewed in ([243]   
 Thioredoxin reductase is a cytoplasmic protein that is necessary for redox 
homeostasis.  It belongs to the class-I pyridine nucleotide-disulfide 
oxidoreductase family and has been identified as a potential antimalarial drug 
target because its function is essential for parasite survival and a crystal structure 
is now available for this protein [244-246].  Thioredoxin in P. falciparum functions 
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as an antioxidant that helps relieve the parasite from oxidative stress [247].  
Treatment with the inhibitor Purvalanol B may have increased oxidative stress on 
parasites and resulted in an upregulation of this protein.  Additionally, in other 
systems, it has been shown that application of proteasome inhibitors in other 
cells leads to an increased vulnerability to oxidative stress and that heat shock 
proteins confer a degree of tolerance to oxidative damage [248].  While not 
expressed at the significance cutoff levels, heat shock proteins 70 
(Q8I5F4_PLAF7) (p-value 0.062, fold change 0.09) and heat shock protein 86 
(Q8IC05_PLAF7)(p-value 0.099 and fold change 1.2) may have been 
upregulated in treatment samples compared to control samples.  Interestingly, as 
previously discussed, the potent antimalarial compound artemisinin also 
functions by increasing oxidative stress on the parasite.   
 The upregulated proteins in treatment samples included proteasome 
component C8 (O77396_PLAF7), which is a cytoplasmic and nuclear protein that 
is part of the proteasome core complex alpha-subunit and is involved in ubiquitin-
dependent catabolic processes such as protein degradation.  Interestingly, two 
additional proteasome proteins were also upregulated in the Purvalanol B-treated 
samples compared to controls.  Subunit of proteasome activator complex 
(Q8I374_PLAF7) and proteasome subunit alpha (Q8IDG3_PLAF7).  While some 
P. falciparum proteasome subunits have been characterized, little is known about 
these three protein subunits.  However, it has been shown that proteasome 
inhibitors are able to attenuate intraerythrocytic P. falciparum growth [249].  
Further, it has been shown that while the proteasome in other organisms plays a 
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role in diverse cellular processes such as response to stress and metabolic 
adaptation, it generally has two primary roles:  1) the ubiquitin-dependent 
proteolytic degradation of aberrantly folded or assembled proteins; and 2) the 
control of cell cycle by the temporally precise proteolysis of selected cell cycle 
modulators like cyclins and transcription factors (as reviewed in [250]).   
 It may be possible that the P. falciparum proteasome also plays a role in 
cell cycle regulation [251].  Application of Purvalanol B to synchronized P. 
falciparum cultures resulted in an inability to complete schizogony as evidenced 
by a significant reduction in the number of parasite cells able to form multiple 
nuclei when compared to control cultures and an upregulation of proteasome 
subunits in treatment cultures.  Purvalanol B application in treatment cultures 
may have resulted in proteasome inhibition, which in turn lead to upregulation of 
proteasome subunits and the inability to degrade certain cell cycle machinery 
such as structure specific recognition protein (Q8IL56_PLAF7), which is a 
nuclear protein that is involved in single-stranded DNA binding necessary to 
stabilize negatively charged DNA when it is unwound.   
 Interestingly, while the following proteins did not meet both criteria for 
significance, proliferating cell nuclear antigen (PCNA_PLAF7 (+1))(p-value 0.063, 
fold change 1.6), cell division cycle protein 48 homolog (C6KT34_PLAF7)(p-
value 0.022, fold change 1.3), and replication factor A-related protein 
(Q8I3A1_PLAF7)(p-value 0.08, fold change 2.8) may have been upregulated in 
treatment samples.  Proliferating cell nuclear antigen was previously discussed 
and is a processivity factor for DNA polymerase.  Cell division cycle protein 48 is 
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a homolog of yeast cdc48p and human p97 [252].  The yeast protein was first 
isolated in yeast mutants and the nonfunctional cdc48p was found to cause G2/M 
arrest.  Later it was observed that cdc48p also functions during a G1 checkpoint 
in yeast that is equivalent to the restriction point in mammals and that 
progression through this checkpoint was mediated by the cdc48p-dependent 
degradation of cyclin-dependent kinase inhibitor Far1p [253].  The final probable 
upregulated cell cycle protein is replication factor A, which is a single stranded 
binding protein that, in yeast, is phosphorylated at the G1/S phase transition by 
cdc2 (CDK1) and dephosphorylated directly prior to mitosis [159, 254].  
Additionally, cdc2 is the yeast homolog of PfPK5 in P. falciparum, which has 
been shown to be inhibited by the CDK inhibitor Purvalanol B at 130nM, a 
concentration well below the applied concentration in this experiment [255].  
PfPK5 activity has also been shown to be necessary for the completion of the 
intraerythrocytic life cycle specifically during schizogony [133] . 
  Taken together these data show an upregulation of proteasome 
components in Purvalanol B-treated parasites compared to control parasites and 
may indicate an increase in oxidative stress levels.  Further, the inability of 
Purvalanol-B treated parasites to form multiple nuclei at 36 hpi and the 
upregulation of cell cycle proteins may indicate the Purvalanol B-mediated 
inhibition of a factor necessary for completion of parasite schizogony. 
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
 P. falciparum, a causative agent of malaria is one of the most deadly 
parasites known to man.  Malaria devastates developing, poverty-stricken 
populations across the globe and given the emergence of multi-drug resistant P. 
falciparum strains, the dawn of a future with no effective treatment for this 
disease seems increasingly likely.  However, the aid of organizations such as the 
Malaria Vaccine Initiative (www.malariavaccine.org) and the Roll Back Malaria 
Partnership (www.rollbackmalaria.org) with funding from sources such as the Bill 
and Melinda Gates Foundation (www.gatesfoundation.org), researchers are 
making strides in drug and vaccine development as well as malaria eradication 
strategies.  However, given that malaria is still the primary killer of children under 
five years of age in tropical areas, it is imperative that research aimed at 
understanding this lethal organism continue.  Drug targets as well as compounds 
with antimalarial activity must be identified and we must leverage what we know 
to better understand basic parasite biology. 
 The goal of this research was to investigate the P. falciparum kinase 
PfPK7 as a potential antimalarial drug target by screening a library of known 
kinase inhibitors against this protein and to define interactions between small 
molecules and the PfPK7 ATP-binding site that are potentially important for 
compound affinity.  In addition, the screening of kinase inhibitor libraries against 
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P. falciparum strain W2 blood culture parasites provided information as to 
whether kinase inhibitors would be able to attenuate intraerythrocytic growth of 
the parasite and, in particular, whether application of small molecule inhibitors 
targeting PfPK7 would result in decreased growth rates.  Finally, by treating 
blood stages cultures with cyclin-dependent kinase inhibitor Purvalanol B, it was 
possible to investigate large scale protein changes between inhibitor-treated and 
wildtype parasites, thus describing for the first time proteomic changes of P. 
falciparum parasites after drug challenge with a kinase inhibitor.  
 A screen of 244 well-characterized kinase inhibitors against recombinant 
PfPK7 yielded eight molecules that were able to inhibit kinase activity at 
concentrations below 100 µM.  In silico docking of these small molecules to the 
binding site revealed interactions between a leucine and isoleucine-rich 
hydrophobic pocket, pi/pi stacking interactions at Tyr119 and Tyr117, as well as 
hydrogen bonds at Asn35, Glu118, Met120, Asp123, and Ser176 contribute to 
small molecule affinity for the binding site.  In addition, in silico methods revealed 
structural properties as well as predicted pharmacokinetic/pharmacodynamic 
properties that contribute to druglikeness.  As no analogs for the eight small 
molecules that hit against PfPK7 in this screen were commercially available, it 
was not possible to establish a true structure-activity relationship.  Synthesis of 
analogs especially for small molecule 528116 would allow for better definition 
properties that contribute to the affinity of these molecules for the binding site of 
PfPK7.  
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 Small molecule kinase inhibitor libraries were also screened for their ability 
to inhibit intraerythrocytic parasite growth.  Twenty-two molecules from this 
screen were shown to inhibit greater than 75 percent of intraerythrocytic parasite 
growth at 1 µM.  When PfPK7 small molecule inhibitors were tested in the SYBR 
Green I assay, three of the eight PfPK7 inhibitors were able to attenuate parasite 
growth with IC50 concentrations of approximately 2 µM; however, due to the 
noted promiscuity displayed by two of the three compounds, it is likely that much 
of the inhibitory activity of these molecules was due to off target effects.  In the 
future it would be advantageous to determine the IC50 concentrations for the 22 
small molecules that were good inhibitors of intraerythrocytic parasite growth.  In 
addition, given the structural similarity between these molecules it would be 
advantageous to determine the molecular target of the compounds.  If many of 
the small molecules from this screen affect the same protein in the parasite, that 
protein may prove a promising target for antimalarial drug design. 
 Application of the CDK inhibitor Purvalanol B to blood stage cultures of P. 
falciparum strain W2 at 25 hpi resulted in morphological differences between 
wildtype and inhibitor-treated parasites after 12 hours of incubation.  More 
specifically, inhibitor-treated cultures were significantly less able to form the 
multinucleated cells typical of Plasmodium schizonts when compared to control 
parasites.  Evidence of Purvalanol B effects was further substantiated with 
proteomic analysis of treated and control cultures using MudPIT.  The resulting 
data revealed a significant upregulation (p-value ≥ 0.05, fold change ≥ 1.5) of 
proteasome machinery and a protein necessary for redox homeostasis.  In 
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addition, a trend towards upregulation of certain cell cycle modulators was also 
present in treatment cultures.  In the future, it would be advantageous use 
western blot analysis to further validate the upregulation of these proteins.  In 
addition, it has been suggested in this manuscript that the mechanism of 
Plasmodium cell cycle disruption that was observed in the Purvalanol B 
experiment resulted from an inhibition of the proteasome complex and the 
subsequent inability of the parasite to temporally regulate the destruction of cell 
cycle modulators such as cyclins and transcription factors.  It may be possible to 
first determine the extent to which Purvalanol B binds to subunits of the malaria 
proteasome using coimmunoprecipitation and to then determine if application of 
Purvalanol B to parasite cultures affects the temporal presence the 
aforementioned Pfcyc proteins (Plasmodium cyclins) using western blot.  If 
inhibition of the Plasmodium proteasome is able to decrease the ability of 
parasites to form multinucleated cells, it may be a promising and much needed 
drug target for antimalarial drug design.   
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Identified Proteins UniProt 
Accession 
Number 
Molecular 
Weight 
Sample 
W
2C
1 
W
2C
2 
W
2C
3 
W
2T
1 
W
2T
2 
W
2T
3 
Enolase OS=Plasmodium falciparum (isolate 3D7) 
GN=ENO PE=3 SV=1 
ENO_PLA
F7 
49 kDa X X X X X X 
Glyceraldehyde-3-phosphate dehydrogenase 
OS=Plasmodium falciparum (isolate 3D7) 
GN=GAPDH PE=3 SV=1 
Q8IKK7_P
LAF7 (+1) 
37 kDa X X X X X X 
Heat shock 70 kDa protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF08_0054 PE=3 SV=1 
Q8IB24_P
LAF7 
74 kDa X X X X X X 
Phosphoglycerate kinase OS=Plasmodium falciparum 
(isolate 3D7) GN=PGK PE=1 SV=1 
PGK_PLA
F7 
45 kDa X X X X X X 
L-lactate dehydrogenase OS=Plasmodium falciparum 
GN=LDH-P PE=1 SV=1 
Q71T02_P
LAFA 
34 kDa X X X X X X 
Elongation factor 1-alpha OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0304 PE=3 SV=1 
Q8I0P6_P
LAF7 
49 kDa X X X X X X 
Heat shock protein 86 OS=Plasmodium falciparum 
(isolate 3D7) GN=PF07_0029 PE=1 SV=1 
Q8IC05_P
LAF7 
86 kDa X X X X X X 
Ornithine aminotransferase OS=Plasmodium 
falciparum (isolate 3D7) GN=OAT PE=1 SV=1 
OAT_PLA
F7 (+1) 
46 kDa X X X X X X 
Phosphoethanolamine N-methyltransferase 
OS=Plasmodium falciparum GN=PMT PE=1 SV=1 
Q6T755_P
LAFA (+1) 
31 kDa X X X X X X 
Heat shock protein 70 (HSP70) homologue 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFI0875w PE=3 SV=1 
Q8I2X4_P
LAF7 
72 kDa X X X X X X 
Adenosine deaminase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0289 PE=4 SV=1 
Q8IJA9_P
LAF7 
42 kDa X X X X X X 
Fructose-bisphosphate aldolase OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0425 PE=3 SV=1 
ALF_PLA
F7 (+1) 
40 kDa X X X X X X 
Merozoite surface protein 1 OS=Plasmodium 
falciparum (isolate mad20 / Papua New Guinea) 
GN=MSP-1 PE=3 SV=3 
MSP1_PL
AFM 
194 kDa X X X X X X 
M1-family aminopeptidase OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL13P1.56 PE=4 
SV=1 
Q8IEK1_P
LAF7 
126 kDa X X X X X X 
Elongation factor 2 OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0486 PE=4 SV=1 
Q8IKW5_
PLAF7 
94 kDa X X X X X X 
Histone H4 (Fragment) OS=Plasmodium falciparum 
PE=3 SV=1 
Q7JSX6_
PLAFA 
(+1) 
11 kDa X X X X X X 
Hypoxanthine phosphoribosyltransferase 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF10_0121 PE=4 SV=1 
Q8IJS1_P
LAF7 
26 kDa X X X X X X 
Protein disulfide isomerase OS=Plasmodium 
falciparum (isolate 3D7) GN=PfPDI-8 PE=3 SV=1 
C0H4Y6_
PLAF7 
56 kDa X X X X X X 
14-3-3 protein, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=MAL8P1.69 PE=3 SV=1 
C0H4V6_
PLAF7 
30 kDa X X X X X X 
Endoplasmin homolog, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL1070c PE=1 SV=1 
Q8I0V4_P
LAF7 
95 kDa X X X X X X 
Pyruvate kinase OS=Plasmodium falciparum (isolate 
3D7) GN=PFF1300w PE=1 SV=1 
C6KTA4_
PLAF7 
56 kDa X X X X X X 
Cell division cycle protein 48 homologue, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFF0940c PE=3 SV=1 
C6KT34_
PLAF7 
92 kDa X X X X X X 
Antigen Pfg27/25 OS=Plasmodium falciparum 
GN=Pfg 27-25 PE=2 SV=1 
Q27336_P
LAFA (+1) 
26 kDa X X X X X X 
Triosephosphate isomerase OS=Plasmodium 
falciparum (isolate 3D7) GN=TPI PE=3 SV=1 
TPIS_PLA
F7 (+1) 
28 kDa X X X X X X 
Histone H2B OS=Plasmodium falciparum (isolate 
3D7) GN=PF11_0062 PE=3 SV=1 
Q8IIV1_P
LAF7 
13 kDa X X X X X X 
GTP-binding nuclear protein ran/tc4 OS=Plasmodium 
falciparum (isolate 3D7) GN=Ran PE=4 SV=1 
Q7KQK6_
PLAF7 
25 kDa X X X X X X 
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Identified Proteins UniProt 
Accession 
Number 
Molecular 
Weight 
Sample 
W
2C
1 
W
2C
2 
W
2C
3 
W
2T
1 
W
2T
2 
W
2T
3 
S-adenosylmethionine synthetase OS=Plasmodium 
falciparum (isolate 3D7) GN=PfSAMS PE=3 SV=1 
Q7K6A4_
PLAF7 
45 kDa X X X X X X 
Purine nucleotide phosphorylase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE0660c PE=1 SV=1 
Q8I3X4_P
LAF7 
27 kDa X X X X X X 
CG4 OS=Plasmodium falciparum GN=cg4 PE=3 
SV=1 
O15797_P
LAFA 
98 kDa X X X X X X 
Actin-1 OS=Plasmodium falciparum (isolate HB3) 
PE=1 SV=1 
ACT1_PL
AFX 
42 kDa X X X X X X 
Tubulin beta chain OS=Plasmodium falciparum 
(isolate 3D7) GN=PF10_0084 PE=3 SV=1 
TBB_PLA
F7 (+1) 
50 kDa X X X X X X 
Histone H2A OS=Plasmodium falciparum (isolate 
3D7) GN=PFF0860c PE=3 SV=1 
C6KT18_
PLAF7 
(+1) 
14 kDa X X X X X X 
Histone H2A OS=Plasmodium falciparum (isolate 
3D7) GN=PFC0920w PE=3 SV=1 
O97320_P
LAF7 
16 kDa X X X X X X 
Peptidyl-prolyl cis-trans isomerase OS=Plasmodium 
falciparum PE=1 SV=1 
Q25756_P
LAFA (+1) 
19 kDa X X X X X X 
RhopH2 OS=Plasmodium falciparum GN=rhoph2 
PE=2 SV=1 
B0M0V9_
PLAFA 
(+1) 
163 kDa X X X X X X 
Endoplasmic reticulum-resident calcium binding 
protein OS=Plasmodium falciparum (isolate 3D7) 
GN=ERC PE=4 SV=1 
Q8IIR7_P
LAF7 
39 kDa X X X X X X 
Karyopherin beta OS=Plasmodium falciparum PE=4 
SV=1 
Q7KAU3_
PLAFA 
(+1) 
127 kDa X X X X X X 
Phosphoglycerate mutase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0208 PE=1 SV=1 
Q8IIG6_P
LAF7 
29 kDa X X X X X X 
DNA/RNA-binding protein Alba, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF08_0074 PE=4 SV=1 
Q8IAX8_P
LAF7 
27 kDa X X X X X X 
6-phosphofructokinase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFI0755c PE=4 SV=1 
Q8I2Z8_P
LAF7 
159 kDa X X X X X X 
Myo-inositol 1-phosphate synthase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE0585c PE=4 SV=1 
Q8I3Y8_P
LAF7 
69 kDa X X X X X X 
Exp-2 protein OS=Plasmodium falciparum GN=Exp-2 
PE=4 SV=1 
O61141_P
LAFA (+1) 
33 kDa X X X X X X 
Histone H3 OS=Plasmodium falciparum PE=2 SV=1 Q27719_P
LAFA 
15 kDa X X X X X X 
RhopH3 OS=Plasmodium falciparum (isolate 3D7) 
GN=PFI0265c PE=4 SV=1 
Q8I395_P
LAF7 
105 kDa X X X X X X 
Falcilysin OS=Plasmodium falciparum (isolate 3D7) 
GN=flN PE=1 SV=1 
Q76NL8_
PLAF7 
139 kDa X X X X X X 
Aspartic acid-rich protein OS=Plasmodium falciparum 
GN=ARP PE=2 SV=1 
Q8I9F4_P
LAFA 
32 kDa X X X X X X 
Heat shock protein hsp70 homologue 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0351 PE=3 SV=1 
Q8II24_PL
AF7 
73 kDa X X X X X X 
Glucose-6-phosphate isomerase OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0341 PE=1 SV=1 
Q8ILA4_P
LAF7 
67 kDa X X X X X X 
Histone H2B OS=Plasmodium falciparum (isolate 
3D7) GN=PF07_0054 PE=3 SV=1 
Q8IBV7_P
LAF7 
14 kDa X X X X X X 
M17 leucyl aminopeptidase OS=Plasmodium 
falciparum (isolate 3D7) GN=LAP PE=1 SV=1 
Q8IL11_P
LAF7 
68 kDa X X X X X X 
4-methyl-5(B-hydroxyethyl)-thiazol monophosphate 
biosynthesis enzyme OS=Plasmodium falciparum 
(isolate 3D7) GN=PFF1335c PE=4 SV=1 
C6KTB1_
PLAF7 
20 kDa X X X X X X 
Peptidase, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0517 PE=3 SV=1 
Q8IKT5_P
LAF7 
89 kDa X X X X X X 
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Identified Proteins UniProt 
Accession 
Number 
Molecular 
Weight 
Sample 
W
2C
1 
W
2C
2 
W
2C
3 
W
2T
1 
W
2T
2 
W
2T
3 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.95 PE=4 SV=1 
C0H4U4_
PLAF7 
36 kDa X X X X X X 
Elongation factor 1-gamma, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0214 PE=4 SV=2 
Q8IDV0_P
LAF7 
48 kDa X X X X X X 
Pyridoxine/pyridoxal 5-phosphate biosynthesis 
enzyme OS=Plasmodium falciparum (isolate 3D7) 
GN=PFF1025c PE=4 SV=1 
C6KT50_
PLAF7 
33 kDa X X X X X X 
Uncharacterized protein OS=Plasmodium falciparum 
(isolate 3D7) GN=MAL13P1.237 PE=4 SV=1 
Q8IDM3_
PLAF7 
42 kDa X X X X X X 
QF122 antigen OS=Plasmodium falciparum (isolate 
3D7) GN=PF10_0115 PE=4 SV=1 
Q8IJS7_P
LAF7 
132 kDa X X X X X X 
Histone H3 OS=Plasmodium falciparum PE=3 SV=1 Q86QI3_P
LAFA 
15 kDa X X X X X X 
Rhoptry-associated protein 1 OS=Plasmodium 
falciparum PE=4 SV=1 
D7NSU0_
PLAFA 
90 kDa X X X X X X 
Heat shock protein 60 OS=Plasmodium falciparum 
(isolate 3D7) GN=PF10_0153 PE=3 SV=1 
Q8IJN9_P
LAF7 
63 kDa X X X X X X 
RhopH1/Clag3.1 OS=Plasmodium falciparum 
GN=rhoph1/clag3.1 PE=2 SV=1 
Q4AE85_
PLAFA 
169 kDa X X X X X X 
Acidic leucine-rich nuclear phosphoprotein 32-related 
protein OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0257 PE=3 SV=1 
AN32_PL
AF7 
33 kDa X X X X X X 
Helicase 45 OS=Plasmodium falciparum (isolate 3D7) 
GN=H45 PE=3 SV=1 
Q8IKF0_P
LAF7 
45 kDa X X X X X X 
Plasmepsin IV OS=Plasmodium falciparum (isolate 
3D7) GN=PF14_0075 PE=1 SV=1 
Q8IM16_P
LAF7 
51 kDa X X X X X X 
Polyubiquitin OS=Plasmodium falciparum (isolate 
3D7) GN=pUB PE=4 SV=1 
Q7KQK2_
PLAF7 
(+1) 
43 kDa X X X X X X 
Adenosylhomocysteinase OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE1050w PE=1 SV=2 
SAHH_PL
AF7 
54 kDa X X X X X X 
Eukaryotic initiation factor 5a, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL0210c PE=4 SV=1 
Q8I603_P
LAF7 (+1) 
18 kDa X X X X X X 
DNA/RNA-binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0063 PE=4 SV=1 
Q8IJX8_P
LAF7 
12 kDa X X X X X X 
Mature parasite-infected erythrocyte surface antigen 
(MESA) or PfEMP2 OS=Plasmodium falciparum 
(isolate 3D7) GN=MESA PE=4 SV=1 
Q8I492_P
LAF7 
168 kDa X X X X X X 
Hexokinase OS=Plasmodium falciparum (isolate 3D7) 
GN=PFF1155w PE=3 SV=1 
C6KT76_
PLAF7 
55 kDa X X X X X X 
DEAD box helicase, UAP56 OS=Plasmodium 
falciparum (isolate 3D7) GN=UAP56 PE=4 SV=1 
Q9TY94_
PLAF7 
52 kDa X X X X X X 
Polyadenylate-binding protein OS=Plasmodium 
falciparum PE=2 SV=1 
A1EAA0_
PLAFA 
(+1) 
97 kDa X X X X X X 
Proliferating cell nuclear antigen OS=Plasmodium 
falciparum (isolate 3D7) GN=PCNA PE=3 SV=1 
PCNA_PL
AF7 (+1) 
31 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFI1270w PE=4 SV=1 
Q8I2Q0_P
LAF7 
25 kDa X X X X X X 
STI1-like protein OS=Plasmodium falciparum (isolate 
3D7) GN=PF14_0324 PE=4 SV=1 
STI1L_PL
AF7 
66 kDa X X X X X X 
Merozoite capping protein 1 OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0268 PE=4 SV=1 
Q8IJD0_P
LAF7 
44 kDa X X X X X X 
V-type proton ATPase catalytic subunit A 
OS=Plasmodium falciparum (isolate 3D7) GN=vapA 
PE=3 SV=1 
VATA_PL
AF7 (+1) 
69 kDa X X X X X X 
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Number 
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W
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W
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1 
W
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2 
W
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3 
Alpha tubulin OS=Plasmodium falciparum (isolate 
3D7) GN=PFI0180w PE=3 SV=1 
Q6ZLZ9_
PLAF7 
(+1) 
50 kDa X X X X X X 
Malaria protein EXP-1 OS=Plasmodium falciparum 
GN=EXP-1 PE=2 SV=2 
EXP1_PL
AFA 
17 kDa X X X X X X 
Thioredoxin OS=Plasmodium falciparum GN=trx 
PE=3 SV=1 
Q9NFK9_
PLAFA 
(+1) 
12 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFD0090c PE=4 SV=1 
Q8I206_P
LAF7 
50 kDa X X X X X X 
Nucleosome assembly protein 1, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL0185c PE=1 SV=2 
Q8I608_P
LAF7 
40 kDa X X X X X X 
T-complex protein beta subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFC0285c PE=3 SV=3 
O97247_P
LAF7 
59 kDa X X X X X X 
Peptidyl-prolyl cis-trans isomerase OS=Plasmodium 
falciparum GN=CyP gene PE=2 SV=1 
Q27745_P
LAFA (+1) 
22 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFI1780w PE=4 SV=1 
Q8I2F2_P
LAF7 
46 kDa X X X X X X 
HAP protein OS=Plasmodium falciparum (isolate 
3D7) GN=PF14_0078 PE=1 SV=1 
Q8IM15_P
LAF7 
52 kDa X X X X X X 
Serine hydroxymethyltransferase OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL1720w PE=3 SV=1 
Q8I566_P
LAF7 (+1) 
50 kDa X X X X X X 
Thioredoxin peroxidase 1 OS=Plasmodium falciparum 
(isolate 3D7) GN=TPx1 PE=4 SV=1 
Q8IL80_P
LAF7 (+1) 
22 kDa X X X X X X 
40S ribosomal protein S3, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0627 PE=3 SV=1 
Q8IKH8_P
LAF7 
25 kDa X X X X X X 
ADP-ribosylation factor 1 OS=Plasmodium falciparum 
(isolate 3D7) GN=ARF1 PE=1 SV=1 
ARF1_PL
AF7 (+1) 
21 kDa X X X X X X 
Plasmepsin 2 (Fragment) OS=Plasmodium falciparum 
PE=3 SV=1 
Q17SC2_
PLAFA 
51 kDa X X X X X X 
Heat shock protein 70 (Hsp70), putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL13P1.540 PE=3 SV=1 
C0H5H0_
PLAF7 
108 kDa X X X X X X 
Receptor for activated C kinase homolog, PfRACK 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PfRACK PE=4 SV=1 
Q8IBA0_P
LAF7 
36 kDa X X X X X X 
60S ribosomal protein P0 OS=Plasmodium falciparum 
(isolate 3D7) GN=PF11_0313 PE=3 SV=1 
Q8II61_PL
AF7 
35 kDa X X X X X X 
Translationally-controlled tumor protein homolog 
OS=Plasmodium falciparum (isolate 3D7) GN=TCTP 
PE=1 SV=1 
TCTP_PL
AF7 
20 kDa X X X X X X 
Haloacid dehalogenase-like hydrolase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF10_0325 PE=4 SV=1 
Q8IJ74_P
LAF7 
33 kDa X X X X X X 
Rhoptry neck protein 3, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL2505c PE=4 SV=1 
Q8I4R5_P
LAF7 
263 kDa X X X X X X 
T-complex protein 1 subunit delta OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL13P1.283 PE=3 
SV=1 
C0H5I7_P
LAF7 
58 kDa X X X X X X 
Methionine-tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0340 PE=4 SV=1 
Q8IJ60_P
LAF7 
104 kDa X X X X X X 
Ethanolamine kinase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0257 PE=4 SV=1 
Q8IIB7_P
LAF7 
50 kDa X X X X X X 
RNA binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0068 PE=4 SV=1 
Q8IJX3_P
LAF7 
30 kDa X X X X X X 
Ribosomal P2 phosphoprotein OS=Plasmodium 
falciparum GN=P2 PE=4 SV=1 
Q548Y1_
PLAFA 
(+1) 
12 kDa X X X X X X 
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Lysine--tRNA ligase OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0262 PE=3 SV=1 
Q8IDJ8_P
LAF7 
68 kDa X X X X X X 
T-complex protein 1, gamma subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL1425w PE=3 SV=1 
Q8I5C4_P
LAF7 
61 kDa X X X X X X 
Uncharacterized protein OS=Plasmodium falciparum 
(isolate 3D7) GN=MAL13P1.308 PE=4 SV=1 
C0H5J9_P
LAF7 
289 kDa X X X X X X 
CAMP-dependent protein kinase regulatory subunit, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PKAr PE=4 SV=1 
Q7KQK0_
PLAF7 
(+1) 
51 kDa X X X X X X 
Ribonucleotide reductase small subunit 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0053 PE=4 SV=1 
Q8IM38_P
LAF7 
41 kDa X X X X X X 
Cofilin/actin-depolymerizing factor homolog 1 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE0165w PE=1 SV=1 
CADF1_P
LAF7 (+1) 
14 kDa X X X X X X 
Vacuolar ATP synthase subunit b OS=Plasmodium 
falciparum (isolate 3D7) GN=PFD0305c PE=3 SV=1 
Q6ZMA8_
PLAF7 
(+1) 
56 kDa X X X X X X 
Nucleic acid binding protein, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL13P1.233 PE=4 SV=1 
Q8IDN4_P
LAF7 
25 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0329 PE=4 SV=1 
Q8ILB6_P
LAF7 
29 kDa X X X X X X 
HSP40, subfamily A, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0359 PE=4 SV=1 
Q8IL88_P
LAF7 
48 kDa X X X X X X 
Nucleoside diphosphate kinase b, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0349 PE=1 SV=1 
Q8ID43_P
LAF7 
17 kDa X X X X X X 
Early transcribed membrane protein 10.2 (Fragment) 
OS=Plasmodium falciparum PE=4 SV=1 
C5HWR7_
PLAFA 
(+1) 
36 kDa X X X X X X 
Protein phosphatase 2C OS=Plasmodium falciparum 
(isolate 3D7) GN=PF11_0396 PE=3 SV=2 
Q8IHY0_P
LAF7 
105 kDa X X X X X X 
Proteasome subunit alpha type OS=Plasmodium 
falciparum (isolate 3D7) GN=PF07_0112 PE=3 SV=1 
Q8IBI3_P
LAF7 
28 kDa X X X X X X 
T-complex protein 1 subunit alpha OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0331 PE=3 SV=1 
Q8II43_PL
AF7 
60 kDa X X X X X X 
Thioredoxin-related protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0272 PE=4 SV=1 
Q8IDH5_P
LAF7 
24 kDa X X X X X X 
Casein kinase II, alpha subunit OS=Plasmodium 
falciparum (isolate 3D7) GN=CK2alpha PE=4 SV=1 
Q8IIR9_P
LAF7 
40 kDa X X X X X X 
Conserved GTP-binding protein, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL7P1.122 PE=4 SV=1 
Q8IBM9_
PLAF7 
45 kDa X X X X X X 
Adenylate kinase 2 OS=Plasmodium falciparum PE=1 
SV=1 
Q7Z0H0_
PLAFA 
28 kDa X X X X X X 
Macrophage migration inhibitory factor homologue 
OS=Plasmodium falciparum (isolate 3D7) GN=MIF 
PE=1 SV=1 
Q8I5C5_P
LAF7 
13 kDa X X X X X X 
Isoleucine-tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0179 PE=3 SV=1 
Q8IDZ9_P
LAF7 
151 kDa X X X X X X 
40S ribosomal protein S2, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0448 PE=3 SV=1 
Q8IL02_P
LAF7 
30 kDa X X X X X X 
Conserved protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PF11_0055 PE=4 SV=1 
Q8IIV8_P
LAF7 
49 kDa X X X X X X 
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Proliferation-associated protein 2g4, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0261 PE=4 SV=1 
Q8ILI2_PL
AF7 
43 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFD0080c PE=4 SV=1 
Q8I207_P
LAF7 
60 kDa X X X X X X 
Ubiquitin-activating enzyme E1, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL1245w PE=4 SV=1 
Q8I5F9_P
LAF7 
132 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE1600w PE=4 SV=1 
Q8I3F1_P
LAF7 
60 kDa X X X X X X 
Acyl-CoA synthetase, PfACS10 OS=Plasmodium 
falciparum (isolate 3D7) GN=PfACS10 PE=4 SV=1 
Q8I3L4_P
LAF7 
77 kDa X X X X X X 
60S ribosomal protein L4, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0350c PE=4 SV=1 
Q8I431_P
LAF7 
46 kDa X X X X X X 
Asparagine-tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFB0525w PE=3 SV=1 
O96198_P
LAF7 
71 kDa X X X X X X 
RabGDI protein OS=Plasmodium falciparum 
GN=rabGDI PE=2 SV=1 
Q26001_P
LAFA (+1) 
52 kDa X X X X X X 
40S ribosomal protein S19, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFD1055w PE=4 SV=1 
Q8IFP2_P
LAF7 
20 kDa X X X X X X 
Proteasome subunit alpha type 2, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFF0420c PE=4 SV=1 
C6KST3_
PLAF7 
27 kDa X X X X X X 
Importin subunit alpha OS=Plasmodium falciparum 
PE=3 SV=1 
Q7KAV0_
PLAFA 
(+1) 
61 kDa X X X X X X 
Nascent polypeptide associated complex alpha chain, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PFF1050w PE=4 SV=1 
C6KT55_
PLAF7 
21 kDa X X X X  X 
Histone binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL0280c PE=4 SV=1 
Q8I5Y9_P
LAF7 
39 kDa X X X X X X 
Ubiquitin domain containing protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0142 PE=4 SV=1 
Q8IIM8_P
LAF7 
43 kDa X X X X X X 
40S ribosomal protein S6, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0228 PE=4 SV=1 
Q8IDR9_P
LAF7 
35 kDa X X X X X X 
Profilin OS=Plasmodium falciparum (isolate 3D7) 
GN=Pfn PE=3 SV=1 
PROF_PL
AF7 
19 kDa X X X X X X 
Transketolase OS=Plasmodium falciparum (isolate 
3D7) GN=PfTK PE=4 SV=1 
C6KSV3_
PLAF7 
76 kDa X X X X X X 
Chaperonin CPN60, mitochondrial OS=Plasmodium 
falciparum (isolate FCR-3 / Gambia) PE=3 SV=1 
CH60_PL
AFG 
79 kDa X X X X X X 
T-complex protein 1 epsilon subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFC0900w PE=3 SV=1 
O97282_P
LAF7 
59 kDa X X X X X X 
Threonine--tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0270 PE=3 SV=1 
Q8IIA4_P
LAF7 
120 kDa X X X X X X 
Glutamate--tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0257 PE=3 SV=1 
Q8IDK7_P
LAF7 
101 kDa X X X X X X 
High mobility group protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PfHMGB2 PE=4 SV=1 
Q8IB14_P
LAF7 
12 kDa X X X  X  
Pre-mRNA splicing factor, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFD0265w PE=4 SV=1 
Q8I1X5_P
LAF7 
366 kDa X X X X   
Proteosome subunit alpha type 1, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0716 PE=4 SV=1 
Q8IK90_P
LAF7 
29 kDa X 
 
 
X X X X X 
Nuclear transport factor 2, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0122 PE=4 SV=2 
Q8ILX1_P
LAF7 
14 kDa X X X X X X 
26S proteasome regulatory subunit 7, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0063 PE=3 SV=2 
Q8IEK3_P
LAF7 
47 kDa X X X X  X 
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Antigen 332, DBL-like protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0506 PE=4 SV=2 
Q8IHN4_P
LAF7 
689 kDa X   X  X 
Phosphoribosylpyrophosphate synthetase 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0143 PE=3 SV=1 
Q8IE67_P
LAF7 
49 kDa X X X X X X 
Early transcribed membrane protein 5, ETRAMP5 
OS=Plasmodium falciparum (isolate 3D7) 
GN=ETRAMP5 PE=4 SV=1 
Q8I3F3_P
LAF7 
19 kDa X X X X X X 
Eukaryotic translation initiation factor 3 37.28 kDa 
subunit, putative OS=Plasmodium falciparum (isolate 
3D7) GN=MAL7P1.81 PE=4 SV=1 
Q8IBT2_P
LAF7 
37 kDa X X X X X X 
Ribonucleoside-diphosphate reductase 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0352 PE=3 SV=1 
Q8IL94_P
LAF7 
97 kDa X X X X X X 
40S ribosomal protein S8 OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0083 PE=3 SV=1 
Q8IM10_P
LAF7 
25 kDa X X X X X X 
Small ubiquitin-related modifier, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PfSUMO PE=4 SV=1 
Q8I444_P
LAF7 
11 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0546 PE=4 SV=1 
Q8IKQ7_P
LAF7 
76 kDa X X X X X X 
60S ribosomal protein L7, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFC0300c PE=4 SV=2 
O97250_P
LAF7 
31 kDa X X X X X X 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0302 PE=4 SV=1 
Q8II72_PL
AF7 
52 kDa X X X X X X 
Translation elongation factor 1 beta OS=Plasmodium 
falciparum GN=EF-1b PE=2 SV=1 
Q9NI00_P
LAFA 
32 kDa X X X X X X 
Insulinase, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF11_0189 PE=3 SV=1 
Q8III5_PL
AF7 
174 kDa X X X X X X 
1-cys peroxiredoxin OS=Plasmodium falciparum 
(isolate 3D7) GN=1-cyspxn PE=4 SV=1 
Q8IAM2_
PLAF7 
(+1) 
25 kDa X X X X X X 
26S proteasome regulatory subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0033 PE=3 SV=1 
Q8IEQ1_P
LAF7 
45 kDa X X X X X X 
Eukaryotic translation initiation factor 3 subunit 7, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PF10_0077 PE=4 SV=1 
Q8IJW4_P
LAF7 
63 kDa X X X X X X 
RNA binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0315 PE=4 SV=1 
Q8IDB7_P
LAF7 
57 kDa X X X X X X 
Adenylosuccinate synthetase OS=Plasmodium 
falciparum (isolate 3D7) GN=Adss PE=3 SV=1 
PURA_PL
AF7 (+1) 
50 kDa X X X X X X 
Ran binding protein 1, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFD0950w PE=4 SV=1 
Q76NN6_
PLAF7 
(+1) 
33 kDa X X X X X X 
60S ribosomal protein L12, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0850c PE=3 SV=2 
Q8I3T8_P
LAF7 
18 kDa X X X X X X 
Plasmepsin-1 OS=Plasmodium falciparum PE=1 
SV=2 
PLM1_PL
AFA (+1) 
51 kDa X X X X X X 
Ribonucleotide reductase small subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF10_0154 PE=4 SV=2 
Q8IJN8_P
LAF7 
40 kDa X X X X X X 
Inosine-5'-monophosphate dehydrogenase 
OS=Plasmodium falciparum PE=2 SV=1 
O96387_P
LAFA (+1) 
56 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFD1170c PE=4 SV=1 
Q8IFM0_P
LAF7 
36 kDa X X X X X X 
   
 
  
 
 
163 
Identified Proteins UniProt 
Accession 
Number 
Molecular 
Weight 
Sample 
W
2C
1 
W
2C
2 
W
2C
3 
W
2T
1 
W
2T
2 
W
2T
3 
7,8-dihydro-6-hydroxymethylpterin 
pyrophosphokinase-dihydropteroate synthase 
OS=Plasmodium falciparum GN=PPPK-DHPS PE=4 
SV=1 
Q25704_P
LAFA 
83 kDa X X X X  X 
60S ribosomal protein L5, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0230 PE=3 SV=1 
Q8ILL3_P
LAF7 
34 kDa X X X X X X 
Small heat shock protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0021 PE=3 SV=1 
Q8IES0_P
LAF7 
25 kDa X X X X X X 
Glutaredoxin OS=Plasmodium falciparum GN=fulmal4 
PE=4 SV=1 
Q7KXR4_
PLAFA 
(+1) 
12 kDa X X  X   
Proteasome subunit alpha type OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL13P1.270 PE=3 
SV=1 
Q8IDG2_
PLAF7 
27 kDa X X X X X X 
T-complex protein 1 subunit eta OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL3P3.6 PE=3 SV=1 
TCPH_PL
AF7 
60 kDa X X X X X X 
60S ribosomal protein L3, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0272 PE=3 SV=1 
Q8IJC6_P
LAF7 
44 kDa X  X   X 
Beta3 proteasome subunit, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFA_0400c PE=4 SV=1 
Q8I261_P
LAF7 
23 kDa X X X X X  
Hsp70-x OS=Plasmodium falciparum (isolate 3D7) 
PE=2 SV=1 
K7NTP5_
PLAF7 
75 kDa X X X X X X 
Chromatin assembly factor 1 protein WD40 domain, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PFA_0520c PE=4 SV=1 
Q8I238_P
LAF7 
51 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF1295w PE=4 SV=1 
C6KTA3_
PLAF7 
44 kDa X X X X X X 
Calcyclin binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL1845c PE=4 SV=2 
Q8I542_P
LAF7 
27 kDa X X X X X X 
Cysteine-rich surface protein (Fragment) 
OS=Plasmodium falciparum PE=4 SV=1 
C5HXB3_
PLAFA 
91 kDa X X X X X X 
p23 co-chaperone, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=SBA1 PE=4 SV=2 
Q8IKU1_P
LAF7 
30 kDa X X X X X X 
Glutamate dehydrogenase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF08_0132 PE=4 SV=1 
Q8IAM0_
PLAF7 
160 kDa X   X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF0220w PE=4 SV=1 
C6KSP3_
PLAF7 
334 kDa X  X X X X 
DNAJ protein, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0700 PE=4 SV=1 
Q8IKA6_P
LAF7 
52 kDa X X X X X X 
40S ribosomal protein SA OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0264 PE=3 SV=1 
RSSA_PL
AF7 
30 kDa X X X X X X 
Valine-tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0589 PE=3 SV=1 
Q8IKL5_P
LAF7 
128 kDa X X X X X X 
Glutathione S-transferase OS=Plasmodium 
falciparum (isolate 3D7) GN=GST PE=3 SV=1 
GST_PLA
F7 (+1) 
25 kDa X X X X X X 
Eukaryotic translation initiation factor 3 subunit 10, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL0625c PE=4 SV=1 
Q8I5S6_P
LAF7 
166 kDa X   X  X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL7P1.171 PE=4 
SV=1 
Q8IBF2_P
LAF7 
244 kDa X  X X  X 
Multidrug resistance protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PfMDR1 PE=3 SV=1 
Q7K6A5_
PLAF7 
162 kDa X X X X X X 
Ubiquitin conjugating enzyme E2, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFC0255c PE=1 SV=1 
O97241_P
LAF7 
16 kDa X  X X X  
Probable cathepsin C OS=Plasmodium falciparum 
(isolate 3D7) GN=PF11_0174 PE=1 SV=1 
CATC_PL
AF7 
80 kDa X X  X X  
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ATPase OS=Plasmodium falciparum PE=3 SV=1 Q27721_P
LAFA (+2) 
122 kDa X  X X  X 
Eukaryotic translation initiation factor 2 gamma 
subunit, putative OS=Plasmodium falciparum (isolate 
3D7) GN=PF14_0104 PE=4 SV=1 
Q8ILY9_P
LAF7 
51 kDa X X X X X X 
Eukaryotic translation initiation factor 3 subunit B 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE0885w PE=3 SV=1 
Q8I3T1_P
LAF7 
84 kDa X X X X X X 
6-phosphogluconate dehydrogenase, decarboxylating 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0520 PE=3 SV=1 
Q8IKT2_P
LAF7 
53 kDa X X X X X X 
26S proteasome subunit, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0632 PE=4 SV=1 
Q8IKH3_P
LAF7 
133 kDa X  X X X X 
Seryl-tRNA synthetase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF07_0073 PE=4 SV=1 
Q8IBS3_P
LAF7 
62 kDa X X X X X X 
Clathrin heavy chain, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL0930w PE=4 SV=1 
Q8I5L6_P
LAF7 
233 kDa X   X X X 
Proteasome subunit alpha type OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0282 PE=3 SV=1 
Q8IDG3_
PLAF7 
28 kDa X X X X X X 
Prefoldin subunit 2, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0167 PE=4 SV=1 
Q8ILS7_P
LAF7 
17 kDa X X X  X X 
Leucyl tRNA synthase OS=Plasmodium falciparum 
(isolate 3D7) GN=PFF1095w PE=3 SV=1 
C6KT64_
PLAF7 
170 kDa X  X X X X 
40S ribosomal protein S18, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0272 PE=3 SV=1 
Q8IIA2_P
LAF7 
18 kDa X X X X X X 
Glycophorin-binding protein OS=Plasmodium 
falciparum (isolate FCR-3 / Gambia) GN=GBP PE=2 
SV=2 
GBP_PLA
FG 
90 kDa X X X X  X 
FK506-binding protein (FKBP)-type peptidyl-propyl 
isomerase OS=Plasmodium falciparum (isolate 3D7) 
GN=FKBP35 PE=1 SV=1 
Q8I4V8_P
LAF7 
35 kDa X  X X X  
26S protease subunit regulatory subunit 6a, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0314 PE=3 SV=1 
Q8II60_PL
AF7 
50 kDa X X X X X X 
tRNA binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0401 PE=4 SV=1 
Q8IL48_P
LAF7 
46 kDa X X X X X X 
10 kd chaperonin OS=Plasmodium falciparum (isolate 
3D7) GN=Cpn10 PE=3 SV=2 
Q8I5Q3_P
LAF7 
11 kDa X X X X X X 
Alanine--tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0354 PE=3 SV=1 
Q8ID31_P
LAF7 
165 kDa X X X X X X 
Tat-binding protein homolog OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL2345c PE=3 SV=1 
Q8I4U5_P
LAF7 
50 kDa X   X X  
Hsp70 interacting protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE1370w PE=4 SV=1 
Q8I3J0_P
LAF7 
51 kDa X X X X X X 
26S proteasome AAA-ATPase subunit RPT3, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFD0665c PE=3 SV=1 
Q8I1V1_P
LAF7 
45 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0344 PE=4 SV=1 
Q8ILA1_P
LAF7 
112 kDa X X X X X X 
Proteasome 26S regulatory subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFB0260w PE=4 SV=3 
O96153_P
LAF7 
108 kDa X X X X X X 
GMP synthetase OS=Plasmodium falciparum (isolate 
3D7) GN=PF10_0123 PE=1 SV=1 
Q8IJR9_P
LAF7 
64 kDa X X X X X X 
Pyrroline carboxylate reductase OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL13P1.284 PE=1 
SV=1 
Q8IDC6_P
LAF7 
28 kDa X X X X X X 
Small GTP-binding protein sar1 OS=Plasmodium 
falciparum (isolate 3D7) GN=sar1 PE=3 SV=1 
Q8I1S0_P
LAF7 (+1) 
22 kDa X X X X X X 
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Conserved Plasmodium membrane protein 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL1825w PE=4 SV=1 
Q8I546_P
LAF7 
24 kDa X X X  X  
Liver stage antigen 3 OS=Plasmodium falciparum 
GN=LSA-3 PE=4 SV=1 
C7DU25_
PLAFA 
(+1) 
171 kDa X   X  X 
Helicase, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0437 PE=3 SV=2 
Q8IL13_P
LAF7 
60 kDa X X X X  X 
Plastidic co-chaperonin OS=Plasmodium falciparum 
GN=Cpn20 PE=2 SV=1 
Q50JA7_P
LAFA (+1) 
29 kDa X X X X X X 
Proteasome subunit alpha, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.128 PE=4 
SV=2 
Q8IAR3_P
LAF7 
30 kDa  X X X X X 
Merozoite surface protein 1 OS=Plasmodium 
falciparum (isolate 3D7) GN=MSP1 PE=4 SV=1 
Q8I0U8_P
LAF7 
196 kDa X X  X X X 
Merozoite surface protein 9 (Fragment) 
OS=Plasmodium falciparum PE=4 SV=1 
C5HEE5_
PLAFA 
83 kDa X X X X X X 
Proteasome subunit beta type OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.142 PE=3 
SV=1 
Q7K6A9_
PLAF7 
(+1) 
31 kDa X X X X X  
Dynamin-like protein OS=Plasmodium falciparum 
(isolate 3D7) GN=dyn1 PE=3 SV=1 
Q8IHR4_P
LAF7 
96 kDa X  X X X X 
High mobility group protein OS=Plasmodium 
falciparum PE=4 SV=1 
Q25871_P
LAFA (+2) 
11 kDa X  X X   
Proline--tRNA ligase OS=Plasmodium falciparum 
(isolate 3D7) GN=proRS PE=1 SV=1 
SYP_PLA
F7 
87 kDa X X X X X X 
Rhoptry-associated protein 2 (Fragment) 
OS=Plasmodium falciparum GN=RAP2 PE=4 SV=1 
B9VGG5_
PLAFA 
(+3) 
42 kDa X X X X X X 
Proteasome subunit beta type OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0915c PE=3 SV=1 
C0H4E8_
PLAF7 
27 kDa X X X X X X 
PfRab7, GTPase OS=Plasmodium falciparum (isolate 
3D7) GN=Rab7 PE=3 SV=1 
C0H516_
PLAF7 
(+1) 
24 kDa X X X X X X 
Heat shock protein 101, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0175 PE=3 SV=1 
Q8IIJ8_PL
AF7 
103 kDa X  X X X X 
60S ribosomal protein P1, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0043 PE=4 SV=1 
Q8IIX0_P
LAF7 
13 kDa X X X X X  
40S ribosomal protein S14, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0810c PE=3 SV=1 
Q8I3U6_P
LAF7 
16 kDa X X X X X X 
DNAJ protein, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=RESA PE=4 SV=1 
Q8I0U6_P
LAF7 
127 kDa X X X X X X 
Acyl-coA synthetase, PfACS5 OS=Plasmodium 
falciparum (isolate 3D7) GN=PfACS5 PE=4 SV=1 
Q8I6Z1_P
LAF7 
93 kDa X X X X X X 
Protein disulfide isomerase OS=Plasmodium 
falciparum (isolate 3D7) GN=PDI-11 PE=4 SV=1 
Q8II23_PL
AF7 
49 kDa X  X X X X 
Proteasome component C8, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFC0745c PE=4 SV=1 
O77396_P
LAF7 
29 kDa X X  X X X 
Bifunctional dihydrofolate reductase-thymidylate 
synthase OS=Plasmodium falciparum GN=DHFR-TS 
PE=1 SV=1 
D9N170_
PLAFA 
72 kDa X X X X  X 
Eukaryotic translation initiation factor 3 subunit 8, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL0310c PE=4 SV=1 
Q8I5Y3_P
LAF7 
116 kDa X X X X X X 
T-complex protein 1, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFB0635w PE=3 SV=3 
O96220_P
LAF7 
61 kDa X X X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL7P1.202 PE=4 
SV=1 
C0H4L1_
PLAF7 
146 kDa X X X X X X 
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Merozoite surface protein 1 OS=Plasmodium 
falciparum GN=msp1 PE=4 SV=1 
Q764L1_P
LAFA 
193 kDa X X X X X X 
Structure specific recognition protein 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0393 PE=4 SV=1 
Q8IL56_P
LAF7 
59 kDa X  X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL7P1.29 PE=4 SV=1 
REVERSE
_Q8IBZ1_
PLAF7-R 
274 kDa X  X   X 
PIESP2 erythrocyte surface protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0060w PE=4 SV=1 
Q8I488_P
LAF7 
49 kDa X X  X X  
Falstatin (Fragment) OS=Plasmodium falciparum 
PE=2 SV=1 
Q2PZB1_
PLAFA 
(+1) 
44 kDa X X X  X  
Mannose-6-phosphate isomerase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL8P1.156 PE=4 SV=1 
Q8IAL6_P
LAF7 
118 kDa X  X  X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFI0495w PE=4 SV=1 
REVERSE
_Q8I350_
PLAF7-R 
368 kDa X      
Exportin 1, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PFC0135c PE=4 SV=2 
O77312_P
LAF7 
148 kDa X  X X X X 
40S ribosomal protein S12 OS=Plasmodium 
falciparum (isolate 3D7) GN=RPS12 PE=3 SV=1 
RS12_PL
AF7 
15 kDa X X X X X X 
DNA replication licensing factor MCM2 
OS=Plasmodium falciparum GN=mcm2 PE=3 SV=1 
Q9GR05_
PLAFA 
112 kDa X X X X X X 
40S ribosomal protein S3a OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL3P7.35 PE=3 SV=1 
RS3A_PL
AF7 
30 kDa X X X X X X 
60S ribosomal protein L1, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0391 PE=4 SV=1 
Q8IL58_P
LAF7 
25 kDa X X X X  X 
Translation initiation factor eIF-1A, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0447 PE=3 SV=2 
Q8IHT2_P
LAF7 
18 kDa X X  X  X 
Sec31p putative OS=Plasmodium falciparum (isolate 
3D7) GN=Sec31p PE=4 SV=3 
O96221_P
LAF7 
167 kDa X X X X X X 
Merozoite surface protein 7 OS=Plasmodium 
falciparum PE=4 SV=1 
C5HWK9_
PLAFA 
41 kDa X  X X  X 
Deoxyribose-phosphate aldolase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF10_0210 PE=4 SV=1 
Q8IJI7_PL
AF7 
29 kDa X X X  X  
40S ribosomal protein S4, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0065 PE=4 SV=2 
Q8IIU8_P
LAF7 
30 kDa X X X X X X 
Chromodomain protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PFL1005c PE=4 SV=1 
Q8I5K4_P
LAF7 
31 kDa X X X X X  
Proteasome subunit beta type OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0156 PE=3 SV=1 
Q8I6T3_P
LAF7 
30 kDa X X X X X  
26S proteasome regulatory subunit 4, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF10_0081 PE=3 SV=2 
Q8IJW0_P
LAF7 
50 kDa X  X X X X 
Serine repeat antigen 5 (Fragment) OS=Plasmodium 
falciparum GN=sera5 PE=3 SV=1 
I0IZS8_PL
AFA 
109 kDa X  X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL7P1.225.1 PE=4 
SV=1 
C0H4J3_P
LAF7 (+1) 
34 kDa X X X X X  
RNA binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.40 PE=4 SV=1 
Q8IB66_P
LAF7 
32 kDa X  X  X  
Surface protein, Pf113 OS=Plasmodium falciparum 
(isolate 3D7) GN=Pf113 PE=4 SV=1 
Q8ILP3_P
LAF7 
113 kDa X   X   
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0191 PE=4 SV=1 
Q8ILQ3_P
LAF7 
60 kDa X X X X  X 
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Thioredoxin reductase 2 OS=Plasmodium falciparum 
(isolate 3D7) GN=trxr2 PE=2 SV=2 
TRXR2_P
LAF7 (+1) 
69 kDa   X X X X 
MIF4G domain containing protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0086 PE=4 SV=1 
Q8IIS9_P
LAF7 
382 kDa X  X   X 
Eukaryotic translation initiation factor 2 alpha subunit, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PF07_0117 PE=4 SV=1 
Q8IBH7_P
LAF7 
38 kDa X    X  
Transcriptional regulator, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0870w PE=4 SV=1 
Q8I3T4_P
LAF7 
133 kDa X  X X X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFC0435w PE=4 SV=1 
O77361_P
LAF7 
154 kDa X X   X  
Subunit of proteaseome activator complex, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFI0370c PE=4 SV=1 
Q8I374_P
LAF7 
33 kDa X X X X X X 
GTPase (Rab6) OS=Plasmodium falciparum 
GN=rab6 PE=1 SV=1 
Q26000_P
LAFA 
24 kDa X X X X X X 
Pre-mRNA splicing factor, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0217 PE=4 SV=1 
Q8IJI0_PL
AF7 
62 kDa X  X X  X 
Proton-pumping vacuolar pyrophosphatase 
OS=Plasmodium falciparum GN=VP1 PE=3 SV=1 
O97154_P
LAFA (+1) 
76 kDa X X X X X  
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0649 PE=4 SV=1 
Q8IKF6_P
LAF7 
296 kDa X  X X X X 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFB0115w PE=4 SV=1 
O96127_P
LAF7 
142 kDa X X X   X 
Carbamoyl phosphate synthetase II OS=Plasmodium 
falciparum PE=4 SV=1 
Q27732_P
LAFA 
276 kDa X  X X  X 
Eukaryotic translation initiation factor 3 subunit E 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE1405c PE=3 SV=1 
Q8I3I5_PL
AF7 
61 kDa X X X X X X 
Minichromosome maintenance protein 3, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE1345c PE=3 SV=1 
Q8I3J5_P
LAF7 
110 kDa X X X X X X 
Co-chaperone GrpE, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0258 PE=3 SV=2 
Q8IIB6_P
LAF7 (+1) 
35 kDa X  X X X X 
60S ribosomal protein L7-3, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0231 PE=4 SV=2 
Q8ILL2_P
LAF7 
33 kDa X X X X  X 
Glutathione reductase OS=Plasmodium falciparum 
(isolate K1 / Thailand) GN=GR2 PE=1 SV=3 
GSHR_PL
AFK 
57 kDa X  X X  X 
Glideosome-associated protein 50 OS=Plasmodium 
falciparum (isolate 3D7) GN=GAP50 PE=1 SV=1 
Q8I2X3_P
LAF7 
45 kDa X X X X  X 
Rab1b, GTPase OS=Plasmodium falciparum (isolate 
3D7) GN=Rab1b PE=4 SV=1 
Q7K6A8_
PLAF7 
23 kDa X X  X   
Basic transcription factor 3b, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0241 PE=4 SV=1 
Q8ILK2_P
LAF7 
19 kDa  X X X X X 
26s proteasome subunit p55, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF10_0174 PE=4 SV=1 
Q8IJM0_P
LAF7 
55 kDa X X X X X X 
40S ribosomal protein S17, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL2055w PE=3 SV=1 
Q8I502_P
LAF7 
16 kDa X X X X X X 
Prefoldin subunit 3, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL7P1.94 PE=4 SV=1 
Q8IBR6_P
LAF7 
23 kDa X X X X X X 
Adenine nucleotide translocase OS=Plasmodium 
falciparum PE=2 SV=1 
Q25692_P
LAFA (+1) 
34 kDa X X  X  X 
Uncharacterized protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0153 PE=4 SV=1 
Q8IE45_P
LAF7 
116 kDa X  
 
X X X X 
Elongation factor 1 (EF-1), putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFC0870w PE=4 SV=2 
O97319_P
LAF7 
18 kDa X X X  X  
Chaperone, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PFF0430w PE=3 SV=1 
C6KST5_
PLAF7 
62 kDa X X  X  X 
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Tyrosyl-tRNA synthetase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.125 PE=1 
SV=1 
Q8IAR7_P
LAF7 
43 kDa  X X X X  
Cytoadherence linked asexual protein (Fragment) 
OS=Plasmodium falciparum GN=clag9 PE=2 SV=1 
O77090_P
LAFA 
161 kDa X     X 
Translation initiation factor IF-2, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFF0345w PE=4 SV=1 
C6KSR8_
PLAF7 
112 kDa X   X  X 
RNA binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0096 PE=4 SV=1 
Q8ILZ7_P
LAF7 
59 kDa X X X X X X 
60S ribosomal protein L27, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0579 PE=4 SV=2 
Q8IKM5_
PLAF7 
17 kDa X X X X X X 
Chromatin assembly protein (ASF1), putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL1180w PE=4 SV=1 
Q8I5H2_P
LAF7 
32 kDa X X X  X X 
cAMP-dependent protein kinase catalytic subunit 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PfPKAc PE=4 SV=1 
Q7K6A0_
PLAF7 
40 kDa X X X X X  
Eukaryotic translation initiation factor 3 subunit G 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL8P1.83 PE=3 SV=1 
Q8IAZ3_P
LAF7 
31 kDa X X X  X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF08_0081 PE=4 SV=1 
C0H4U5_
PLAF7 
77 kDa X  X  X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE1605w PE=4 SV=1 
Q8I3F0_P
LAF7 
61 kDa X  X X X  
Splicing factor, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PFE0865c PE=4 SV=2 
Q8I3T5_P
LAF7 
35 kDa X   X   
Uncharacterized protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0165 PE=4 SV=1 
Q8IE18_P
LAF7 
68 kDa   X X   
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.103 PE=4 
SV=1 
C0H4U0_
PLAF7 
71 kDa    X  X 
40S ribosomal protein S7, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0014 PE=4 SV=1 
Q8IET7_P
LAF7 
22 kDa X X X X X  
Rhoptry associated membrane antigen (Fragment) 
OS=Plasmodium falciparum PE=4 SV=1 
C5HXN1_
PLAFA 
92 kDa X  X X  X 
40S ribosomal protein S25, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0205 PE=4 SV=2 
Q8ILN8_P
LAF7 
12 kDa X X  X X X 
Clustered-asparagine-rich protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL1745c PE=4 SV=2 
Q8I562_P
LAF7 
52 kDa X X X X X  
Polyadenylate-binding protein, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL13P1.303 PE=4 SV=1 
C0H5J5_P
LAF7 
48 kDa X    X X 
Erythrocyte membrane-associated antigen 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL7P1.12 PE=4 SV=1 
Q8IC35_P
LAF7 
263 kDa X   X   
Tudor staphylococcal nuclease OS=Plasmodium 
falciparum (isolate 3D7) GN=TSN PE=4 SV=1 
Q8II01_PL
AF7 
129 kDa   X X X X 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0361 PE=4 SV=1 
Q8IJ39_P
LAF7 
193 kDa X  X X X  
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0046 PE=4 SV=1 
Q8IM45_P
LAF7 
35 kDa X X X X X 0 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL2120w PE=4 SV=1 
Q8I4Y9_P
LAF7 
155 kDa    X X X 
Actin-2 OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0124 PE=3 SV=1 
ACT2_PL
AF7 (+2) 
43 kDa X  X X X  
ATP synthase subunit beta OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL1725w PE=3 SV=1 
Q8I0V2_P
LAF7 
58 kDa X X X X X  
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Glutamate-rich protein OS=Plasmodium falciparum 
GN=GLURP PE=4 SV=1 
Q9GTX2_
PLAFA 
141 kDa X    X X 
Phenylalanyl-tRNA synthetase beta chain, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0051 PE=4 SV=1 
Q8IIW2_P
LAF7 
73 kDa X  X X X X 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0413 PE=4 SV=2 
Q8IHW3_
PLAF7 
53 kDa X X X X X X 
Glutathione peroxidase OS=Plasmodium falciparum 
PE=3 SV=1 
Q27742_P
LAFA (+1) 
24 kDa X   X X X 
PFI1785w OS=Plasmodium falciparum PE=2 SV=1 B2BZB8_
PLAFA 
43 kDa X X X X X  
Aspartate aminotransferase OS=Plasmodium 
falciparum (isolate 3D7) GN=PFB0200c PE=1 SV=1 
O96142_P
LAF7 
47 kDa X  X X X X 
40S ribosomal protein S15/S19, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL13P1.92 PE=3 SV=1 
C0H5C2_
PLAF7 
17 kDa X  X   X 
Uncharacterized protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0275 PE=4 SV=1 
Q8IDG9_
PLAF7 
33 kDa X  X X X  
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE1465w PE=4 SV=1 
C0H4G7_
PLAF7 
188 kDa    X   
Casein kinase 1, PfCK1 OS=Plasmodium falciparum 
(isolate 3D7) GN=PfCK1 PE=4 SV=1 
C6S3F7_
PLAF7 
38 kDa X  X X X X 
Ubiquitin conjugating enzyme, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE1350c PE=1 SV=1 
Q8I3J4_P
LAF7 
17 kDa X   X X X 
Fibrillarin, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0068 PE=3 SV=1 
Q8IM23_P
LAF7 
34 kDa X  X    
Aspartyl-tRNA synthetase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFA_0145c PE=3 SV=1 
Q8I2B1_P
LAF7 
73 kDa X  X X  X 
Vacuolar ATP synthase subunit G, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0130 PE=4 SV=1 
Q8IE84_P
LAF7 
14 kDa X X X   X 
Rhoptry-associated protein 3 OS=Plasmodium 
falciparum GN=RAP3 PE=4 SV=1 
Q8MUN1_
PLAFA 
47 kDa X X  X X  
60S ribosomal protein L21e, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0240 PE=4 SV=1 
Q8ILK3_P
LAF7 
19 kDa  X X  X X 
26S proteasome regulatory complex subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0303 PE=4 SV=2 
Q8II71_PL
AF7 
47 kDa X  X X X X 
Glycine-tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0198 PE=4 SV=2 
Q8ILP6_P
LAF7 
104 kDa X    X X 
DNA repair protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0270c PE=3 SV=1 
Q8I447_P
LAF7 
156 kDa      X 
Histidine--tRNA ligase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0428 PE=4 SV=1 
Q8IL22_P
LAF7 
134 kDa X   X   
Protein disulfide isomerase OS=Plasmodium 
falciparum (isolate 3D7) GN=PfPDI-9 PE=4 SV=1 
Q8I2V9_P
LAF7 
61 kDa X   X   
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFC0910w PE=4 SV=1 
O97284_P
LAF7 
50 kDa X X X X X X 
Superoxide dismutase [Fe] OS=Plasmodium 
falciparum (isolate 3D7) GN=SODB PE=1 SV=1 
SODF_PL
AF7 (+2) 
23 kDa X X   X X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF08_0004 PE=4 SV=1 
Q8IBD0_P
LAF7 
16 kDa X  
 
 X  X 
Proteasome regulatory subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL13P1.343 PE=4 SV=1 
Q8ID28_P
LAF7 
35 kDa X      
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Proteasome subunit alpha type 5, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF08_0109 PE=4 SV=1 
Q8IAR6_P
LAF7 
55 kDa X     X 
DNA replication licensing factor MCM4-related 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0095 PE=3 SV=1 
Q8IEE5_P
LAF7 
115 kDa X X X X  X 
Glutamine synthetase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFI1110w PE=3 SV=1 
C0H551_
PLAF7 
63 kDa X  X X   
Cof-like hydrolase, had-superfamily, subfamily iib 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL1270w PE=4 SV=1 
Q8I5F4_P
LAF7 
33 kDa X   X X X 
Sec24 subunit, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0324 PE=4 SV=1 
C0H5J6_P
LAF7 
107 kDa   X X X X 
60S ribosomal protein L6, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0129 PE=4 SV=1 
Q8IE85_P
LAF7 
22 kDa X     X 
2-Cys peroxiredoxin, putative OS=Plasmodium vivax 
(strain Salvador I) GN=PVX_118545 PE=1 SV=1 
A5K421_P
LAVS 
22 kDa  X     
40S ribosomal protein S28e, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0585 PE=4 SV=1 
Q8IKL9_P
LAF7 
7 kDa     X  
10b antigen, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF10_0213 PE=4 SV=1 
Q8IJI4_PL
AF7 
267 kDa      X 
Ubiquitination-mediated degradation component, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PF08_0020 PE=4 SV=1 
C0H4Y0_
PLAF7 
155 kDa    X   
eIF4E OS=Plasmodium falciparum PE=2 SV=1 A0MTS9_
PLAFA 
(+1) 
27 kDa X X     
Skeleton binding protein 1 OS=Plasmodium 
falciparum GN=sbp1 PE=4 SV=1 
Q9NFF5_
PLAFA 
37 kDa X X  X  X 
Lsm6 homologue, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0142 PE=4 SV=1 
Q8IE68_P
LAF7 
9 kDa   X X X  
60S ribosomal protein L10, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0141 PE=4 SV=1 
Q8ILV2_P
LAF7 
25 kDa   X X   
60S ribosomal protein L6-2, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0213 PE=4 SV=1 
Q8IDV1_P
LAF7 
26 kDa X  X  X X 
Replication factor A-related protein, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFI0235w PE=4 SV=1 
Q8I3A1_P
LAF7 
56 kDa   X X X  
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFA_0410w PE=4 SV=1 
Q8I259_P
LAF7 
255 kDa X  X  X X 
Protein kinase c inhibitor-like protein, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF08_0059 PE=4 SV=2 
Q7K6B1_
PLAF7 
21 kDa X      
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF07_0016 PE=4 SV=1 
Q8IC27_P
LAF7 
218 kDa    X   
40S ribosomal protein S9, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE1005w PE=3 SV=1 
Q8I3R0_P
LAF7 
22 kDa X  X X X X 
Phosphoglucomutase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0122 PE=3 SV=1 
Q8IJS0_P
LAF7 
68 kDa X   X   
Cysteinyl-tRNA synthetase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0149 PE=3 SV=2 
Q8IJP3_P
LAF7 
80 kDa  X  X  X 
Falcipain-3 OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0162 PE=3 SV=1 
Q8IIL0_PL
AF7 
57 kDa  X     
60S ribosomal protein L17, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0268 PE=3 SV=1 
Q8IDI5_P
LAF7 
23 kDa X   X  X 
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Vacuolar ATP synthase subunit E, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFI1670c PE=3 SV=2 
Q8I2H3_P
LAF7 
27 kDa    X  X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF07_0008 PE=4 SV=1 
Q8IC42_P
LAF7 
28 kDa X  X X   
Hexose transporter 1 OS=Plasmodium falciparum 
GN=ht1 PE=2 SV=1 
O97467_P
LAFA (+1) 
56 kDa X X X X  X 
V-type ATPase, subunit C, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFA_0300c PE=4 SV=1 
Q8I280_P
LAF7 
45 kDa    X   
Enhancer of rudimentary homolog OS=Plasmodium 
falciparum (isolate 3D7) GN=ERH PE=3 SV=1 
Q8IJ30_P
LAF7 
12 kDa X   X   
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0292 PE=4 SV=1 
Q8II82_PL
AF7 
29 kDa X X  X   
Uncharacterized protein MAL13P1.336 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL13P1.336 PE=4 SV=1 
Y13P2_PL
AF7 
79 kDa X   X X X 
Uncharacterized protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0099 PE=4 SV=1 
Q8IEE2_P
LAF7 
23 kDa   X    
Protein phosphatase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0281 PE=4 SV=2 
Q8II93_PL
AF7 
34 kDa X  X    
Arginyl-tRNA synthetase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL0900c PE=3 SV=1 
Q8I5M2_P
LAF7 
68 kDa      X 
40S ribosomal protein S13, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0316 PE=3 SV=1 
Q8IDB0_P
LAF7 
17 kDa X   X  X 
Heat shock protein DnaJ homologue Pfj4 
OS=Plasmodium falciparum GN=pfj4 PE=4 SV=1 
Q9GUX2_
PLAFA 
28 kDa X      
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0390 PE=4 SV=1 
Q8IL59_P
LAF7 
26 kDa   X X X  
ATP-dependent DNA helicase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0330 PE=4 SV=1 
Q8ID85_P
LAF7 
55 kDa X      
Transportin OS=Plasmodium falciparum GN=PFTRN 
PE=4 SV=1 
Q8WSV8_
PLAFA 
132 kDa X      
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0332 PE=4 SV=1 
Q8II42_PL
AF7 
32 kDa    X   
Probable prefoldin subunit 6 OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0595w PE=3 SV=2 
PFD6_PL
AF7 
14 kDa X    X  
40S ribosomal protein S16, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF08_0076 PE=3 SV=1 
Q8IAX5_P
LAF7 
16 kDa X X X X   
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF1410c PE=4 SV=1 
C6KTC6_
PLAF7 
77 kDa X  X X X  
DEAD-box helicase 11 OS=Plasmodium falciparum 
PE=3 SV=1 
A7U5X1_
PLAFA 
(+2) 
109 kDa X      
Inorganic pyrophosphatase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFC0710w.1 PE=4 
SV=1 
C0H477_
PLAF7 
51 kDa X   X   
Uncharacterized protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0136 PE=4 SV=1 
REVERSE
_Q8IE78_
PLAF7-R 
45 kDa X      
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFI1590c PE=4 SV=1 
Q8I2I8_PL
AF7 
159 kDa X   X   
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0990w PE=4 SV=1 
C0H4F1_
PLAF7 
23 kDa    X  X 
Ribosomal protein L15 OS=Plasmodium falciparum 
(isolate 3D7) GN=PFD0770c PE=3 SV=1 
C0H4A6_
PLAF7 
24 kDa   X X  X 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFB0490c PE=4 SV=1 
O96191_P
LAF7 
33 kDa X   X   
PfSec61 OS=Plasmodium falciparum GN=PfSec61 
PE=3 SV=1 
O60992_P
LAFA (+1) 
52 kDa X      
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Proteasome regulatory component, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=MAL13P1.190 PE=4 SV=1 
Q8IDV2_P
LAF7 
59 kDa X   X  X 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFB0835c PE=4 SV=1 
O96259_P
LAF7 
61 kDa X   X  X 
PfRab18, GTPase OS=Plasmodium falciparum 
(isolate 3D7) GN=rab18 PE=3 SV=1 
Q7K6B0_
PLAF7 
(+1) 
23 kDa X   X   
RNA binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF0250w PE=4 SV=1 
C6KSP9_
PLAF7 
86 kDa   X    
60S ribosomal protein L23, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0171 PE=3 SV=1 
Q8IE09_P
LAF7 
15 kDa  X    X 
Proteasome, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PFI1545c PE=4 SV=1 
Q8I0U7_P
LAF7 
33 kDa    X X  
DNA-directed RNA polymerase OS=Plasmodium 
falciparum (isolate 3D7) GN=PFC0805w PE=3 SV=1 
O77375_P
LAF7 
279 kDa    X   
Centrin-2 OS=Plasmodium falciparum (isolate 3D7) 
GN=CEN2 PE=4 SV=1 
Q8IL07_P
LAF7 
19 kDa X   X   
PfSNF2L OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0053 PE=4 SV=1 
Q8IIW0_P
LAF7 
167 kDa X      
RNAse L inhibitor protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL13P1.344 PE=3 
SV=1 
Q8I6Z4_P
LAF7 
70 kDa X      
Phosphatase, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0222 PE=4 SV=1 
Q8IDT0_P
LAF7 
68 kDa X  X X X  
Glutaminyl-tRNA synthetase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0170 PE=3 SV=1 
Q8IE10_P
LAF7 
109 kDa X     X 
Pfs38 OS=Plasmodium falciparum PE=4 SV=1 A8QVQ2_
PLAFA 
41 kDa X X   X  
Isocitrate dehydrogenase [NADP] OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0242 PE=3 SV=1 
Q8I6T2_P
LAF7 
54 kDa X X X    
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0069 PE=4 SV=2 
Q8IIU5_P
LAF7 
31 kDa X   X   
60S ribosomal protein L18a OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0224 PE=3 SV=1 
Q8IDS6_P
LAF7 
22 kDa X  X X   
Cytosolic glyoxalase II OS=Plasmodium falciparum 
(isolate 3D7) GN=cGloII PE=3 SV=1 
C0H490_
PLAF7 
31 kDa   X X   
40S ribosomal protein S21 OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0454 PE=3 SV=1 
Q8IHS5_P
LAF7 
9 kDa X   X   
Methionine aminopeptidase OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0327 PE=3 SV=1 
Q8ILB8_P
LAF7 
72 kDa   X X   
P-type calcium transporting ATPase OS=Plasmodium 
falciparum GN=serca PE=3 SV=1 
E1CC54_
PLAFA 
140 kDa      X 
60S ribosomal protein L23a, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0132 PE=3 SV=1 
Q8IE82_P
LAF7 
22 kDa    X   
Coatomer alpha subunit, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF0330w PE=4 SV=1 
C6KSR5_
PLAF7 
177 kDa      X 
Pfmdr2 protein OS=Plasmodium falciparum 
GN=pfmdr2 PE=3 SV=1 
Q25693_P
LAFA (+1) 
119 kDa    X   
60S ribosomal protein L14, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0296 PE=4 SV=1 
Q8ILE8_P
LAF7 
19 kDa    X   
Smarca-related protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PFF1185w PE=4 SV=1 
C6KT82_
PLAF7 
316 kDa X      
Small GTPase rab11 OS=Plasmodium falciparum 
GN=rab11 PE=2 SV=1 
Q25999_P
LAFA (+1) 
25 kDa X   X   
Proteasome subunit beta type OS=Plasmodium 
falciparum (isolate 3D7) GN=PF10_0111 PE=3 SV=1 
Q8IJT1_P
LAF7 
31 kDa X   X X  
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Heat shock protein DnaJ homologue Pfj2 
OS=Plasmodium falciparum GN=pfj2 PE=4 SV=1 
O77048_P
LAFA (+1) 
62 kDa X  X   X 
Proteasome regulatory protein, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFC0785c PE=4 SV=1 
O77379_P
LAF7 
26 kDa  X     
Heat shock protein 90, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0188 PE=3 SV=1 
Q8III6_PL
AF7 
108 kDa    X  X 
DNA replication licensing factor MCM5, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL0580w PE=3 SV=1 
Q8I5T4_P
LAF7 
86 kDa X   X   
Ubiquitin conjugating enzyme, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0301 PE=3 SV=1 
Q8IDD9_P
LAF7 
23 kDa X   X X  
Falcipain-2' OS=Plasmodium falciparum PE=3 SV=1 Q56CY9_
PLAFA 
(+1) 
56 kDa X X   X  
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF08_0091 PE=4 SV=1 
Q8IAV1_P
LAF7 
144 kDa X      
ORF 2 protein (Fragment) OS=Plasmodium 
falciparum GN=ORF 2 PE=2 SV=1 
Q02602_P
LAFA 
87 kDa      X 
Replication factor a protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFD0470c PE=4 SV=1 
Q9U0J0_
PLAF7 
134 kDa   X    
Ring-exported protein 1 OS=Plasmodium falciparum 
(isolate 3D7) GN=REX1 PE=4 SV=1 
Q8I2G1_P
LAF7 
83 kDa    X   
40S ribosomal protein S24 OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0975c PE=3 SV=1 
Q8I3R6_P
LAF7 
15 kDa    X   
Glutamate--cysteine ligase (Gamma-glutamylcysteine 
synthetase) OS=Plasmodium falciparum GN=GCS 
PE=2 SV=1 
Q9TY17_
PLAFA 
(+1) 
137 kDa    X   
Activator of Hsp90 ATPase homolog 1-like protein, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PFC0360w PE=4 SV=2 
O97256_P
LAF7 (+1) 
16 kDa     X  
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0092 PE=4 SV=2 
Q8IM01_P
LAF7 
31 kDa X      
Ubiquitin conjugating enzyme E2, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFL0190w PE=3 SV=1 
Q8I607_P
LAF7 
17 kDa      X 
Coatamer protein, beta subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0277 PE=4 SV=2 
Q8ILG6_P
LAF7 
160 kDa    X  X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.62 PE=4 SV=1 
Q8IB31_P
LAF7 
32 kDa    X  X 
Replication licensing factor, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0291 PE=3 SV=1 
Q8IDF0_P
LAF7 
106 kDa X X     
M18 aspartyl aminopeptidase OS=Plasmodium 
falciparum (isolate 3D7) GN=PfM18AAP PE=1 SV=1 
Q8I2J3_P
LAF7 
66 kDa   X X   
60S ribosomal protein L36 OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0106 PE=3 SV=2 
Q8I713_P
LAF7 
13 kDa    X   
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0050w PE=4 SV=1 
Q8I490_P
LAF7 
31 kDa X   X   
Serine rich protein homologue OS=Plasmodium 
falciparum PE=3 SV=1 
Q26015_P
LAFA 
120 kDa    X   
Apicoplast 1-acyl-sn-glycerol-3-phosphate 
acyltransferase, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0421 PE=4 SV=2 
Q8IL28_P
LAF7 
34 kDa X   X  X 
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0228 PE=4 SV=1 
Q8ILL5_P
LAF7 
184 kDa X      
6-cysteine protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=Pf41 PE=4 SV=1 
Q8I1Y0_P
LAF7 
43 kDa     X  
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Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFA_0420w PE=4 SV=1 
Q8I257_P
LAF7 
20 kDa X   X  X 
DNA replication licensing factor mcm7 homologue, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PF07_0023 PE=3 SV=1 
Q8IC16_P
LAF7 
94 kDa    X X  
RNA binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFI1175c PE=4 SV=1 
Q8I2R8_P
LAF7 
23 kDa X X X  X  
60S ribosomal protein L19, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF0700c PE=4 SV=1 
C6KSY6_
PLAF7 
22 kDa X   X   
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF0880c PE=4 SV=1 
C6KT22_
PLAF7 
23 kDa X      
60S ribosomal protein L30e, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF10_0187 PE=4 SV=1 
Q8IJK8_P
LAF7 
12 kDa   X X   
Rab2, GTPase OS=Plasmodium falciparum (isolate 
3D7) GN=Rab2 PE=3 SV=1 
Q8I5A9_P
LAF7 
24 kDa      X 
Cytidine triphosphate synthetase OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0100 PE=4 SV=1 
Q8ILZ3_P
LAF7 
99 kDa      X 
Proteosome subunit, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0025 PE=4 SV=1 
Q8IM66_P
LAF7 
78 kDa X      
Merzoite surface protein 1 OS=Plasmodium 
reichenowi GN=msp1 PE=4 SV=1 
Q4W2V7_
PLARE 
198 kDa X      
Ubiquitin carboxyl-terminal hydrolase 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFE1355c PE=3 SV=1 
Q8I3J3_P
LAF7 
71 kDa    X X  
Proteasome subunit beta type OS=Plasmodium 
falciparum (isolate 3D7) GN=PF14_0676 PE=3 SV=2 
Q8IKC9_P
LAF7 
23 kDa  X   X  
Conserved protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PF11_0287 PE=4 SV=2 
Q8II87_PL
AF7 
35 kDa  X     
Uncharacterized protein OS=Plasmodium falciparum 
(isolate 3D7) GN=PF13_0190 PE=4 SV=1 
Q8IDY6_P
LAF7 
63 kDa X   X   
Proliferating cell nuclear antigen OS=Plasmodium 
falciparum (isolate 3D7) GN=PCNA2 PE=3 SV=1 
Q7KQJ9_
PLAF7 
30 kDa X  X X   
Early transcribed membrane protein 4, ETRAMP4 
OS=Plasmodium falciparum (isolate 3D7) 
GN=ETRAMP4 PE=4 SV=1 
Q8IFM9_P
LAF7 
15 kDa X     X 
Glycogen synthase kinase 3 OS=Plasmodium 
falciparum (isolate 3D7) GN=PfGSK-3 PE=4 SV=2 
O77344_P
LAF7 
52 kDa    X   
Dynamin homologue OS=Plasmodium falciparum 
GN=dyn PE=3 SV=1 
Q6KF55_
PLAFA 
82 kDa X      
Asparagine synthetase OS=Plasmodium falciparum 
(isolate 3D7) GN=PFC0395w PE=4 SV=1 
O77330_P
LAF7 
70 kDa X    X  
Acetyl-CoA synthetase OS=Plasmodium falciparum 
(isolate 3D7) GN=PFF1350c PE=4 SV=1 
C6KTB4_
PLAF7 
114 kDa     X  
Chloroquine resistance transporter OS=Plasmodium 
falciparum GN=CRT PE=1 SV=1 
CRT_PLA
FA 
49 kDa X X  X   
DNAJ protein, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PF08_0032 PE=4 SV=1 
Q8IB72_P
LAF7 
77 kDa    X  X 
NAD synthase, putative OS=Plasmodium falciparum 
(isolate 3D7) GN=PFI1310w PE=4 SV=1 
Q8I2P2_P
LAF7 
98 kDa   X   X 
Translation elongation factor EF-1, subunit alpha, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0245 PE=4 SV=1 
Q8IIC9_P
LAF7 
63 kDa X      
DNA primase small subunit OS=Plasmodium 
falciparum (isolate K1 / Thailand) PE=3 SV=1 
PRI1_PLA
FK 
53 kDa X      
Elongation factor 2 OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0486 PE=4 SV=1 
REVERSE
_Q8IKW5
_PLAF7-R 
94 kDa      X 
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DNA topoisomerase 2 OS=Plasmodium falciparum 
(isolate 3D7) GN=PF14_0316 PE=3 SV=1 
Q8ILC8_P
LAF7 
169 kDa      X 
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL0895c PE=4 SV=1 
Q8I5M3_P
LAF7 
123 kDa    X  X 
Spermidine synthase OS=Plasmodium falciparum 
(isolate 3D7) GN=PF11_0301 PE=1 SV=1 
Q8II73_PL
AF7 (+1) 
37 kDa    X   
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PF08_0137 PE=4 SV=1 
Q8IAK9_P
LAF7 
147 kDa    X   
ATP synthase (C/AC39) subunit, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0615 PE=4 SV=1 
Q8IKJ0_P
LAF7 
45 kDa   X  X  
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFL2355w PE=4 SV=1 
Q8I4U3_P
LAF7 
45 kDa X  X X   
PfSec23 protein OS=Plasmodium falciparum (isolate 
3D7) GN=Pfsec23 PE=2 SV=1 
Q8IB60_P
LAF7 
86 kDa     X  
Helicase (Fragment) OS=Plasmodium falciparum 
PE=2 SV=1 
A6N5Z1_
PLAFA 
66 kDa X      
Replication factor C subunit 1 OS=Plasmodium 
falciparum GN=rfc1 PE=4 SV=1 
Q9GQW6
_PLAFA 
104 kDa    X   
60S ribosomal protein L8, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0845c PE=4 SV=1 
Q8I3T9_P
LAF7 
28 kDa     X  
40S ribosomal protein S26e, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFB0830w PE=4 SV=1 
O96258_P
LAF7 
13 kDa X    X X 
Vacuolar proton translocating ATPase subunit A, 
putative OS=Plasmodium falciparum (isolate 3D7) 
GN=PF08_0113 PE=4 SV=1 
Q8IAQ8_P
LAF7 
123 kDa  X     
Ran-binding protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFI0490c PE=4 SV=1 
C0H530_
PLAF7 
139 kDa X      
Ubiquitin carboxyl-terminal hydrolase a, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PFD0680c PE=4 SV=1 
Q8I1U8_P
LAF7 
98 kDa    X   
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL8P1.52 PE=4 SV=1 
Q8IB48_P
LAF7 
14 kDa X    X  
Aquaglyceroporin OS=Plasmodium falciparum 
(isolate 3D7) GN=AQP PE=3 SV=1 
Q8II36_PL
AF7 (+1) 
28 kDa X      
40S ribosomal protein S5, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF07_0088 PE=3 SV=1 
Q8IBN5_P
LAF7 
22 kDa X      
Orotate phosphoribosyltransferase OS=Plasmodium 
falciparum GN=oprt PE=2 SV=1 
Q8N0R1_
PLAFA 
33 kDa    X   
Uncharacterized protein OS=Plasmodium falciparum 
(isolate 3D7) GN=MAL13P1.257 PE=1 SV=1 
Q8IDI8_P
LAF7 
19 kDa X   X   
Ser/Arg-rich splicing factor, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0160c PE=4 SV=1 
Q8I468_P
LAF7 
38 kDa X      
Calmodulin OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0323 PE=3 SV=2 
CALM_PL
AF7 (+1) 
17 kDa      X 
MYND finger protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFF0105w PE=4 SV=1 
C6KSM2_
PLAF7 
29 kDa   X X   
Merozoite-related surface protein 2 (Fragment) 
OS=Plasmodium falciparum PE=4 SV=1 
C5HE50_
PLAFA 
(+5) 
33 kDa X      
Haloacid dehalogenase-like hydrolase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF11_0190 PE=4 SV=1 
Q8III4_PL
AF7 
36 kDa    X   
Sexual stage antigen s16 OS=Plasmodium falciparum 
GN=s16 PE=4 SV=1 
Q9U6T9_
PLAFA 
17 kDa X   X   
Nuclear movement protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0204 PE=4 SV=1 
Q8IDW4_
PLAF7 
46 kDa X      
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Bacterial histone-like protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PfHU PE=4 SV=1 
Q8I3A2_P
LAF7 
23 kDa X      
Thymidylate kinase, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=TMK PE=1 SV=1 
Q8I4S1_P
LAF7 
25 kDa    X   
Phosphoenolpyruvate carboxylase, putative 
OS=Plasmodium falciparum (isolate 3D7) 
GN=PF14_0246 PE=4 SV=1 
Q8ILJ7_P
LAF7 
134 kDa X      
Myosin-A OS=Plasmodium falciparum (isolate FCBR / 
Columbia) PE=2 SV=1 
MYOA_PL
AFB 
92 kDa    X   
Bet3 transport protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFD0895c PE=4 SV=1 
Q8I1Q2_P
LAF7 
21 kDa   X    
Putative uncharacterized protein OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL7P1.67 PE=4 SV=1 
C0H4M7_
PLAF7 
24 kDa X      
Probable DNA-directed RNA polymerase II subunit 
RPB11 OS=Plasmodium falciparum (isolate 3D7) 
GN=PF13_0023 PE=3 SV=1 
RPB11_P
LAF7 
14 kDa     X  
Zinc finger protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF13_0313 PE=4 SV=1 
Q8IDC0_P
LAF7 
70 kDa    X   
60S ribosomal protein L28, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PF11_0437 PE=4 SV=1 
Q8IHU0_P
LAF7 
14 kDa      X 
Skp1 family protein, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=MAL13P1.337 PE=4 
SV=2 
Q8ID38_P
LAF7 
19 kDa X   X   
60S ribosomal protein L31, putative OS=Plasmodium 
falciparum (isolate 3D7) GN=PFE0185c PE=4 SV=1 
Q8I463_P
LAF7 
14 kDa   X    
Conserved Plasmodium protein OS=Plasmodium 
falciparum (isolate 3D7) GN=PFB0620w PE=4 SV=1 
O96217_P
LAF7 
18 kDa X      
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Identified Proteins UniProt 
Accession 
Number 
Molecular 
Weight 
Sample 
W
2C
1 
W
2C
2 
W
2C
3 
W
2T
1 
W
2T
2 
W
2T
3 
Spectrin alpha chain, erythrocytic 1 
OS=Homo sapiens GN=SPTA1 PE=1 
SV=5 
 
sp|P02549|SPTA
1_HUMAN 
280 kDa X 
 
 
X X X X X 
Spectrin beta chain, erythrocytic 
OS=Homo sapiens GN=SPTB PE=1 
SV=5 
 
sp|P11277|SPTB
1_HUMAN 
246 kDa X X X X X X 
Band 3 anion transport protein 
OS=Homo sapiens GN=SLC4A1 PE=1 
SV=3 
 
B3AT_HUMAN 102 kDa X X X X X X 
Hemoglobin subunit beta OS=Homo 
sapiens GN=HBB PE=1 SV=2 
 
HBB_HUMAN 16 kDa X X X X X X 
Isoform Er11 of Ankyrin-1 OS=Homo 
sapiens GN=ANK1 
 
sp|P16157-
12|ANK1_HUMA
N (+3) 
209 kDa X X X X X X 
Hemoglobin subunit alpha OS=Homo 
sapiens GN=HBA1 PE=1 SV=2 
 
HBA_HUMAN 15 kDa X X X X X X 
Actin, cytoplasmic 1 OS=Homo sapiens 
GN=ACTB PE=1 SV=1 
 
ACTB_HUMAN 42 kDa X X X X X X 
Isoform Long of Erythrocyte membrane 
protein band 4.2 OS=Homo sapiens 
GN=EPB42 
 
sp|P16452-
2|EPB42_HUMA
N 
80 kDa X X X X X X 
Isoform 2 of Protein 4.1 OS=Homo 
sapiens GN=EPB41 
 
sp|P11171-
2|41_HUMAN 
(+2) 
93 kDa X X X X X X 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=1 SV=3 
 
G3P_HUMAN 36 kDa X X X X X X 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 
 
H4_HUMAN 11 kDa X X X X X X 
Elongation factor 1-alpha 2 OS=Homo 
sapiens GN=EEF1A2 PE=1 SV=1 
 
EF1A2_HUMAN 50 kDa X X X X X X 
Erythrocyte band 7 integral membrane 
protein OS=Homo sapiens GN=STOM 
PE=1 SV=3 
 
sp|P27105|STOM
_HUMAN 
32 kDa X X X X X X 
Heat shock protein HSP 90-beta 
OS=Homo sapiens GN=HSP90AB1 
PE=1 SV=4 
 
HS90B_HUMAN 83 kDa X X X X X X 
Solute carrier family 2, facilitated glucose 
transporter member 1 OS=Homo sapiens 
GN=SLC2A1 PE=1 SV=2 
 
GTR1_HUMAN 54 kDa X X X X X X 
Apolipoprotein A-I OS=Homo sapiens 
GN=APOA1 PE=1 SV=1 
 
APOA1_HUMAN 31 kDa X X X X X X 
Isoform 2 of Heat shock cognate 71 kDa 
protein OS=Homo sapiens GN=HSPA8 
 
sp|P11142-
2|HSP7C_HUMA
N (+1) 
54 kDa X X X X X X 
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Identified Proteins UniProt 
Accession 
Number 
Molecular 
Weight 
Sample 
W
2C
1 
W
2C
2 
W
2C
3 
W
2T
1 
W
2T
2 
W
2T
3 
Isoform 2 of Tropomyosin alpha-3 chain 
OS=Homo sapiens GN=TPM3 
 
sp|P06753-
2|TPM3_HUMAN 
29 kDa X X X X X X 
Selenium-binding protein 1 OS=Homo 
sapiens GN=SELENBP1 PE=1 SV=2 
 
sp|Q13228|SBP1
_HUMAN 
52 kDa X X X X X X 
Calpain-1 catalytic subunit OS=Homo 
sapiens GN=CAPN1 PE=1 SV=1 
 
CAN1_HUMAN 82 kDa X X X X X X 
Superoxide dismutase [Cu-Zn] 
OS=Homo sapiens GN=SOD1 PE=1 
SV=2 
 
SODC_HUMAN 16 kDa X X X X X X 
Alpha-adducin OS=Homo sapiens 
GN=ADD1 PE=2 SV=1 
 
E7ENY0_HUMA
N (+1) 
73 kDa X X X X X X 
Hemoglobin subunit delta OS=Homo 
sapiens GN=HBD PE=1 SV=2 
 
HBD_HUMAN 16 kDa X X X X X X 
Isoform Short of Dematin OS=Homo 
sapiens GN=EPB49 
 
sp|Q08495-
2|DEMA_HUMAN 
43 kDa X X X X X X 
Tropomodulin-1 OS=Homo sapiens 
GN=TMOD1 PE=1 SV=1 
 
TMOD1_HUMAN 41 kDa X X X X X X 
Carbonic anhydrase 1 OS=Homo 
sapiens GN=CA1 PE=1 SV=2 
 
CAH1_HUMAN 29 kDa X X X X X X 
Peroxiredoxin-2 OS=Homo sapiens 
GN=PRDX2 PE=1 SV=5 
 
sp|P32119|PRDX
2_HUMAN 
22 kDa X X  X X X 
Beta-adducin OS=Homo sapiens 
GN=ADD2 PE=1 SV=3 
 
sp|P35612|ADDB
_HUMAN 
81 kDa X X X X X X 
Catalase OS=Homo sapiens GN=CAT 
PE=1 SV=3 
 
CATA_HUMAN 60 kDa X X   X  
Isoform 2 of Triosephosphate isomerase 
OS=Homo sapiens GN=TPI1 
 
sp|P60174-
1|TPIS_HUMAN 
(+1) 
27 kDa X X X X X X 
Keratin, type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 
 
K2C1_HUMAN 66 kDa X X  X  X 
Polyubiquitin-C (Fragment) OS=Homo 
sapiens GN=UBC PE=2 SV=1 
 
F5H388_HUMAN 17 kDa X X X XX X X 
Calpain small subunit 1 OS=Homo 
sapiens GN=CAPNS1 PE=1 SV=1 
 
CPNS1_HUMAN 28 kDa X X X X X X 
Tubulin beta-4B chain OS=Homo 
sapiens GN=TUBB4B PE=1 SV=1 
 
TBB4B_HUMAN 50 kDa X X X X X X 
Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 
 
K1C10_HUMAN 59 kDa  X     
Isoform 8a of Blood group Rh(CE) 
polypeptide OS=Homo sapiens 
GN=RHCE 
sp|P18577-
11|RHCE_HUMA
N (+1) 
38 kDa X X X    
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Identified Proteins UniProt 
Accession 
Number 
Molecular 
Weight 
Sample 
W
2C
1 
W
2C
2 
W
2C
3 
W
2T
1 
W
2T
2 
W
2T
3 
 
Histone H2A type 2-A OS=Homo sapiens 
GN=HIST2H2AA3 PE=1 SV=3 
 
H2A2A_HUMAN 
(+1) 
14 kDa X X X X X X 
Flotillin-1 OS=Homo sapiens GN=FLOT1 
PE=1 SV=3 
 
FLOT1_HUMAN 47 kDa X X X X X X 
Histone H2B type 1-M OS=Homo 
sapiens GN=HIST1H2BM PE=1 SV=3 
 
H2B1M_HUMAN 14 kDa  X     
78 kDa glucose-regulated protein 
OS=Homo sapiens GN=HSPA5 PE=1 
SV=2 
 
GRP78_HUMAN 72 kDa  X     
Isoform Glycophorin-D of Glycophorin-C 
OS=Homo sapiens GN=GYPC 
 
sp|P04921-
2|GLPC_HUMAN 
(+1) 
11 kDa X X X X X X 
Golgi-associated plant pathogenesis-
related protein 1 OS=Homo sapiens 
GN=GLIPR2 PE=1 SV=3 
 
GAPR1_HUMAN 17 kDa  X X  X  
14-3-3 protein gamma OS=Homo 
sapiens GN=YWHAG PE=1 SV=2 
 
1433G_HUMAN 28 kDa X X X X X X 
Isoform 2 of Dynein heavy chain 9, 
axonemal OS=Homo sapiens 
GN=DNAH9 
 
REVERSE_sp|Q
9NYC9-
2|DYH9_HUMAN
-DECOY (+2) 
503 kDa  X     
Tropomyosin alpha-1 chain OS=Homo 
sapiens GN=TPM1 PE=2 SV=1 
 
B7Z596_HUMAN 
(+2) 
32 kDa X X  X  X 
Apolipoprotein B-100 OS=Homo sapiens 
GN=APOB PE=1 SV=2 
 
APOB_HUMAN 516 kDa X  X X X X 
Flotillin-2 OS=Homo sapiens GN=FLOT2 
PE=1 SV=2 
 
FLOT2_HUMAN 47 kDa X  X X X X 
Tubulin alpha-8 chain (Fragment) 
OS=Homo sapiens GN=TUBA8 PE=2 
SV=1 
 
C9J2C0_HUMAN 
(+2) 
52 kDa X   X X X 
Flavin reductase (NADPH) OS=Homo 
sapiens GN=BLVRB PE=1 SV=3 
 
BLVRB_HUMAN 22 kDa X    X  
GTP-binding nuclear protein Ran 
(Fragment) OS=Homo sapiens GN=RAN 
PE=2 SV=1 
 
F5H018_HUMAN 23 kDa X  X    
Acylamino-acid-releasing enzyme 
OS=Homo sapiens GN=APEH PE=1 
SV=4 
 
ACPH_HUMAN 
(+1) 
81 kDa X    X  
Ras-related protein Rap-2b OS=Homo 
sapiens GN=RAP2B PE=1 SV=1 
 
RAP2B_HUMAN 21 kDa X      
Transitional endoplasmic reticulum 
ATPase OS=Homo sapiens GN=VCP 
PE=1 SV=4 
 
TERA_HUMAN 89 kDa X   X   
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Identified Proteins UniProt 
Accession 
Number 
Molecular 
Weight 
Sample 
W
2C
1 
W
2C
2 
W
2C
3 
W
2T
1 
W
2T
2 
W
2T
3 
Isoform 2 of 55 kDa erythrocyte 
membrane protein OS=Homo sapiens 
GN=MPP1 
 
sp|Q00013-
2|EM55_HUMAN 
(+1) 
49 kDa X  X X X X 
Uncharacterized protein (Fragment) 
OS=Homo sapiens PE=3 SV=1 
K7N7A8_HUMAN 48 kDa X   X   
Apolipoprotein A-II OS=Homo sapiens 
GN=APOA2 PE=1 SV=1 
APOA2_HUMAN 11 kDa X  X X  X 
26S protease regulatory subunit 4 
OS=Homo sapiens GN=PSMC1 PE=2 
SV=1 
B4DR63_HUMA
N 
41 kDa X      
Ras-related protein Rab-7a (Fragment) 
OS=Homo sapiens GN=RAB7A PE=2 
SV=1 
C9IZZ0_HUMAN 
(+6) 
13 kDa X      
Tubulin beta-3 chain OS=Homo sapiens 
GN=TUBB3 PE=1 SV=2 
TBB3_HUMAN 50 kDa   X  X  
Complement C3 OS=Homo sapiens 
GN=C3 PE=1 SV=2 
CO3_HUMAN 187 kDa   X X   
Isoform 2 of Apolipoprotein L1 OS=Homo 
sapiens GN=APOL1 
sp|O14791-
2|APOL1_HUMA
N 
46 kDa    X  X 
Actin, alpha skeletal muscle OS=Homo 
sapiens GN=ACTA1 PE=1 SV=1 
ACTS_HUMAN 42 kDa      X 
Glycophorin A OS=Homo sapiens 
GN=GYPA PE=2 SV=1 
B8Q182_HUMAN 
(+2) 
14 kDa      X 
Complement C4-B OS=Homo sapiens 
GN=C4B PE=1 SV=2 
CO4B_HUMAN 193 kDa   X X   
Alpha-1-antitrypsin OS=Homo sapiens 
GN=SERPINA1 PE=1 SV=3 
sp|P01009|A1AT
_HUMAN 
47 kDa   X X   
Keratin, type I cytoskeletal 9 OS=Homo 
sapiens GN=KRT9 PE=1 SV=3 
K1C9_HUMAN 62 kDa    X   
Apolipoprotein E OS=Homo sapiens 
GN=APOE PE=1 SV=1 
APOE_HUMAN 36 kDa   X    
 
